

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA**

R.J. REYNOLDS TOBACCO)
COMPANY, et al.,)
)
Plaintiffs,)
)
v.)
)
UNITED STATES FOOD AND)
DRUG ADMINISTRATION, et al.,)
)
Defendants.)

No. 1:11-cv-1482 (RJL)

DEFENDANTS' MOTION FOR SUMMARY JUDGMENT

Pursuant to Federal Rule of Civil Procedure 56, the defendants move for summary judgment in this action. The grounds for this motion are set forth in the memorandum filed herewith.

Respectfully submitted,

Dated: October 21, 2011

Of Counsel:

WILLIAM B. SCHULTZ
Acting General Counsel

ELIZABETH H. DICKINSON
Acting Associate General Counsel
Food and Drug Division

TONY WEST
Assistant Attorney General

BETH S. BRINKMANN
Deputy Assistant Attorney General

MAAME EWUSI-MENSAH FRIMPONG
Acting Deputy Assistant Attorney General

ERIC M. BLUMBERG
Deputy Chief Counsel, Litigation

KAREN E. SCHIFTER
Senior Counsel
U.S. Department of Health & Human Services
Office of the General Counsel
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002

/s/

DRAKE CUTINI
DANIEL K. CRANE-HIRSCH
Attorneys, Consumer Protection Branch
PO Box 386
Washington, DC 20044
202-307-0044 (Cutini)
drake.cutini@usdoj.gov

/s/

MARK B STERN
ALISA B. KLEIN
SARANG V. DAMLE
DANIEL TENNY
LINDSEY POWELL
Attorneys, Appellate Staff
Civil Division, Room 7217
U.S. Department of Justice
950 Pennsylvania Ave., NW
Washington, DC 20530
202-514-5735 (Damle)
Fax: 202-514-9405
sarang.damle@usdoj.gov

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA**

R.J. REYNOLDS TOBACCO)	
COMPANY, et al.,)	
)	
Plaintiffs,)	
)	
v.)	No. 1:11-cv-1482 (RJL)
)	
UNITED STATES FOOD AND)	
DRUG ADMINISTRATION, et al.,)	
)	
Defendants.)	

**MEMORANDUM IN SUPPORT OF DEFENDANTS’
MOTION FOR SUMMARY JUDGMENT AND IN OPPOSITION TO
PLAINTIFFS’ MOTION FOR SUMMARY JUDGMENT**

Of Counsel:	TONY WEST Assistant Attorney General
WILLIAM B. SCHULTZ Acting General Counsel	BETH S. BRINKMANN Deputy Assistant Attorney General
ELIZABETH H. DICKINSON Acting Associate General Counsel Food and Drug Division	MAAME EWUSI-MENSAH FRIMPONG Acting Deputy Assistant Attorney General
ERIC M. BLUMBERG Deputy Chief Counsel, Litigation	DRAKE CUTINI DANIEL K. CRANE-HIRSCH Attorneys, Consumer Protection Branch
KAREN E. SCHIFTER Senior Counsel U.S. Department of Health & Human Services Office of the General Counsel 10903 New Hampshire Ave. Silver Spring, MD 20993-0002	MARK B STERN ALISA B. KLEIN SARANG V. DAMLE DANIEL TENNY LINDSEY POWELL Attorneys, Appellate Staff Civil Division, Room 7217 U.S. Department of Justice 950 Pennsylvania Ave., NW Washington, DC 20530

TABLE OF CONTENTS

	<u>Page</u>
INTRODUCTION AND SUMMARY	1
STATEMENT.....	5
A. Background.....	5
B. The Supreme Court's Brown & Williamson Decision.....	8
C. The Tobacco Control Act.....	9
D. FDA's Implementing Rule.....	10
ARGUMENT.....	13
I. Warnings and Other Disclosure Requirements Are Subject To "Less Exacting Scrutiny" Than Restrictions On Commercial Speech.....	13
II. Congress Mandated Health Warnings in a Format that Accurately Conveys the Extraordinary Risks of Smoking and Violates No First Amendment Principle.....	14
A. The Revised Warnings Substantially Advance the Government's Overwhelming Interest in Informing Consumers About the Grave Dangers if Cigarette Smoking.....	14
1. The Current Surgeon General Warnings Are Essentially "Invisible".....	14
2. Evidence Before Congress and the FDA Establishes that the Warnings Mandated by Congress Convey the Health Risks of Smoking More Effectively than Text-Only Warnings of Any Size.....	16
3. The Required Health Warnings Do Not Impermissibly Burden Protected Commercial Speech.....	20
B. Plaintiffs' First Amendment Contentions Are Without Merit.....	23
1. The Warnings Do Not Constitute an "Ideological Message".....	23

2.	The Health Warnings Convey Risks of Addiction and Smoking that Are Not Adequately Appreciated by Consumers Generally and Adolescents in Particular.	29
3.	The Constitutionality of the Required Warnings Does Not Require a Statistical Determination Regarding the Extent to Which the Decline in Smoking Rates in Canada Should Be Attributed to the Introduction of New Health Warnings.	31
III.	FDA Adopted Images to Accompany the Text of the Health Warnings that Accurately Convey the Extraordinary Risks of Smoking Consistent with the First Amendment and the APA.	34
A.	The Images Selected By FDA Raise No First Amendment Concerns.	34
1.	FDA Properly Considered the “Salience” of the Proposed Warnings, i.e., the Extent to Which Consumers Will Notice and Process the Warnings Over Time.	34
2.	Plaintiffs Have Waived Any Challenge to the Specific Warnings Selected by FDA, Which Accurately Convey Consequences of Smoking.	37
3.	The Inclusion of a Phone Number for a Smoking Cessation Resource Raises No First Amendment Concerns.	44
B.	Plaintiffs’ APA Challenge Reduces to the Contention that the Agency Should Have Declined to Implement the Statutory Mandate.	45
1.	The Regulatory Impact Statement.	46
2.	The Consumer Research Study.	49
3.	Other APA Challenges.	51
IV.	There Is No Authority To Issue an Injunction that Would Delay Enforcement of the Warning Requirements Established by Statute.	53
	CONCLUSION.	55

TABLE OF AUTHORITIES

Cases:	<u>Page</u>
<i>Board of Trustees v. Fox</i> , 492 U.S. 469 (1989).....	13
<i>Brown v. Entertainment Merchants Ass’n</i> , 131 S. Ct. 2729 (2011).....	28, 29
<i>Canada v. JTI-Macdonald Corp.</i> , [2007] 2 S.C.R. 610, 2007 SCC 30.....	21
<i>Central Hudson</i> , 477 U.S. at 566.....	13, 14
<i>Central Hudson Gas & Electric Corp. v. Public Service Commission</i> , 447 U.S. 557 (1980).....	2, 13
* <i>Commonwealth Brands, Inc. v. United States</i> , 678 F. Supp. 2d 512 (W.D. Ky. 2010), <i>appeals pending sub nom.</i> <i>Discount Tobacco City & Lottery, Inc. v. United States</i> , Nos. 10-5234 & 10-5235 (6th Cir.).....	1, 16, 17, 20, 21, 22, 31
<i>Entertainment Software Ass’n v. Blagojevich</i> , 469 F.3d 641 (7th Cir. 2006).....	28
* <i>FDA v. Brown & Williamson Tobacco Corp.</i> , 529 U.S. 120 (2000).....	3, 5, 8, 9, 25
<i>Larus & Brother Co. v. FCC</i> , 447 F.2d 876 (4th Cir. 1971).....	26
<i>Miami Herald Publishing Co. v. Tornillo</i> , 418 U.S. 241 (1974).....	14
* <i>Milavetz, Gallop & Milavetz, P.A. v. United States</i> , 130 S. Ct. 1324 (2010).....	13
<i>Nat’l Citizens Comm. for Broad. v. FCC</i> , 567 F.2d 1095 (D.C. Cir. 1977).....	26

* Authorities chiefly relied upon are marked with an asterisk.

Nat’l Petrochemical & Refiners Ass’n v. EPA,
630 F.3d 145 (D.C. Cir. 2010)..... 55

**National Electrical Manufacturers Ass’n v. Sorrell*,
272 F.3d 104 (2d Cir. 2001)..... 28, 29, 32

Pacific Gas & Electric Co. v. Public Utilities Commission,
475 U.S. 1 (1986)..... 29

Pub. Citizen v. Fed. Motor Carrier Safety Admin.,
374 F.3d 1209 (D.C. Cir. 2004)..... 46

SEC v. Chenery Corp.,
318 U.S. 80, 63 S.Ct. 454, 87 L.Ed. 626 (1943)..... 55

United States v. Philip Morris USA, Inc., et al.,
449 F. Supp. 2d 1 (D.D.C. 2006)..... 3, 7, 8, 19, 25, 30, 31, 41

United States v. Philip Morris USA, Inc., et al.,
566 F.3d 1095 (D.C. Cir. 2009), *cert. denied*, 130 S. Ct. 3501 (2010). 3, 8, 15, 16, 27, 29

WJG Tel. Co., Inc. v. FCC,
675 F.2d 386 (D.C. Cir. 1982)..... 53

West Virginia State Bd. of Ed. v. Barnette,
319 U.S. 624 (1943)..... 14

Wooley v. Maynard,
430 U.S. 705 (1977)..... 4, 14, 24, 27, 28

* *Zauderer v. Office of Disciplinary Counsel of Supreme Court of Ohio*,
471 U.S. 626 (1985)..... 2, 4, 13, 14, 21, 27, 28, 29

Statutes:

5 U.S.C. § 706 55

15 U.S.C. § 1333, Note..... 1, 9, 10, 24, 45, 53

15 U.S.C. § 1333(b)(4). 54

21 U.S.C. § 387, Note..... 3, 6, 7, 8

* Authorities chiefly relied upon are marked with an asterisk.

21 U.S.C. § 387f(d)(1). 54

49 U.S.C. § 31506(d). 47

Pub. L. 89-92, 79 Stat. 282 (1965). 14

Pub. L. 98-474, 98 Stat. 2200 (1984). 14, 15

Pub. L. No. 111-31, 123 Stat. 1776 (2009). 1, 54

Regulations:

58 Fed. Reg. 51,735 (1993). 47

61 Fed. Reg. 44,396 (Aug. 28, 1996). 5, 8, 9

75 Fed. Reg. 7,604 (Feb. 22, 2010). 52

75 Fed. Reg. 52,352 (Aug. 25, 2010). 51, 52

75 Fed. Reg. 69,524 (Nov. 12, 2010). 1, 5, 6, 7, 10, 16, 17, 27, 32, 33, 50, 52

75 Fed. Reg. 75,936 (Dec. 7, 2010). 53

76 Fed. Reg. 3821 (2011). 47

*76 Fed. Reg. 36,628 (June 22, 2011). 1, 2, 5, 7, 11, 12, 20, 31, 33, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 47, 48, 49, 50, 51, 52, 54

Orders:

Executive Order 12,866. 46, 47

Executive Order 13,563. 46, 47

Rules:

Local Rule 7(n). 2

* Authorities chiefly relied upon are marked with an asterisk.

Legislative Materials:

146 Cong. Rec. H1849 (April 5, 2000)..... 6

Family Smoking Prevention & Tobacco Control Act: Hearing Before the
House Subcommittee on Health, Committee on Energy and Commerce,
110th Cong. 42 (2007). 15

Testimony of Richard Bonnie, Chair of IOM’s Committee on Reducing Tobacco Use
H.R. 1108. 15

Other Authorities:

Australia Department of Health and Ageing, *Fact Sheet: Graphic Health Warnings*,
at [http://www.quitnow.gov.au/internet/quitnow/publishing.nsf/
Content/fact-sheet-health-warnings](http://www.quitnow.gov.au/internet/quitnow/publishing.nsf/Content/fact-sheet-health-warnings). 11

Campaign for Tobacco-Free Kids, Press Release (May 8, 2003). 22

David Hammond, *Health Warnings Messages on Tobacco Products: A Review*,
20 Tobacco Control 327 (2011). 17, 33, 34

David Hammond, *et al.*, *Effectiveness of Cigarette Warning Labels in Informing
Smokers about the Risks of Smoking*, 15 Tobacco Control iii19 (2005). 17

Ellen Peters, *et al.*, *the Impact and Acceptability of Canadian-style Cigarette
Warning Labels Among U.S. Smokers and Nonsmokers*,
9 Nicotine & Tobacco Research 473 (Apr. 2007)..... 23

European Commission Directorate General For Health and Consumers,
Pictorial Health Warnings,
at http://ec.europa.eu/health/tobacco/law/pictorial/index_en.htm. 11

FDA, Experimental Study of Graphic Cigarette Warning Labels,
Final Results Report (Dec. 2010). 11, 34, 35, 50, 51

Health Canada, *Graphic Health Warnings*, [http://www.hc-sc.gc.ca/hc-ps/tobac-
tabac/legislation/label-etiquette/graph/index-eng.php](http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/legislation/label-etiquette/graph/index-eng.php). 11

*Institute of Medicine, *Ending the Tobacco Problem:
A Blueprint for the Nation* (2007). 6, 7, 15, 30

* Authorities chiefly relied upon are marked with an asterisk.

Karine Gallopel-Morvan *et al.*, *The Use of Visual Warnings in Social Marketing: The Case of Tobacco*, 64 J. Business Research 7 (2011)..... 17

Paul Slovic, *Cigarette Smokers: Rational Actors or Rational Fools?*, in SMOKING: RISK, PERCEPTION, & POLICY 97 (Paul Slovic ed., 2001)..... 7, 18

Physicians for a Smoke-Free Canada, *Canada’s Graphic Health Warnings*, <http://www.smoke-free.ca/warnings/canada-warnings.htm>..... 16

President’s Cancer Panel, *Promoting Healthy Lifestyles* (2007)..... 30, 42

R.J. Reynolds, *Guiding Principles and Beliefs*, available at www.rjrt.com/prinbeliefs.aspx..... 26

Robert A. Schnoll & Caryn Lerman, *Smoking Behavior and Smoking Cessation among Head and Neck Cancer Patients*, in HEAD AND NECK CANCER: EMERGING PERSPECTIVES 185 (John F. Ensley ed. 2003)..... 38

S. David Leonard, *et al.*, *Comprehension and Memory*, in WARNINGS AND RISK COMMUNICATION 149 (Michael S. Wogalter *et al.*, eds. 1999)..... 18

Steven Young & Michael Wogalter, *Comprehension and Memory of Instruction Manual Warnings: Conspicuous Print and Pictorial Icons*, 32(6) Human Factors 637 (1990)..... 18

Surgeon General, *Preventing Tobacco Use Among Young People* (1994)..... 14, 15

Tobacco Products Information Regulations, SOR/2000-272 (Can.) 55

W. Howard Levie & Richard Lentz, *Effects of Text Illustrations: A Review of Research*, 30 Educ. Comm. & Tech. J. 195 (1982). 19

Wendy A. Rogers, *et al.*, *Warning Research: An Integrative Perspective*, 42 Human Factors 102 (Spring 2000)..... 18

* Authorities chiefly relied upon are marked with an asterisk.

INTRODUCTION AND SUMMARY

1. The Family Smoking Prevention and Tobacco Control Act, Pub. L. No. 111-31, 123 Stat. 1776 (2009), empowers the Food and Drug Administration (“FDA”) to regulate the manufacture and sale of tobacco products, including cigarettes and smokeless tobacco. As relevant here, the Act revises the content and format of the health warnings that, for decades, have been required on cigarette packaging and advertising.

The Act specifies the text of nine health warnings, which include messages such as “Cigarettes are addictive,” “Cigarettes cause cancer,” “Tobacco smoke can harm your children,” and “Quitting smoking now greatly reduces serious risks to your health.” 15 U.S.C. § 1333 Note. The Act also specifies the format of the warnings, which will comprise the top 50% of the front and rear panels of cigarette packs and 20% of cigarette advertising. *Ibid.* In addition, Congress directed the Secretary of Health and Human Services to “issue regulations that require color graphics depicting the negative health consequences of smoking” to accompany the new warning statements. *Ibid.* Congress “informed its warning requirement by looking at the use of a nearly identical warning requirement in Canada,” which had proven significantly more effective in conveying the risks of smoking than the warnings used in the United States. *Commonwealth Brands, Inc. v. United States*, 678 F. Supp. 2d 512, 531 (W.D. Ky. 2010), *appeals pending sub nom. Discount Tobacco City & Lottery, Inc. v. United States*, Nos. 10-5234 & 10-5235 (6th Cir.).

Pursuant to Congress’s directive, FDA published for public comment 36 proposed images. *See* 75 Fed. Reg. 69,524, 69,534 (Nov. 12, 2010). In selecting the final set of nine images, FDA reviewed over a thousand public comments as well as the results of an 18,000-person consumer research study, and a wealth of other relevant scientific and academic material. *See* 76 Fed. Reg.

36,628, 36,629, 36,637 (June 22, 2011); *see also* Certified Index to the Administrative Record.¹ FDA explained that the final set of images is “generally consistent with the graphic health warnings used in other countries,” *id.* at 36,647, and “effectively communicates risk information to a diverse range of audiences,” including the adolescent population that has been “targeted by tobacco industry marketing efforts.” *Id.* at 36,636.

2. Plaintiffs acknowledge, as they must, that the warnings prescribed by Congress are accurate. Cigarettes *are* addictive, and they *do* kill smokers when used as intended, by causing cancer, fatal lung disease, strokes and heart disease. Secondhand smoke *does* kill family and friends. And it is not controversial that “[q]uitting smoking now greatly reduces serious risks to your health.”

Congress does not infringe on protected First Amendment interests when it requires accurate disclosures in marketing. As the Supreme Court explained in *Zauderer v. Office of Disciplinary Counsel of Supreme Court of Ohio*, 471 U.S. 626, 650 (1985), there are “material differences between disclosure requirements and outright prohibitions on speech.” Unlike restrictions on speech, warnings and other disclosure requirements do not prevent advertisers “from conveying information to the public”; they only require sellers to provide “more information than they might otherwise be inclined to present.” *Ibid.* Claims that disclosure requirements are so burdensome that they “chill[] protected commercial speech,” *id.* at 651, are reviewed under the framework established by *Central Hudson Gas & Electric Corp. v. Public Service Commission*, 447 U.S. 557 (1980), for restrictions on commercial speech. *See Zauderer*, 471 U.S. at 651 & n.14. The health warnings mandated by Congress easily survive scrutiny under any applicable standard.

¹ On October 19, we served on plaintiffs’ counsel the certified index to the administrative record, which is attached to this memorandum. As per Local Rule 7(n) of this Court, within 14 days of the final brief, we will file an appendix with the administrative materials which the parties have cited or on which they have relied. If the Court requires access to parts of the record not cited by the parties, we will submit them to the Court.

3. The plaintiff cigarette manufacturers can no longer directly dispute the adverse health consequences of smoking or the nature of nicotine addiction, as they did for decades in a massive scheme of fraud and deception. *See United States v. Philip Morris USA, Inc., et al.*, 566 F.3d 1095 (D.C. Cir. 2009), *cert. denied*, 130 S. Ct. 3501 (2010). They are, however, quite capable of ignoring those consequences, and ask this Court to do the same in considering the interests advanced by the health warnings, and the relationship between the warning format and the public health threats posed by plaintiffs' products. Plaintiffs' pleadings give no inkling "that tobacco use, particularly among children and adolescents, poses perhaps the single most significant threat to public health in the United States." *FDA v. Brown & Williamson Tobacco Corp.*, 529 U.S. 120, 161 (2000). They nowhere acknowledge the tenacity of nicotine addiction, even though the manufacturers have "engineered their products around creating and sustaining this addiction." *Philip Morris*, 566 F.3d at 1107. Their pleadings give no hint that the "overwhelming majority" of new victims of nicotine addiction begin using tobacco products "while they are minors and become addicted to the nicotine in those products before reaching the age of 18." Legislative Finding 31.² And no reader would discern from plaintiffs' submissions that the "[a]dvertising, marketing, and promotion of tobacco products have been especially directed to attract young persons to use tobacco products," Legislative Finding 15, and that "[t]he central purpose of the tobacco companies' image advertising is motivating adolescents to smoke." *United States v. Philip Morris USA, Inc., et al.*, 449 F. Supp. 2d 1, 572 (D.D.C. 2006).

Only by ignoring the findings of Congress, the courts, and countless public health officials, can plaintiffs discount the compelling governmental interest in communicating health risks to consumers and potential consumers of their product—including the underage and often

² The Legislative Findings are codified at 21 U.S.C. § 387, Note.

undereducated persons who constitute the bulk of their new clientele. And only by ignoring the record before Congress, and the overwhelming international consensus of public health officials, can plaintiffs attempt to claim that a text-only disclosure of the same size as the current Surgeon General warnings could communicate the health risks of smoking as effectively as the revised warnings prescribed by Congress.

Perhaps most notably, it is only by ignoring the addictive and lethal nature of their products that plaintiffs can with a straight face describe the disclosures mandated by Congress as “an ideological message” akin to the “compelled speech” involved in cases such as *Wooley v. Maynard*, 430 U.S. 705 (1977). Pl. S.J. Br. 24. Decisions such as *Wooley* reflect the core First Amendment principle that government shall not “prescribe what shall be orthodox in politics, nationalism, religion, or other matters of opinion or force citizens to confess by word or act their faith therein.” *Zauderer*, 471 U.S. at 651 (internal quotation marks omitted). Those decisions have no application here. That “smoking can kill you” is not an ideological message: it is a fact. There is no competing “ideology” maintaining that smoking does *not* account for more than 400,000 deaths each year.

4. Plaintiffs move seamlessly from decrying the burden of the disclosure requirements to insisting that the revised warnings would have no impact on smoking rates and thus serve no legitimate purpose. This relentlessly repeated refrain ignores two critical points. First, the purpose of the new disclosure format is to convey the health risks of smoking. Plaintiffs offer no basis whatsoever for disregarding Congress’s judgment that the revised health warnings communicate those risks more effectively than warnings without accompanying graphics, even as compared to text-only warnings that are far larger than the current Surgeon General warnings. The precise extent to which the enhanced communication of risks will ultimately reduce smoking rates is not a relevant metric in assessing plaintiffs’ constitutional claim. Second, plaintiffs’ contention fails on its own

terms. Contrary to plaintiffs' assertion, researchers have *not* concluded that the introduction of new warnings in Canada had no bearing on the subsequent decrease in Canadian smoking rates. Instead, researchers have recognized that the decline in Canadian smoking rates was influenced by a variety of regulatory measures and that it is difficult to make statistically significant determinations about the extent to which any single factor contributed to the decline.

STATEMENT

A. Background

Congress crafted the provisions of the Tobacco Control Act on the basis of evidence gathered over decades by all three branches of government regarding the health risks posed by cigarettes and the tobacco industry's marketing of those products. This background is crucial to understanding the nature and scope of the problems addressed by the new health warnings, the reasons that Congress required the new format, and why the revised warnings do not run afoul of the First Amendment.

First, when used as intended by the manufacturers, cigarettes are deadly. “[T]obacco use, particularly among children and adolescents, poses perhaps the single most significant threat to public health in the United States.” *Brown & Williamson*, 529 U.S. at 161. Smoking “is responsible for at least 443,000 premature deaths per year in the United States.” 76 Fed. Reg. at 36,630. It “kills more people each year in the United States than acquired immunodeficiency syndrome (AIDS), car accidents, alcohol, homicides, illegal drugs, suicides, and fires, combined.” *Brown & Williamson*, 529 U.S. at 134–35 (quoting 61 Fed. Reg. 44,396, 44,398 (Aug. 28, 1996)); *see also* 75 Fed. Reg. at 69,526 (same). Because cigarettes are inherently dangerous when used as intended by their manufacturers, they would be banned outright if they were subject to regulation as drugs under the Federal Food, Drug, and Cosmetic Act (“FDCA”), *see Brown & Williamson*, 529 U.S. at 136, and, in light of current knowledge, if cigarettes “were being introduced for the first time,” they

“would not be allowed to enter the marketplace.” Institute of Medicine, *Ending the Tobacco Problem: A Blueprint for the Nation*, at 152 (2007) (“IOM Report”) (discussed in H.R. Rep. No. 111-58(I) (2009)).

Second, “the magnitude of public health harm caused by cigarettes is inextricably linked” to nicotine addiction. 75 Fed. Reg. at 69,528. “The pharmacologic and behavioral processes that determine tobacco addiction are similar to those that determine addiction to drugs such as heroin and cocaine,” *ibid.*, and the force of nicotine addiction is illustrated by the failure rate of individual smoking cessation efforts. Data for 2004, for example, showed “that although approximately 40.5 percent of adult smokers reported attempting to quit in that year, only between 3 and 5 percent were successful.” *Id.* at 69,529.

The tobacco industry has long understood the importance of nicotine addiction to their sales. An internal R.J. Reynolds memo from 1972, quoted by Congressman Ganske in 2000, acknowledged: “In a sense, the tobacco industry may be thought of as being a specialized, highly ritualized and stylized segment of the pharmaceutical industry. Tobacco products uniquely contain and deliver nicotine, a potent drug with a variety of physiologic effects.” 146 Cong. Rec. H1849 (April 5, 2000).³ Plaintiffs’ own expert in *Commonwealth Brands* emphasized the tenacity of the addiction to nicotine, which, he explained, is the “substance in tobacco that inveterate smokers crave.” Rodu Decl. ¶ 40 (R. 72-2, No. 1:09-cv-117 (W.D. Ky.)). Tobacco companies “have designed their cigarettes to precisely control nicotine delivery levels and provide doses of nicotine sufficient to create and sustain addiction.” Legislative Finding 49.

Third, the tobacco industry has long depended on recruiting underage users who become

³ All citations to the Congressional Record are to the daily editions, and can be found at <http://www.gpoaccess.gov/crecord/>.

addicted by age 18. A 2008 study found that *each day*, nearly 4,000 Americans under the age of 18 experiment with cigarettes for the first time, and approximately 1,000 children become new daily smokers. 75 Fed. Reg. at 69,526–27. Congress found that—despite laws prohibiting the sale of tobacco products to minors—the “overwhelming majority of Americans who use tobacco products begin using such products while they are minors and become addicted to the nicotine in those products before reaching the age of 18.” Legislative Finding 31; *see also* 75 Fed. Reg. at 69,526 (“more than 80 percent of established adult smokers began smoking before age 18”); *Philip Morris*, 449 F. Supp. 2d at 562 (“over 80% of smokers start smoking before they turn eighteen”). According to a national survey of U.S. high-school students conducted in 2009, “almost half (46.3 percent) . . . had tried cigarette smoking, and an estimated 19.5 percent . . . were current cigarette smokers.” 75 Fed. Reg. at 69,526.

The adolescents who become the industry’s new customers systematically “misperceive the magnitude of smoking harms and the addictive properties of tobacco and fail to appreciate the long-term dangers of smoking, especially when they apply the dangers to their own behavior.” IOM Report at 93; *see also Philip Morris*, 449 F. Supp. 2d at 576–80. One survey showed that “fewer than 5 percent of daily smokers in high school think that they still will be smoking at all in 5 years, yet more than 60 percent of high school smokers are regular daily smokers 7 to 9 years later.” 76 Fed. Reg. at 36,633. Indeed, scientific research has shown that “adolescents begin to show evidence of nicotine dependence within *days to weeks* of the onset of occasional use of tobacco.” Paul Slovic, *Cigarette Smokers: Rational Actors or Rational Fools?*, in *SMOKING: RISK, PERCEPTION, & POLICY* 97, 109 (Paul Slovic ed., 2001) (emphasis added).

Tobacco companies have long known that they must reach potential customers while they are underage, and have targeted their marketing accordingly. Congress found that “[a]dvertising,

marketing, and promotion of tobacco products have been especially directed to attract young persons to use tobacco products, and these efforts have resulted in increased use of such products by youth.” Legislative Finding 15; *see also, e.g., Philip Morris*, 449 F. Supp. 2d at 572 (finding that “[t]he central purpose of the tobacco companies’ image advertising is motivating adolescents to smoke”).

Fourth, the tobacco industry has for decades misled customers and potential customers about the health risks and addictiveness of cigarettes. The tobacco companies’ “efforts to deny and distort the scientific evidence of smoking’s harms are demonstrated by not only decades of press releases, reports, booklets, newsletters, television and radio appearances, and scientific symposia and publications, but also by evidence of their concerted[] efforts to attack and undermine the studies in mainstream scientific publications such as the Reports of the Surgeon General.” *Philip Morris*, 449 F. Supp. 2d at 855. The D.C. Circuit expressly concluded, when it rejected the companies’ First Amendment defenses to racketeering liability, that the tobacco companies’ public statements were “clearly and deliberately false,” and that they “knew of their falsity at the time and made the statements with the intent to deceive.” *Philip Morris*, 566 F.3d at 1124. Indeed, the industry’s joint public relations representative admitted internally that the industry’s ““basic position in the cigarette controversy is subject to the charge, and may be subject to a finding, that we are making false or misleading statements to promote the sale of cigarettes.”” *Id.* at 1120 (citation omitted).

B. The Supreme Court’s *Brown & Williamson* Decision

FDA issued regulations in 1996 to regulate cigarettes and smokeless tobacco. 61 Fed. Reg. 44,396 (Aug. 28, 1996). The Supreme Court ultimately concluded that FDA generally lacked authority under the FDCA to promulgate those regulations, but the Court left no doubt as to the seriousness of the public health crisis that FDA had addressed. *Brown & Williamson*, 529 U.S. at 126. The Court emphasized that, “[i]n its rulemaking proceeding, the FDA quite exhaustively

documented that ‘tobacco products are unsafe,’ ‘dangerous,’ and ‘cause great pain and suffering from illness.’” *Id.* at 134 (quoting 61 Fed. Reg. at 44,412). The Court recognized that “tobacco use, particularly among children and adolescents, poses perhaps the single most significant threat to public health in the United States.” 529 U.S. at 161.

Indeed, the dangers of smoking were central to the Supreme Court’s reasoning. The Court concluded that *because* cigarettes are inherently dangerous when used as intended by their manufacturers, cigarettes would have to be banned outright if they were subject to regulation as drugs under the FDCA—a result that Congress had not authorized. *Id.* at 136; *see also id.* at 142 (“As the FDA has documented in great detail, cigarettes and smokeless tobacco are an unsafe means to obtaining *any* pharmacological effect.” (emphasis in original)).

The Court also noted FDA’s determination that a cigarette ban was not a practicable means to address the public health crisis caused by cigarettes, given “the high level of addiction” among smokers. *Id.* at 139. The Court did not question FDA’s conclusion that, if cigarettes were banned, “current tobacco users could suffer from extreme withdrawal, the health care system and available pharmaceuticals might not be able to meet the treatment demands of those suffering from withdrawal, and a black market offering cigarettes even more dangerous than those currently sold legally would likely develop.” *Ibid.* (citing 61 Fed. Reg. at 44,413). The Court concluded, however, that the FDCA did not permit FDA to take such considerations into account. *See id.* at 139-142.

C. The Tobacco Control Act

Congress enacted the Tobacco Control Act in 2009 to fill the regulatory void left by *Brown & Williamson*. As relevant here, the Act updated, for the first time since 1984, the health warnings that must appear by federal law on cigarette packaging and advertising, to ensure that cigarette manufacturers effectively inform smokers and potential smokers of the health risks and

addictiveness of cigarettes. 15 U.S.C. § 1333 Note. The Act provides that product labels and advertisements for cigarettes must bear one of several prominent warning statements describing the adverse health effects of smoking, including statements regarding addictiveness and the impact on smokers and nonsmokers. *Ibid.* The required statements are:

- WARNING: Cigarettes are addictive.
- WARNING: Tobacco smoke can harm your children.
- WARNING: Cigarettes cause fatal lung disease.
- WARNING: Cigarettes cause cancer.
- WARNING: Cigarettes cause strokes and heart disease.
- WARNING: Smoking during pregnancy can harm your baby.
- WARNING: Smoking can kill you.
- WARNING: Tobacco smoke causes fatal lung disease in nonsmokers.
- WARNING: Quitting smoking now greatly reduces serious risks to your health.

Ibid.

The Act also revised the format of the warnings, by providing that they must comprise the top 50% of the front and rear panels of cigarette packs and 20% of cigarette advertising. *Ibid.* In addition, Congress directed the Secretary to promulgate regulations “that require color graphics depicting the negative health consequences of smoking to accompany” the text of these nine warnings. *Ibid.*

D. FDA’s Implementing Rule

Pursuant to that statutory directive, FDA published for comment a total of 36 proposed images to accompany the textual warnings. *See* 75 Fed. Reg. at 69,534. In developing the proposed images, FDA drew upon the advice of “various experts in the fields of health communications, marketing research, graphic design and advertising,” a substantial body of scientific literature analyzing the effectiveness of such warnings, and the experience of the more than thirty countries and jurisdictions that have, since 2001, implemented pictorial health warnings on cigarette packages. *Id.* at 69,525, 69,534.

In selecting the final nine images, FDA reviewed well over a thousand public comments, including joint comments submitted by plaintiffs R.J. Reynolds (“Reynolds”), Lorillard, and Commonwealth Brands. *See* 76 Fed. Reg. at 36,629. FDA also reviewed the results of an 18,000-person consumer study that tested the relative effectiveness of the 36 proposed images in communicating the information in the text. *See* FDA, Experimental Study of Graphic Cigarette Warning Labels, Final Results Report (Dec. 2010) (hereinafter “FDA Study Report”). FDA emphasized “the importance of selecting a set of required warnings that includes a diversity of styles (*e.g.*, photographic versus illustrative), themes, and human images (*e.g.*, race, gender, age).” 76 Fed. Reg. at 36,636. That diversity is necessary to ensure that “the final set of required warnings effectively communicates risk information to a diverse range of audiences,” including audiences, like youth, that “have been targeted by tobacco industry marketing efforts.” *Ibid.*

The pictorial health warnings included in the final rule are, FDA explained, “generally consistent with the graphic health warnings used in other countries.” 76 Fed. Reg. at 36,647. For instance, in Canada, images similar to the ones selected by FDA have appeared on cigarette packs for more than a decade. *See* Health Canada, *Graphic Health Warnings*.⁴ Similar warnings have appeared on cigarette packs in Australia since 2006 and in the United Kingdom since 2008.⁵ *See also, e.g.*, European Commission Directorate General For Health and Consumers, *Pictorial Health Warnings*, at http://ec.europa.eu/health/tobacco/law/pictorial/index_en.htm.

When FDA evaluated the comments to the rulemaking, it specifically addressed contentions

⁴ <http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/legislation/label-etiquette/graph/index-eng.php>. The websites cited in this brief were last visited on October 10, 2011.

⁵ Australia Department of Health and Ageing, *Fact Sheet: Graphic Health Warnings*, at <http://www.quitnow.gov.au/internet/quitnow/publishing.nsf/Content/fact-sheet-health-warnings>; U.K. Health Department, *Picture Warnings on Tobacco Products*, at <http://www.dh.gov.uk/en/PublicHealth/Healthimprovement/Tobacco/Picturewarningsontobaccoproductspressimages/>.

that images provoke emotions rather than convey information. The agency noted, for example, that some comments had criticized various proposed images as “disturbing” or “eliciting emotions,” including the image “depicting a man smoking through a tracheostomy opening,” the image “depicting healthy lungs juxtaposed with lungs damaged by smoking,” the image “depicting a lesion consistent with that caused by oral cancer,” and the image “depicting a man with an autopsy scar.” 76 Fed. Reg. at 36,696. FDA explained that “[t]he comment did not assert, however, that the effects shown in the images are false, *i.e.*, that they are not manifestations of negative health consequences of smoking, such as throat, lung, and oral cancer, and death.” *Ibid.* The agency emphasized: “The fact that the images are disturbing or evoke emotion does not mean that they are not factual representations of the effects of smoking. . . . As such, it is not surprising that the warnings regarding the negative health consequences of smoking would evoke emotions such as fear of being stricken with life-threatening cancer or disgust at what it might be like to have that happen.” *Ibid.*

FDA explained that the emotional responses are germane because they predict the likelihood that viewers will notice and process the accompanying textual information. The agency stressed that “[t]he overall body of scientific evidence indicates that health warnings that evoke strong emotional responses enhance an individual’s ability to process the warning information, leading to increased knowledge and thoughts about the harms of cigarettes and the extent to which the individual could personally experience a smoking-related disease.” *Id.* at 36,641. The images selected “were designed to correlate with [the] warning statements,” and the “available evidence base highlights the value of the text and images in graphic health warnings relating to one another in a meaningful way.” *Id.* at 36,637 (citations omitted).

ARGUMENT

I. Warnings and Other Disclosure Requirements Are Subject To “Less Exacting Scrutiny” Than Restrictions On Commercial Speech.

The Supreme Court has long recognized that there are “material differences between disclosure requirements and outright prohibitions on speech.” *Zauderer*, 471 U.S. at 650. Warnings and other disclosure requirements do not prevent advertisers “from conveying information to the public”; instead, they require sellers to provide “more information than they might otherwise be inclined to present.” *Ibid.* Thus, the Supreme Court has explained, disclosure requirements are subject to “less exacting scrutiny” than restrictions on commercial speech. *Milavetz, Gallop & Milavetz, P.A. v. United States*, 130 S. Ct. 1324, 1339–40 (2010).

In general, mandated disclosures raise First Amendment concerns only when it is claimed that “unjustified or unduly burdensome disclosure requirements . . . [are] chilling protected commercial speech.” *Zauderer*, 471 U.S. at 651 & n.14. Such claims are evaluated under the framework established by *Central Hudson*, 447 U.S. 557, for review of restrictions on commercial speech. *See Zauderer*, 471 U.S. at 651. In applying those standards, a court upholds restrictions that directly advance a substantial government interest and are no more extensive than is necessary to serve that interest. *Central Hudson*, 447 U.S. at 566. That standard does not require the legislature to employ “the least restrictive means” of regulation or to achieve a perfect fit between means and ends. *Board of Trustees v. Fox*, 492 U.S. 469, 480 (1989). It is sufficient to achieve a “reasonable” fit by adopting regulations “in proportion to the interest served.” *Ibid.* (citation omitted).

When the Supreme Court described in *Zauderer* the standard of scrutiny that applies to disclosure requirements in the commercial speech context, it expressly distinguished its cases involving “compelled speech” in areas of core protected speech. The Court noted that, “to be sure,”

it has “held that in some instances compulsion to speak may be as violative of the First Amendment as prohibitions on speech.” *Zauderer*, 471 U.S. at 650 (citing *Wooley*, 430 U.S. 705; *Miami Herald Publishing Co. v. Tornillo*, 418 U.S. 241 (1974); and *West Virginia State Bd. of Ed. v. Barnette*, 319 U.S. 624 (1943)). The Court stressed, however, that “the interests at stake” in the commercial speech context “are not of the same order as those discussed in *Wooley*, *Tornillo*, and *Barnette*,” which involved attempts by the government to “prescribe what shall be orthodox in politics, nationalism, religion, or other matters of opinion or force citizens to confess by word or act their faith therein.” *Id.* at 651 (quotation marks and citation omitted). “Because the extension of First Amendment protection to commercial speech is justified principally by the value to consumers of the information such speech provides,” an advertiser’s “constitutionally protected interest in *not* providing any particular factual information in his advertising is minimal.” *Ibid.*

As we explain next, the health warnings mandated by Congress and implemented by the FDA readily satisfy the standards established by *Zauderer* and *Central Hudson*, and would even survive the strict scrutiny that plaintiffs (wrongly) insist is required.

II. Congress Mandated Health Warnings for Cigarettes in a Format that Accurately Conveys the Extraordinary Risks of Smoking and Violates No First Amendment Principle.

A. The Revised Warnings Substantially Advance the Government’s Overwhelming Interest in Informing Consumers About the Grave Dangers of Cigarette Smoking.

1. The Current Surgeon General Warnings Are Essentially “Invisible.”

Congress has required that cigarette packaging and advertising bear health warnings since 1965. Federal Cigarette Labeling and Advertising Act of 1965, Pub. L. No. 89-92, 79 Stat. 282 (1965). Prior to the 2009 legislation now at issue, the content and the format of the warnings had not been revised since 1984. Comprehensive Smoking Education Act of 1984, Pub. L. No. 98-474,

98 Stat. 2200 (1984). As early as 1994, however, the Surgeon General reported that empirical studies dealing “with the visibility of cigarette warnings in advertising . . . consistently indicate that the Surgeon General’s warnings are given little attention or consideration by viewers.” Surgeon General, *Preventing Tobacco Use Among Young People* 168 (1994).⁶ Evidence presented to Congress showed that the current warnings “fail to convey relevant information in an effective way,” IOM Report at 291, and are essentially “invisible.” Testimony of Richard Bonnie, Chair of IOM’s Committee on Reducing Tobacco Use, H.R. 1108, Family Smoking Prevention & Tobacco Control Act: Hearing Before the House Subcommittee on Health, Committee on Energy and Commerce, 110th Cong. 42 (2007).

In the intervening quarter century, regulators’ understanding of nicotine addiction and the health risks of smoking has increased dramatically. This enhanced understanding has resulted, in significant part, from the exposure of the tobacco industry’s concerted campaign to discredit public health officials and minimize consumer concerns about health risks and addiction. For decades, the industry sought to convince consumers that they might reasonably choose to smoke because sufficient doubt existed as to the risks of smoking and the nature of nicotine addiction. The D.C. Circuit explained in *Philip Morris* that “[e]vidence at trial revealed that at the same time Defendants were disseminating advertisements, publications, and public statements denying any adverse health effects of smoking and promoting their ‘open question’ strategy of sowing doubt, they internally

⁶ Although plaintiffs cite the Surgeon General’s 1994 report in support of their claim that the revised warnings are unnecessary, Pl. S.J. Br. 15, that report, in fact, concluded that studies dealing “with the visibility of cigarette warnings in advertising . . . consistently indicate that the Surgeon General’s warnings are given little attention or consideration by viewers.” Surgeon General, *Preventing Tobacco Use, supra*, at 168. The report also noted that a “comprehensive review of studies on health risk awareness” conducted by the Federal Trade Commission found that “significant numbers of consumers and still higher numbers of smokers were unaware of even the most rudimentary risk information about smoking,” which led the FTC to “call for a larger and more attention-demanding format.” *Id.* at 169.

acknowledged as fact that smoking causes disease and other health hazards.” 566 F.3d at 1106.

Based on this fuller understanding of health risks, nicotine addiction, and consumption patterns, an international consensus has developed regarding the minimum requirements for warnings that will effectively convey the health risks of smoking. These standards are reflected in the World Health Organization’s Framework Convention on Tobacco Control and include “warnings that are rotating, ‘large, clear, visible and legible,’” that “occupy 50 percent or more of the principal display areas,” and “may be in the form of or include pictures or pictograms.” 75 Fed. Reg. at 69,525 (citation omitted). “Worldwide, over 30 countries/jurisdictions have implemented pictorial warnings on tobacco packages and requirements for pictorial warnings are pending in several other countries/jurisdictions.” *Ibid.*

2. Evidence Before Congress and the FDA Establishes that the Warnings Mandated by Congress Convey the Health Risks of Smoking More Effectively than Text-Only Warnings of Any Size.

In formulating the new health warnings, Congress and the FDA looked, in particular, to the Canadian disclosure requirements that went into effect in 2000. *See Commonwealth Brands*, 678 F. Supp. 2d at 531 (Congress “informed its warning requirement by looking at the use of a nearly identical warning requirement in Canada”). Like the warnings mandated by Congress, those warnings comprised the top 50% of the front and rear panels of cigarette packs and included color graphics depicting the negative health consequences of smoking. *See Physicians for a Smoke-Free Canada, Canada’s Graphic Health Warnings*.⁷

The evidence before Congress and the FDA amply demonstrated that this size and placement attract and retain consumer attention far more effectively than the current Surgeon General warnings, particularly when the textual message is combined with accompanying pictures. One

⁷ <http://www.smoke-free.ca/warnings/canada-warnings.htm>.

study showed that whereas “83 percent of Canadian students mentioned health warnings in a recall test of cigarette packages,’ only ‘7 percent of U.S. students’ did the same.” *Commonwealth Brands*, 678 F. Supp. 2d at 531 (citation omitted). In another study, when “U.S. college students were shown images of the Canadian cigarette warnings and the current warnings appearing on cigarette packs sold in the United States . . . the Canadian graphic warnings significantly increased aided recall of the warnings, increased depth of message processing, and increased the perceived strength of the message.” 75 Fed. Reg. at 69,531. These findings are consistent with focus group research in which young adults in the United States “reported that the Canadian warnings were more visible and more informative than the warnings appearing on cigarette packages in the United States.” *Ibid.*

Recent research confirms that cigarette warnings that combine images and text are more effective than text alone in conveying the risks identified in the text. For instance, from 1995 to 2005, Australia required cigarette manufacturers to display large, text-only warnings that covered the top 25% of the front of the pack. David Hammond, *et al.*, *Effectiveness of Cigarette Warning Labels in Informing Smokers about the Risks of Smoking*, 15 *Tobacco Control* iii19, iii20 (2005). After Australia introduced larger pictorial warnings in 2006, a longitudinal study of youth “found that students were more likely to read, attend to, think about, and talk about health warnings after the pictorial warnings were implemented.” David Hammond, *Health Warnings Messages on Tobacco Products: A Review*, 20 *Tobacco Control* 327, 330 (2011) (discussing 2008 study); *see also* Karine Gallopel-Morvan, *et al.*, *The Use of Visual Warnings in Social Marketing: The Case of Tobacco*, 64 *J. Business Research* 7, 7 (2011) (study comparing the EU’s large text-only warnings to its new pictorial warnings concluded that the results “clearly demonstrate[] that visual messages, as opposed to text warnings, are more effective”). Research also “suggests that larger pictorial warnings sustain their effects longer” than text-only counterparts. *See* 20 *Tobacco Control* at 333.

These results should not be surprising. It is axiomatic in cognitive psychology that “pictures are easier to remember than words.” S. David Leonard, *et al.*, *Comprehension and Memory*, in WARNINGS AND RISK COMMUNICATION 149, 158 (Michael S. Wogalter *et al.*, eds. 1999). The brain has distinct coding systems for words and for images, and information in the “image” memory system is more likely to be retained and is more easily retrieved. *Ibid.* This is particularly the case for words “representing abstract concepts.” *Ibid.* Information that is coded in both systems is particularly easy to remember “because theoretically more ‘paths’ are created in memory, making the information more accessible (more likely to be cued) at later times.” *Ibid.* Thus, even apart from tobacco-specific research, studies have “found that pictorials in combination with conspicuous print facilitated recollection of warning contents,” and that “the enhanced memory was directly related to the fact that the warning was noticed in the first place.” Wendy A. Rogers, *et al.*, *Warning Research: An Integrative Perspective*, 42 *Human Factors* 102, 114 (Spring 2000); *see also, e.g.*, Steven Young & Michael Wogalter, *Comprehension and Memory of Instruction Manual Warnings: Conspicuous Print and Pictorial Icons*, 32(6) *Human Factors* 637, 646 (1990) (comparing the relative effectiveness of instruction-manual warnings with and without pictorials, and finding that “warnings that have both conspicuous print and illustrative pictorial icons enhance comprehension and memory of the warnings’ message content”).

Conveying information in cigarette warnings poses special difficulties that make using images particularly appropriate. First, although the health consequences of smoking are severe, they generally do not become manifest for many years. Because of that time lag, smokers—and adolescents in particular—tend to disregard or discount discomfoting factual information about the long-term consequences of using plaintiffs’ product. Dr. Paul Slovic has explained that “[a]lthough most smokers acknowledge a high degree of risk associated with many years of smoking, many

believe they can get away with some lesser amount of smoking before the risk takes hold.” Paul Slovic, *Cigarette Smokers: Rational Actors or Rational Fools?*, *supra*, at 109.

Dr. Slovic notes that “[m]any young smokers, in particular, believe that smoking for only a few years poses negligible risk,” and “are more prone to belief in this safety of short-term smoking than are young non-smokers.” *Ibid.* This failure to fully appreciate the risks of tobacco smoking is compounded by the powerful nature of nicotine addiction, which starts to take hold “within days to weeks of the onset of occasional use of tobacco.” *Ibid.*; *see also Philip Morris*, 449 F. Supp. 2d at 577 (citing Dr. Slovic’s testimony in finding that “[b]ecause the most serious harmful consequences of smoking are cumulative, and occur in the distant future, and because teenagers are focused on the present rather than the future and lack an understanding of the addictive properties of cigarettes, it is unlikely that the decisions by teenagers to initiate smoking are influenced by concerns about future harmful consequences”).

Second, new consumers, who are not already addicted, are primarily children and adolescents who “are particularly vulnerable to cigarette marketing because they are not capable of making a fully informed decision whether to start or continue smoking for a variety of reasons, including the fact that they underestimate personal risks and lack the judgment which can only be developed through experience.” *Philip Morris*, 449 F. Supp. 2d at 578. Including pictorial content is particularly important in conveying information to underage consumers and potential consumers. Summarizing the results of more than 50 youth studies, one review explained that “[i]llustrations can help learners understand what they read, can help learners remember what they read, and can perform a variety of other instructional functions.” *See* W. Howard Levie & Richard Lentz, *Effects of Text Illustrations: A Review of Research*, 30 *Educ. Comm. & Tech. J.* 195, 226 (1982).

Smoking rates are also closely correlated with education levels. FDA noted that “49.1

percent of adults with a General Education Development certificate (GED) and 28.5 percent of adults with less than a high school diploma were current smokers in 2009, compared with 5.6 percent of adults with a graduate degree,” and “that graphic health warnings may be particularly important communication tools for these smokers, as there is evidence suggesting that countries with graphic health warnings demonstrate fewer disparities in health knowledge across educational levels.” 76 Fed. Reg. at 36,630 (citations omitted); *see also Commonwealth Brands*, 678 F. Supp. 2d at 531 (“[G]raphical warnings ‘may be particularly important for communicating’ with consumers with low levels of education, given evidence that such smokers ‘are less likely to recall health information in text-based messages than people with more education.’”) (citation omitted).

Plaintiffs’ only response is to contend that images, by their nature, do not help to convey the content of the warnings. Accordingly, at the preliminary injunction hearing, plaintiffs’ counsel made clear that, in plaintiffs’ view, the only type of image that could constitutionally be included with the warning “Smoking is addictive” would be “some kind of graphic chart that shows how many people smoke [and] how many people are able to quit.” P.I. Hr’g Tr. 16 (9/21/2011). (Given that plaintiffs also maintain that the warnings cannot exceed the size of the current Surgeon General warnings, *see id.* 21, the proposed graph would convey as much information as a hieroglyph.)

This, of course, is not the type of warning required by Congress, and plaintiffs offer no basis for accepting their overarching position that all images considered by the FDA and, indeed, any remotely similar image, somehow violate the First Amendment.

3. The Required Health Warnings Do Not Impermissibly Burden Protected Commercial Speech.

Plaintiffs fail to demonstrate that the format required by Congress transforms the health warnings into “unjustified or unduly burdensome disclosure requirements [that] might offend the

First Amendment by chilling protected commercial speech.” *Zauderer*, 471 U.S. at 651. The warnings do not in any sense burden such speech because “[h]alf of cigarette packs” and “80% of advertisements remain available for their speech.” *Commonwealth Brands*, 678 F. Supp. 2d at 531.

Plaintiffs’ affiliated companies have operated under comparable warning requirements in Canada for more than a decade. Nevertheless, neither in this case, nor in *Commonwealth Brands*, where they presented the same claim, have plaintiffs offered any evidence that the format chilled their protected commercial speech. Indeed, the Canadian Supreme Court unanimously rejected a challenge analogous to the one asserted here, finding that “[t]he benefits flowing from the larger warnings are clear” while “[t]he detriments to the manufacturers’ expressive interest in creative packaging are small.” *Canada v. JTI-Macdonald Corp.*, [2007] 2 S.C.R. 610, 2007 SCC 30, ¶ 139 (rejecting freedom-of-expression claim under the Canadian Charter of Rights and Freedoms).

Plaintiffs’ contention that the government failed to consider less-speech-restrictive alternatives was considered and rejected by the district court in *Commonwealth Brands*. Notably, the primary support plaintiffs offer for their argument is a declaration that was filed in that case and then resubmitted to FDA during its current rulemaking. *See* Pl. S.J. Br. 29 (citing Reynolds Decl., filed as Exhibit D to Comment Letter). There, as here, plaintiffs argued that Congress should have considered alternatives to the health warnings, such as “requiring states to use CDC-recommended levels of tobacco revenues for tobacco control programs,” “increasing support for interventions that address the personal and social factors that influence tobacco use,” “preventing the unlawful retail sale of tobacco products to youth by, e.g., increasing the compliance rate required by the Synar Amendment, Pub. L. No. 102-321, § 1926,” and “increasing the price of tobacco products.” *Commonwealth Brands*, 678 F. Supp. 2d at 537 (internal quotation marks and brackets omitted); *compare* Pl. S.J. Br. 29.

But the district court in *Commonwealth Brands* correctly observed that “this is not a case where Congress went ‘straight to [plaintiffs’] speech,’” and emphasized that, rather, it is “a case where Congress, after decades of implementing various measures that did not affect Plaintiffs’ speech, decided to add label and advertising restrictions to its comprehensive regulation of the tobacco industry.” 678 F. Supp. 2d at 538. Indeed, the alternatives that plaintiffs offer are not new measures that the government has not yet considered, but instead are all “‘variations on strategies already adopted’”: Congress has already barred tobacco sales to persons under 18, provided civil penalties for retailer violations, directed the Secretary to implement a program to ensure compliance, and enacted a 62-cent increase in the federal excise tax on cigarettes. *Id.* at 537–38 (citations omitted).

Plaintiffs’ proposals would also “impose substantial new costs on state and local governments and private persons.” *Id.* at 537. Plaintiffs themselves have argued that cigarette tax increases can unfairly burden low-income users, encourage illicit purchases, and produce other adverse effects. *See, e.g.*, <http://www.nocigtax.com/why-cig-taxes-hurt-you/taxpayers> (Reynolds-sponsored website); Campaign for Tobacco-Free Kids, Press Release (May 8, 2003) (noting that “Lorillard’s ads, which are running in Delaware, New Jersey and Pennsylvania, argue that cigarette tax increases lead to increased crime and cigarette smuggling”).⁸ Plaintiffs’ other proposals would primarily punish states and retailers for taking inadequate measures to combat the evils of plaintiffs’ products, and minors for becoming addicted to plaintiffs’ product. *See id.* exh. D, Declaration of Cecil Reynolds ¶ 51 (recommending, among other things, measures to “[e]nhance the penalties for underage tobacco use and identify penalties that will be motivational and meaningful to the adolescents involved (*e.g.*, loss of driver’s license)”).

⁸ http://www.tobaccofreekids.org/press_releases/post/id_0639

In short, the congressionally mandated health warnings directly advance a substantial—indeed, compelling—interest in conveying to consumers generally, and adolescents in particular, the devastating consequences of smoking and nicotine addiction. The means chosen by Congress do not chill speech and are narrowly tailored to achieve effective communication. Indeed, “there is no more efficient method of reaching smokers than through the use of graphic and highly visible warning labels.” Ellen Peters, *et al.*, *the Impact and Acceptability of Canadian-style Cigarette Warning Labels Among U.S. Smokers and Nonsmokers*, 9 *Nicotine & Tobacco Research* 473, 479 (Apr. 2007). Thus, plaintiffs’ claim fails under any standard of review given the government interest at stake and the means adopted.

B. Plaintiffs’ First Amendment Contentions Are Without Merit.

Plaintiffs advance three principal contentions, all of which lack merit.⁹ First, they claim that the health warnings constitute impermissible “compelled speech” on the theory that they constitute an “ideological” message. Second, they argue that the warnings serve no purpose because all consumers are already fully aware of the consequences of smoking. Third, they argue that the warnings are impermissible in the absence of empirical proof demonstrating the extent to which larger pictorial warnings have caused the declines in smoking rates in Canada and other countries.

1. The Warnings Do Not Constitute an “Ideological Message.”

Plaintiffs seek to persuade the Court that the required health warnings are an impermissible attempt to require plaintiffs to espouse governmental “ideology.” In plaintiffs’ view, any expansion of the existing format converts the concededly accurate health warning into an ideological

⁹ Because the *Commonwealth Brands* litigation is still pending in the Sixth Circuit, we do not address the extent to which issue or claim preclusion would bar claims brought by Commonwealth Brands, Lorillard, and Reynolds, who are plaintiffs in that litigation, and Reynolds’ corporate affiliate Santa Fe. After the Sixth Circuit rules, we will address the issue as appropriate.

“Government[] anti-smoking message.” Pl. S.J. Br. 2. Thus, in their joint comments to FDA, plaintiffs Reynolds, Lorillard, and Commonwealth Brands argued that the agency should “order that the Tobacco Control Act’s new textual warnings be displayed in the same manner in which the Surgeon General’s warnings have been displayed for years”—that is, without Congress’s changes to the size and placement of the warnings, and without the congressionally required images that depict the negative health consequences of smoking. *See* Comment Letter 3–4.

In their comments, as in their pleadings, plaintiffs laid particular stress on the requirement that the warnings contain “color graphics depicting the negative health consequences of smoking.” 15 U.S.C. § 1333 Note. They urged that images do not “simply convey information intended to enable smokers to make informed decisions about whether to smoke cigarettes” but instead convey “the Government’s viewpoint that the risks associated with smoking cigarettes outweigh the pleasure that smokers derive from them and, therefore, that no one should use these lawful products.” Comment Letter 2. Plaintiffs thus declared that “the proposed warnings convey to smokers the Government’s view that they should change in a significant way how they lead their lives,” and argued that “[t]he viewpoint the Government proposes to be conveyed on the manufacturers’ packaging and advertising is thus every bit as ideological as the message at issue in *Wooley v. Maynard*, 430 U.S. 705 (1977): ‘Live Free or Die.’” *Ibid.* They asserted that, “[i]n effect, the message and viewpoint of FDA’s proposed graphic warnings is: ‘Live Smoke-Free or Die.’” *Ibid.*

Plaintiffs’ attempts to portray the warnings as an ideological message are particularly remarkable because this tactic parallels so closely the tobacco industry’s traditional strategy of characterizing the Surgeon General’s reports on health risks as government propaganda that

appealed to fear rather than to reason.¹⁰ Plaintiffs can no longer overtly question the accuracy of the crippling health consequences of smoking. Instead, they refer to the health warnings as an “ideology” as if they constituted statements of political viewpoint to be weighed against the competing claims of other “ideologies.”

There are no clashing ideologies at work here. The disclosures seek to effectively convey to individual consumers the undisputed facts that “tobacco use, particularly among children and adolescents, poses perhaps the single most significant threat to public health in the United States,” and that smoking “kills more people each year in the United States than acquired immunodeficiency syndrome (AIDS), car accidents, alcohol, homicides, illegal drugs, suicides, and fires, combined.” *Brown & Williamson*, 529 U.S. at 134–35, 161 (internal quotation marks omitted). As discussed in detail below, each of the images chosen by FDA accurately enhances the communication of an entirely noncontroversial disclosure about the risks of smoking.

Plaintiffs’ mistaken attempt to transform accurate warnings into an ideological message is epitomized by their repeated assertion that the FDA Commissioner acknowledged that “the warnings are intended to ensure that ‘every single pack of cigarettes in our country will in effect become a mini-billboard’ for the Government’s anti-smoking message.” Pl. S.J. Br. 2. What the Commissioner actually said is that the warnings are intended to ensure that “every single pack of cigarettes in our country will in effect become a mini-billboard that *will tell the truth about*

¹⁰ Thus the tobacco industry once proclaimed that “opponents of cigarettes are endeavoring to scare pregnant women with such statements as that of the Surgeon General that ‘we are losing babies because of mothers’ smoking.’” *Philip Morris*, 449 F. Supp. 2d at 194. And it responded to the 1988 Surgeon General report by declaring that “CLAIMS THAT CIGARETTES ARE ADDICTIVE IRRESPONSIBLE AND SCARE TACTICS.” *Id.* at 283.

smoking.”¹¹ (Emphasis added.) Plaintiffs have identified no respect in which the warnings do *not* “tell the truth about smoking.”

Indeed, plaintiffs have recognized in a variety of other forums that an “anti-smoking message” has long ceased to be controversial, and it cannot plausibly be characterized as an “ideology.” Plaintiffs not only publicly recognize the risks associated with their own product but further declare that, in light of those undisputed risks, consumers should not begin to smoke or should cease smoking. Santa Fe Natural Tobacco Company offers this message to nonsmokers: “[W]e cannot stress this enough: If you don’t smoke, don’t start.” <http://www.sfntc.com>. Elsewhere on their web site the company asserts: “[W]e never encourage non-smokers to start, or existing smokers to smoke more.” <http://www.sfntc.com/Quit-Smoking/Overview.aspx>. The website provides links to twenty cessation resources and wishes smokers “the best of luck” in trying to quit. *Ibid.* Lorillard’s website states that “[t]he only way to avoid the health effects of cigarette smoking is to not smoke. The best way to reduce the health effects of cigarette smoking is to quit, and quitting smoking greatly reduces serious risks to health.” <http://www.lorillard.com/?s=quit+smoking>. And, in a recent submission to FDA, Reynolds acknowledged that “it is indisputable that quitting is the only safe alternative to using any tobacco product.” R.J. Reynolds, Citizen Petition 4, Docket No. FDA-2011-P-0573 (Jul. 8, 2011); *see also* R.J. Reynolds, *Guiding Principles and Beliefs*, available at www.rjrt.com/prinbeliefs.aspx (“The best course of action for tobacco consumers concerned about their health is to quit.”). Plaintiffs’ expert in *Commonwealth Brands* explained that it is uncontested that persons seeking to avoid the deadly consequences of smoking should not consume cigarettes. Rodu Decl. ¶ 30 (R. 72-2, No. 1:09-cv-117 (W.D. Ky.)); *see also*

¹¹ <http://www.fda.gov/TobaccoProducts/NewsEvents/ucm232556.htm> (audio, minute 21:24) (quoted at Pl. S.J. Br. 2, 16).

Nat'l Citizens Comm. for Broad. v. FCC, 567 F.2d 1095, 1100 n.13 (D.C. Cir. 1977) (citing with approval *Larus & Brother Co. v. FCC*, 447 F.2d 876, 880 (4th Cir. 1971), for upholding the FCC's determination that the broadcast of "anti-smoking messages" did not trigger an obligation under the fairness doctrine to broadcast views advocating smoking "because the issue is no longer a matter of public controversy").

Plaintiffs also assert that the health warnings convey "the Government's viewpoint that the risks associated with smoking cigarettes outweigh the pleasure that smokers derive from them." Comment Letter 2. In doing so, they resurrect the thoroughly discredited claim that consumers continue to smoke for pleasure after rationally weighing their immediate enjoyment against the prospect of lung and heart disease. But plaintiffs have understood for decades that they retain their customers *not* because of their pleasure in smoking, but because smokers must satisfy their need for nicotine, which, plaintiffs' expert explained in *Commonwealth Brands*, is the "substance in tobacco that inveterate smokers crave." Rodu Decl. ¶ 40 (R. 72-2, No. 1:09-cv-117 (W.D. Ky.)). Thus, in the single year of 2004, "approximately 40.5 percent of adult smokers attempted to quit, [but] only between 3 and 5 percent were successful." 75 Fed. Reg. at 69,529. Indeed, as long ago as 1985, Philip Morris's top management was informed that research showed that "the majority of smokers wished they did not smoke." *Philip Morris*, 566 F.3d at 1128 (quotation marks omitted).

Even if an "anti-smoking message" were not so clearly noncontroversial, cases such as *Wooley* would have no bearing on the analysis here. As the Supreme Court in *Zauderer* explained, *Wooley* stands for the proposition that the government may not "prescribe what shall be orthodox in politics, nationalism, religion, or other matters of opinion or force citizens to confess by word or act their faith therein." *Zauderer*, 471 U.S. at 651 (citation and internal quotation marks omitted). In contrast, "[b]ecause the extension of First Amendment protection to commercial speech is

justified principally by the value to consumers of the information such speech provides, [the seller's] constitutionally protected interest in *not* providing any particular factual information in his advertising is minimal.” *Ibid.*

Appellate decisions cited by plaintiffs distinguish between factual disclosures (which are reviewed under the relaxed standard of *Zauderer*) and “subjective” or “opinion-based” disclosures. In *Entertainment Software Ass’n v. Blagojevich*, 469 F.3d 641 (7th Cir. 2006), for example, the Seventh Circuit invalidated a law that required video game manufacturers to place a warning label on games deemed to be “sexually explicit.” *Id.* at 651–52. The label was to be applied only to games “that the average person, applying contemporary community standards would find, with respect to minors, is designed to appeal or pander to the prurient interest.” *Id.* at 643. That definition incorporated “widely divergent local standards” of offensiveness, *id.* at 650, making it “subjective and highly controversial” and therefore subject to strict scrutiny, *id.* at 652.

The Seventh Circuit, *id.* at 651–52, distinguished these subjective warnings from the Vermont statute upheld by the Second Circuit in *National Electrical Manufacturers Ass’n v. Sorrell*, 272 F.3d 104, 107 (2d Cir. 2001), which required manufacturers to label products containing mercury and to inform consumers that these products should be recycled or disposed of as hazardous waste. The Second Circuit applied the *Zauderer* standard, noting that “the compelled disclosure at issue . . . was not intended to prevent ‘consumer confusion or deception’ per se, but rather to better inform consumers about the products they purchase.” *Id.* at 115 (citations omitted). The court stressed that requiring “commercial actors [to] disclose commercial information ordinarily does not offend the important utilitarian and individual liberty interests that lie at the heart of the First Amendment,” and that such requirements will withstand judicial scrutiny as long as there is “a rational connection between the purpose of a commercial disclosure requirement and the means

employed to realize that purpose.” *Id.* at 114–15 (citing *Zauderer*, 471 U.S. at 651).¹²

2. The Health Warnings Convey Risks of Addiction and Smoking that Are Not Adequately Appreciated by Consumers Generally and Adolescents in Particular.

The second prong of plaintiffs’ argument is their insistence that no valid purpose can be served by changing the format of the current warnings because “Americans, young and old alike, are well aware of the health risks of smoking.” Pl. S.J. Br. 14. In this vein they assert that “the health risks of smoking have already been ‘disseminated to and absorbed by an overwhelmingly high percentage of the population’ through the familiar Surgeon General’s warnings and numerous other means.” *Ibid.* (citation omitted).

Such claims are particularly ironic in light of the tobacco industry’s fifty-year enterprise to deceive the American public about the dangers and addictiveness of smoking and to discredit the Surgeon General’s reports of health risks. *Philip Morris*, 566 F.3d 1095. Their arguments about the dissemination of the message of the adverse health consequences of smoking and the consequent lack of need for any further warnings were decisively rejected by the district court in *Philip Morris* and are no more convincing here.

Plaintiffs’ arguments ignore judicial findings and the vast literature regarding perception of the health risks associated with smoking, and rely, instead, on the declaration of their expert, Dr. W.

¹² Plaintiffs’ reliance on *Brown v. Entertainment Merchants Ass’n*, 131 S. Ct. 2729 (2011), is likewise misplaced. *See* Pl. S.J. Br. 28. The Court in that case considered the validity of a law that prohibited the sale or rental of violent video games to minors. As a content-based restriction on protected speech, the Court subjected the law to strict scrutiny, and concluded that it was not narrowly tailored. 131 S. Ct. at 2738. As already explained, the disclosure requirements here at issue are not subject to strict scrutiny. Just as they have nothing in common with the compelled ideological speech at issue in *Wooley*, they are readily distinguishable from the restrictions on access to video games addressed in *Brown*. Nor do plaintiffs advance their argument by relying on *Pacific Gas & Electric Co. v. Public Utilities Commission*, 475 U.S. 1, 8–9 (1986), where the Supreme Court specifically held that the speech at issue was *not* commercial speech.

Kip Viscusi, who admitted at trial in *Philip Morris* that his research was commissioned by tobacco industry law firms for use in litigation. Trial Tr. vol. 88, 17930 (Apr. 6, 2005) (filed as R. 98-1 at A16, *Commonwealth Brands*, No. 1:09-cv-117 (W.D. Ky.)). Myriad independent studies contradict Dr. Viscusi's position. The Institute of Medicine explained in 2007 that "adolescents misperceive the magnitude of smoking harms and the addictive properties of tobacco and fail to appreciate the long-term dangers of smoking, especially when they apply the dangers to their own behavior." IOM Report at 93. Although adolescents overestimate certain risks, such as the statistical risk of lung cancer, they underestimate the degree to which smoking can shorten life and the likelihood that they will suffer tobacco-related disease. *Id.* at 89-90. Both adolescent and adult smokers were more than twice as likely as nonsmokers to doubt that tobacco use, even for a period of 30 to 40 years, would cause death. *Id.* at 90. Adolescents fail to recognize that smoking causes more deaths than gunshots, car accidents, alcohol, and the use of other drugs. *Ibid.* And they "typically underestimate the tenacity of nicotine addiction and overestimate their ability to stop smoking when they choose." President's Cancer Panel, *Promoting Healthy Lifestyles*, at 64 (2007).

Dr. Viscusi disregards this body of investigation, and his limited discussion of scientific studies is inaccurate. For example, Dr. Viscusi invokes the research of Drs. Weinstein and Slovic to support his claim that "young people overestimate the dangers of smoking to an even greater degree [than adult smokers]." Comment Letter exh. A, Statement of W. Kip Viscusi ("Viscusi Statement"), at 28. Drs. Weinstein and Slovic were experts for the government in *United States v. Philip Morris*, and what they actually found is that "most people have only a superficial awareness that smoking is dangerous," 449 F. Supp. 2d at 578 (citing Slovic); "individuals have little knowledge of the reality of the pain, suffering, and despair of those with lung cancer, emphysema, congestive heart failure, and other smoking related diseases," *ibid.* (citing Weinstein & Slovic);

“[m]ore than 70% of adults and 80% of adolescents overestimated the likelihood that lung cancer is curable,” *ibid.* (citing Weinstein & Slovic); “adolescents not only underestimate the harm that results from smoking cigarettes, but are overly optimistic about their ability to quit smoking,” *ibid.* (citing Weinstein); and “[m]ost smokers only begin to think of risk after they have started to smoke regularly and have already become addicted,” *id.* at 576 (citing Slovic). Summarizing, the *Philip Morris* court explained that “the research and expert testimony demonstrate that most youth, at a time when they are deciding whether to start smoking, have a very inadequate understanding of the medical consequences, physical pain, and emotional suffering which results from smoking and the unlikelihood of their being able to quit smoking at some future time.” *Id.* at 579–80. Plaintiffs would have the Court ignore these well-established facts.

3. The Constitutionality of the Required Warnings Does Not Require a Statistical Determination Regarding the Extent to Which the Decline in Smoking Rates in Canada Should Be Attributed to the Introduction of New Health Warnings There.

To bolster their contention that the revised health warnings do not advance the government’s public health interests, plaintiffs argue that the warnings will “have no material impact” on smoking rates. *See* Pl. S.J. Br. 7; *see also id.* at 39 (urging that the administrative record is “devoid of evidence” that the rule will “convinc[e] smokers [to] reduce their smoking, make an attempt to quit, or quit altogether” (internal quotation marks and citation omitted)).

This argument reflects plaintiffs fundamental misunderstanding of the nature and purpose of the warnings. As mandated by Congress, the purpose of the warnings is “to effectively convey the negative health consequences of smoking on cigarette packages and in advertisements.” 76 Fed. Reg. at 36,697; *see also Commonwealth Brands*, 678 F. Supp. 2d at 530 (“[T]he government’s goal is . . . to ensure that the health risk message is actually *seen* by consumers in the first instance.”). Congress concluded, and the FDA affirmed, that the revised warning format *does* more effectively

convey information about health risks to consumers and potential consumers than text-only warnings. Plaintiffs' focus on smoking rates, rather than the conveyance of information, misapprehends relevant constitutional concerns. *See generally Nat'l Elec. Mfrs. Ass'n*, 272 F.3d at 115 (upholding requirement that products containing mercury be labeled with a recommendation that they be recycled or disposed of as hazardous waste, without requiring any showing by the state that the disclosure actually caused consumers to recycle or dispose of the labeled products in the suggested manner, because it is sufficient for First Amendment purposes that the compelled disclosure "better inform[s] consumers about the products they purchase").

In any event, the evidence does *not* indicate that the format required by Congress will have no material impact on smoking rates. Both the World Health Organization and the Institute of Medicine, after examining the full body of scientific research on graphic warnings, concluded that such warnings would reduce smoking rates. 75 Fed. Reg. at 69,531 (discussing Institute of Medicine report concluding that "larger, graphic health warnings would promote greater public knowledge of the health risks of using tobacco and would help reduce consumption"); *ibid.* (discussing WHO report finding that "taken as a whole, the research on graphic health warnings show that they are . . . associated with increased motivation to quit"). Other studies reinforce that conclusion. For example, in one Canadian study, twenty-six percent of smokers who quit after the introduction of graphic warnings reported that the "graphic warnings on cigarette packages helped them remain abstinent." *Id.* at 69,532.

A survey of Australian youth found that "adolescents who were experimenting with smoking or were established smokers indicated that they thought more about forgoing cigarettes after graphic warnings appeared on cigarette packages in 2006." *Ibid.* Summarizing the results of fifteen studies, a more recent review concluded that "significant proportions of adult and youth smokers report that

large text and pictorial health warnings have reduced their consumption levels, increased their likelihood of quitting, increased their motivation to quit and increased the likelihood of remaining abstinent following a quit attempt.” David Hammond, *Health Warnings Messages On Tobacco Products: A Review*, 20 *Tobacco Control* 327, 331 (2011).

Several studies also demonstrated that the introduction of graphic warnings prevented smokers from smoking as much as they normally would, and made smokers abstain from exposing others to secondhand smoke. 75 Fed. Reg. at 69,534. A survey of Canadian smokers indicated that “21 percent of smokers reported that on one or more occasions they chose not to smoke a cigarette due to the warnings on cigarette packages,” and that “27 percent of participants reported that the then-new graphic warnings motivated them to smoke less inside their homes.” *Id.* at 69,532. Another study of young Canadian smokers found that “22.6 percent of current male smokers and 26.6 percent of current female smokers reported that in the past month, noticing the warning on cigarette packages led them to decide not to have a cigarette.” *Ibid.*

As discussed in greater detail below, the FDA did not, as plaintiffs claim, conclude that the new format would have no impact on smoking rates. *See infra* 46–49. FDA noted, after the introduction of graphic warnings in Canada, that smoking rates in that country dropped steeply. 76 Fed. Reg. at 36,710 (explaining that “Canada’s smoking rate has decreased by around seven percentage points . . . since the implementation of graphic warning labels”). FDA’s regulatory impact analysis concluded only that it could not determine in a statistically significant way the extent to which the decline in Canadian smoking rates was attributable to the introduction of new warnings as opposed to other measures. FDA’s lack of certainty as to the causes of the drop in Canadian smoking rates cannot properly be understood as an admission that the warnings here will not reduce smoking rates.

Similarly, Dr. David Hammond recently concluded that, as compared to text-only warnings, “pictorial warnings are more likely to be noticed and read by smokers, [and] are associated with stronger beliefs about the health risks of smoking, as well as increased motivation to quit smoking.” Hammond, 20 Tobacco Control at 330. Plaintiffs nevertheless cite the same publication to insist that Dr. Hammond believes that pictorial warnings are ineffective. *See* P.I. Reply 11 n.12; P.I. Hr’g Tr. 73, 76–77. In the passage quoted by plaintiffs, Dr. Hammond notes the difficulties inherent in determining the extent to which pictorial warnings accounted for the documented decline in Canadian smoking rates following their introduction, noting that the decline may also have been influenced by other public health measures. *See* 20 Tobacco Control at 331.

III. FDA Adopted Images to Accompany the Text of the Health Warnings that Accurately Convey the Extraordinary Risks of Smoking Consistent with the First Amendment and the APA.

A. The Images Selected By FDA Raise No First Amendment Concerns.

1. FDA Properly Considered the “Salience” of the Proposed Warnings, *i.e.*, the Extent to Which Consumers Will Notice and Process the Warnings Over Time.

As discussed in Part II, plaintiffs assert that Congress could not, consistent with the First Amendment, require inclusion of images depicting the negative consequences of smoking of the kind already mandated in Canada, Australia, Great Britain and approximately 30 other countries. Thus, in plaintiffs’ view, *none* of the 36 images considered by the FDA in its rulemaking would pass constitutional muster. The only acceptable form of image in plaintiffs’ view is a graph. P.I. Hr’g Tr. 16. As we have demonstrated, no principle of First Amendment law precludes Congress from requiring images to accompany the text of the health warnings.

Plaintiffs’ challenge to the images selected by FDA to accompany the text of the nine warnings is likewise flawed. In selecting the nine images, FDA reviewed extensive scientific

literature, the experience of other countries, and over a thousand comments. *See* 76 Fed. Reg. at 36,629. FDA also conducted a study to measure consumer responses to the 36 warnings submitted for comment in the proposed rulemaking. That study divided 18,000 participants into three study groups: adult smokers (age 25 or older), young adult smokers (aged 18 to 24), and youth (aged 13 to 17) who currently smoke or who are susceptible to smoking. *Id.* at 36,637. The study randomly exposed study participants to a cigarette package or an advertisement containing one of the prospective warnings proposed by FDA or a control set of text-only warnings. FDA Study Report at 1-3; 4-1. The study then asked each participant to answer a series of questions about the warning. *Id.* at 1-3. These questions were designed to elicit participants' immediate reactions to the warnings. These "salience" measures include cognitive responses (*e.g.*, belief that the warnings were, for instance, informative, meaningful, or difficult to look at) and emotional responses (*e.g.*, worry, disgust, etc.). *Id.* app. A, at A-3.

FDA recognized, based on the substantial body of scientific literature discussed above, that such cognitive and emotional responses reliably predict the likelihood that consumers would understand and appreciate the warnings' messages. *Id.* at 4-1. The study also attempted to assess whether the warnings would enhance recall of the warning statement, change the self-reported beliefs about the health risks of smoking, or impact the participants' intentions to quit or initiate smoking. *Id.* at 1-3; 76 Fed. Reg. at 36,638; *see infra* 37–44 (discussing study results).

Plaintiffs fundamentally misunderstand "salience," which they characterize as "a euphemism for shock value." P.I. Hr'g Tr. 12. FDA repeatedly explained that the "emotional" reactions of consumers are germane because they predict the likelihood that viewers will notice and process the information contained in the text. *See* FDA Study Report at 1-2, 4-1 (citing studies); 76 Fed. Reg. at 36,639 (same). The agency explained that "[t]he overall body of scientific evidence indicates that

health warnings that evoke strong emotional responses enhance an individual's ability to process the warning information, leading to increased knowledge and thoughts about the harms of cigarettes and the extent to which the individual could personally experience a smoking-related disease." *Id.* at 36,641. The images selected "were designed to correlate with [the] warning statements," and the "available evidence base highlights the value of the text and images in graphic health warnings relating to one another in a meaningful way." *Id.* at 36,637 (citations omitted).

FDA noted that some comments criticized specific images as "disturbing" or "eliciting emotions." *Id.* at 36,696. These included the image "depicting a man smoking through a tracheostomy opening," the image "depicting healthy lungs juxtaposed with lungs damaged by smoking," the image "depicting a lesion consistent with that caused by oral cancer," and the image "depicting a man with an autopsy scar." *Ibid.* The comments "did *not* assert, however, that the effects shown in the images are false, *i.e.*, that they are not manifestations of negative health consequences of smoking, such as throat, lung, and oral cancer, and death." *Ibid.* (emphasis added). The agency emphasized: "The fact that the images are disturbing or evoke emotion does not mean that they are not factual representations of the effects of smoking. . . . As such, it is not surprising that the warnings regarding the negative health consequences of smoking would evoke emotions such as fear of being stricken with life-threatening cancer or disgust at what it might be like to have that happen." *Ibid.* The images do not, as plaintiffs claim, "exaggerate the effects of sickness and disease." Pl. S.J. Br. 21. FDA explained that, although "some of the photographs were technologically modified to depict the negative health consequences of smoking, the effects shown in the photographs are, in fact, accurate depictions of the effects of sickness and disease caused by smoking, and the comments did not dispute this fact." 76 Fed. Reg. at 36,696.

Ultimately, plaintiffs' objection is not that these images are false but that they are *true*: they

accurately communicate that smoking causes disease and death. As we have already discussed, *see supra* 23–29, plaintiffs’ attempt to characterize these warnings a controversial, ideological “anti-smoking message” is without basis.

2. Plaintiffs Have Waived Any Challenge to the Specific Warnings Selected by FDA, Which Accurately Convey Consequences of Smoking.

As noted, plaintiffs’ argument does not differentiate among the images considered or selected. Their pleadings offer scattered observations about some of the images chosen by the agency; but they do not contend that these warnings are any more or less constitutionally suspect than the other images reviewed or adopted in the rulemaking. Plaintiffs have thus waived any argument that the Court should hold specific images invalid if it does not accept their contention that *all* the images offend First Amendment constraints.

FDA did respond, at length, to other commenters whose comments with respect to specific images, explained why, in their view, some of the proposed graphics were more effective or less appropriate than others. We therefore address each of the images selected by FDA to accompany the text of the health warnings as well as the general objections advanced by plaintiffs. This section elaborates the previous discussion at 17–20 regarding the interaction of pictorial and text content in conveying the warnings’ messages.

“WARNING: Cigarettes are addictive.” FDA selected the image of a man smoking through a tracheostomy hole in his throat. 76 Fed. Reg. at 36,649. Plaintiffs do not deny that this image is a factual and accurate depiction of a health consequence of smoking. As FDA explained, “[t]he image effectively and concretely communicates the negative health consequences of smoking,” and “clearly portrays the addictive nature of cigarettes, depicting a man who is still smoking despite prior evidence (a stoma in his neck) of surgery for cancer.” *Ibid.* Indeed, smoking rates are “particularly high” even among those who have already been diagnosed with and are being

treated for head and neck cancer; for example, two studies found that “55–69% of head and neck cancer patients are current smokers.” Robert A. Schnoll & Caryn Lerman, *Smoking Behavior and Smoking Cessation among Head and Neck Cancer Patients*, in *HEAD AND NECK CANCER: EMERGING PERSPECTIVES* 185, 187 (John F. Ensley ed. 2003) (citing studies).

The image also performed particularly well in FDA’s consumer study: the image “had a significant effect ($p < 0.001$)^[13] on all salience measures” across “all three study populations.” 76 Fed. Reg. at 36,649. The image also “had a significant impact ($p < 0.05$) on adult beliefs about the health risks of smoking for smokers and a significant impact ($p < 0.05$) on adult beliefs about the health risks of secondhand smoke exposure for nonsmokers, relative to the text-only control.” *Ibid.* Although the image was associated with “lower statement recall at one week follow-up,” FDA explained that “recall of the statement was generally high for the image,” and concluded that “repetitive viewing of the required warning is likely to increase recall.” *Ibid.* Furthermore, many comments—including those from “public health advocacy groups, academics, State and local public health agencies, and health care professionals”—supported use of this image. *Ibid.* FDA was amply warranted in rejecting a comment that “the image would only have a one-time shock value,” explaining that “the research literature suggests that more vivid warnings are more likely to retain their salience over time.” *Ibid.*

“WARNING: Tobacco Smoke Can Harm Your Children.” FDA selected the image of smoke approaching a baby for this warning statement. *Ibid.* Plaintiffs urge that this image does not “even purport to describe, as a factual matter, the health consequences of exposing children to

¹³ The consumer study reported the “p-values”—the significance levels—of each of its findings. For findings that were significant at the 0.001 confidence level ($p < 0.001$), “there is less than one chance in a thousand that the finding happened by coincidence.” 76 Fed. Reg. at 36,648. And for findings that were significant at the 0.05 confidence level ($p < 0.05$), there is less than a 5% chance that the finding was a coincidence. *Ibid.*

second-hand smoke,” P.I. Reply 6, echoing comments that “the child does not appear to be suffering harms to his health” and “looks too healthy,” *id.* at 36,650. But as FDA explained, “[g]raphic depictions of the visible effects of disease are not the only way of communicating the health risks of second hand smoke for children, some of which (such as impaired lung growth), are not necessarily visible in a photograph of a child exposed to secondhand smoke.” *Id.* at 36,650. The chosen image also performed well in the consumer study, showing a significant effect on all the salience measures in all three study populations. *Id.* at 36,649–50. Moreover, the image “had a statistically significant effect ($p < 0.05$) on youth intentions to not smoke in the next year, with 71.6 percent of youth viewing the image reporting that they would not be likely to smoke in the next year, compared to 56.9 percent in the text only control.” *Id.* at 36,650. Thus, as FDA concluded, the warning “depicts the health consequences of secondhand smoke exposure in a manner that has an impact on both smokers and potential smokers.” *Id.* at 36,650–51.

“WARNING: Cigarettes Cause Fatal Lung Disease.” FDA selected the image comparing healthy and diseased lungs to accompany this warning statement. *Id.* at 36,651. Plaintiffs do not deny that this image is a factual and accurate depiction of a health consequence of smoking. In FDA’s consumer study, the image “had a significant effect ($p < 0.001$) on all the salience measures . . . in all three study populations” as compared to the text-only control, and “showed some of the largest effect sizes for image recall (at baseline and at 1 week follow-up) in adults and youth across the images proposed for use with this warning statement.” *Ibid.*

“WARNING: Cigarettes Cause Cancer.” FDA selected the image showing a cancerous lesion on a lip. *Ibid.* Plaintiffs do not deny that this image is a factual and accurate depiction of a health consequence of smoking. FDA received “a large number of comments supporting the use of [this] image” including comments from “public health advocacy groups, a medical organization,

academics, State and local public health agencies, and health care professionals.” *Id.* at 36,652. Several of those comments noted that the image “has a very high potential to reach consumers and positively influence their behavior.” *Ibid.* Other comments “addressed the benefits of using an image that shows the public that cigarettes cause oral cancers, noting that public awareness of this negative health consequence is low, and that many smokers and nonsmokers only relate cigarettes to lung cancer.” *Ibid.*

FDA also found that “the selected image . . . is likely to have particular relevance for youth,” because “the research literature suggests that youth are likely to relate to and be susceptible to cigarette warnings depicting the negative short-term impacts of smoking on their personal appearance, including their lips and teeth.” *Ibid.* FDA’s consumer study indicated that the image had “a significant effect ($p < 0.001$) on all the salience measures . . . in all three study populations,” and the “numerically largest effects of the images proposed for use with this warning statement on the emotional reaction scale and had the numerically largest effects on the cognitive reaction scale in young adults and youth.” *Id.* at 36,651.

“WARNING: Cigarettes Cause Strokes and Heart Disease.” FDA selected the image depicting a man with an oxygen mask on his face. *Id.* at 36,652. Plaintiffs do not deny that this image is a factual and accurate depiction of a health consequence of smoking. FDA selected this image in part because “the person shown in this image is an older man,” while other images “show younger people.” *Id.* at 36,653. FDA explained that this image thus helped fulfill the goal of “selecting a set of required warnings that includes a diversity of . . . human images (*e.g.*, race, gender, age),” such that “the nine selected required warnings will effectively communicate to a wide range of consumers, including both young and older smokers.” *Ibid.* Moreover, in FDA’s consumer study the image “had a significant effect ($p < 0.001$) on all the salience measures . . . in all three study

populations (adults, young adults, and youth).” *Id.* at 36,652. The image “also showed some of the largest effect sizes for image recall (at baseline and 1 week follow-up) in adults and youth across the images proposed for use with this warning statement.” *Id.* at 36,653. The image was identified by public health groups as “the best image for use with this warning statement.” *Ibid.*

“WARNING: Smoking During Pregnancy Can Harm Your Baby.” FDA selected a graphic illustration of a baby in an incubator. Plaintiffs criticize this image as a “non-factual cartoon drawing[],” Pl. S.J. Br. 21, but do not contend that a graphic illustration cannot convey factual and accurate information. FDA correctly noted that “[t]he style of the depiction—here, a graphic illustration—does not make it less factual,” *id.* at 36,696, and further explained that “the importance of selecting a set of required warnings that includes a diversity of styles (*e.g.*, photographic versus illustrative),” is demonstrated by the experience of other countries, *id.* at 36,653.

More important, plaintiffs suggest no respect in which the use of the image contained in the FDA warning fails to convey the health risks described in the undisputed accompanying text. Cigarette manufacturers maintained for decades that smoking during pregnancy would have no adverse impact long after they knew the contrary to be true. *See Philip Morris*, 449 F. Supp. 2d at 194. At this point, however, plaintiffs no longer dispute that “smoking during pregnancy has negative effects, including increasing rates of preterm delivery and shortened gestation.” 76 Fed. Reg. at 36,696. Nor do they offer any basis for setting aside the agency’s conclusion that the image “accurately depicts the health consequences smoking during pregnancy can have for infants born to mothers who smoke.” *Ibid.*

FDA’s consumer research study showed that this image “had a significant effect ($p < 0.001$) on all the salience measures . . . in all three study populations (adults, young adults, and youth).” *Id.* at 36,653. Those effects were the “numerically largest” among of the “images proposed for use

with this warning statement.” *Ibid.* The image also had significant effects on recall of the warning statement as compared to the text-only baseline in all three study populations. *Ibid.* Although the image also had a significant effect on the beliefs about the risks of smoking among adults, it was associated with a decreased awareness of health risks for youth smokers. *Ibid.* But, “given the strength of the effects observed for this image on the salience measures,” which FDA found to be the most relevant metric, FDA found that the warning is “is likely to increase awareness of the health risks of smoking and increase the likelihood that smokers will reduce their smoking, make an attempt to quit, or quit altogether.” *Ibid.*

“WARNING: Smoking Can Kill You.” FDA selected the image depicting a man on an autopsy table with an autopsy scar. *Id.* at 36,654. Plaintiffs claim that this image is inaccurate because “autopsies [are not] a common result of cigarette smoking.” Pl. S.J. Br. 21. Plaintiffs do not dispute, however, that smoking kills 443,000 Americans each year, *id.* at 36,629, or that, among children that become regular smokers, “about half eventually will die from a disease caused by tobacco use,” *Promoting Healthy Lifestyles, supra*, at 64 (emphasis added). As FDA explained, “[v]iewers will understand that the image shows someone who has died from a smoking-related cause,” particularly because “the image is not used in isolation, but accompanies the textual warning statement, which provides additional context for what is shown.” 76 Fed. Reg. at 36,655. The autopsy image thus underscores the factual, non-controversial information contained in the warning statement, and is a good deal less “disturbing” than photographs of the most common ravages of the diseases caused by plaintiffs’ products.

FDA’s consumer study indicated “that viewers from all age groups understood and reacted to this image in desirable ways.” *Ibid.* The image had “a significant effect ($p < 0.001$) on all the salience measures . . . in all three study populations (adults, young adults, and youth).” *Id.* at

36,654. The image was also “associated with higher intentions to quit smoking compared to the text-only control ($p < 0.05$) in adults.” *Ibid.*

“WARNING: Tobacco Smoke Causes Fatal Lung Disease In Nonsmokers.” FDA selected the image of a woman crying to accompany this warning statement. *Id.* at 36,655. Plaintiffs do not dispute FDA’s conclusion that “the image is a realistic portrayal of how the negative health consequences caused by exposure to secondhand smoke can affect people.” *Id.* at 36,656. FDA explained that “the negative health consequences caused by secondhand smoke exposure, including fatal lung disease, have many dimensions, including emotional suffering,” and that the selected image “highlights that dimension.” *Ibid.* Moreover, as FDA explained “the image is not used in isolation, but accompanies the textual warning statement, which provides additional context for what is shown.” *Ibid.* The image performed well in FDA’s consumer study: it had significant effects across the salience metrics in all three study populations, and “a significant impact ($p < 0.05$) on beliefs about the health risks of smoking for smokers in young adults.” *Id.* at 36,655.

“WARNING: Quitting Smoking Now Greatly Reduces Serious Risks To Your Health.” FDA selected the image of a man wearing a t-shirt that says “I Quit” to accompany the warning statement. *Id.* at 36,656. Plaintiffs urge that this image “says absolutely nothing about the risks of smoking or the benefits of quitting.” P.I. Reply 6. FDA explained that research indicates “that warnings that focus on the benefits of quitting are effective at encouraging cessation, and suggests that positive, self-efficacy messages can be used effectively as one component of graphic health warnings to increase smokers’ motivations and confidence about quitting.” 76 Fed. Reg. at 36,656. The agency observed that “[t]he research literature also highlights the importance of including one or more warnings that provide solutions, such as the ‘man I Quit t-shirt’ required warning, in a set of warnings conveying the negative health consequences of smoking.” *Ibid.* Thus, “the literature

recommends that, in addition to communicating the health risks of smoking, some warnings should also provide information on how to avoid these risks (*i.e.*, by quitting), in order to optimize the effectiveness of the overall set of warning messages.” *Ibid.* The image showed significant effects in FDA’s consumer study: it had a significant impact in the cognitive reaction scale in all three study populations, and “showed the largest effect sizes for image recall (at baseline and 1 week follow-up) in adults, young adults, and youth across the images proposed for this warning statement.” *Ibid.*

In sum, individually and as a group, the warnings combine text and image to convey accurate information of the consequences of smoking.

3. The Inclusion of a Phone Number for a Smoking Cessation Resource Raises No First Amendment Concerns.

Plaintiffs do not advance their argument by insisting that inclusion of a telephone number for a nationally recognized smoking cessation resource—1-800-QUIT-NOW—in the health warnings violates the First Amendment. FDA explained (and it is not disputed) that studies have found that “health warnings are more effective if they are combined with cessation-related information.” 76 Fed. Reg. at 36,681. Indeed, because of the powerfully addictive nature of plaintiffs’ products, the overwhelming majority of smokers who try to quit fail in their efforts in any given quit attempt. *Id.* at 36,700.

The phone number plaintiffs complain about is that of the preexisting “National Network of Tobacco Cessation Quitlines (Network), which uses the telephone portal 1-800-QUIT-NOW” provided by the National Cancer Institute. *Id.* at 36,681. Based on the caller’s area code, the Network “routes calls to the appropriate State quitline.” *Ibid.* These state quitlines receive “significant support and oversight” from the Centers for Disease Control and Prevention, which will now require that these quitlines comply with all the requirements set out in the final rule. *Ibid.*

Plaintiffs’ sole objection is that this smoking-cessation resource uses the telephone number

“1-800-QUIT-NOW.” *See* Pl. S.J. Br. 23. The use of dashes and the fact that it begins with “1-800” makes plain to any reasonable reader that it is a telephone number to call, and the fact that the number is in an easy-to-remember form does not make it a “subjective policy message.” *Ibid.* At most, the telephone number conveys that quitting smoking is beneficial, which is plainly permissible. One of the textual warnings, which the tobacco companies “do not challenge” because it contains “purely factual information,” *id.* at 20, states: “WARNING: Quitting smoking now greatly reduces serious risks to your health.” 15 U.S.C. § 1333 Note.

Plaintiffs’ arguments recapitulate their contention that the warnings reflect a government “ideology,” a contention wholly without merit. *See supra* 23–29. As discussed, plaintiffs’ own websites convey the same warnings and, indeed, Lorillard’s web site instructs consumers who follow that advice to call the same phone number that plaintiffs challenge here on constitutional grounds: “For help in quitting smoking call 1-800-QUITNOW (TTY 1-800-322-8615), which is a 24-hour toll-free number to the National Network of Tobacco Cessation Quitlines.”¹⁴

B. Plaintiffs’ APA Challenge Reduces to the Contention that the Agency Should Have Declined to Implement the Statutory Mandate.

Plaintiffs’ quarrel is not with the FDA but with Congress. They asserted in the rulemaking, and continue to maintain, that the only constitutionally acceptable course for the agency would be to require warnings that include the new text mandated by Congress but that appear in precisely “the same manner in which the Surgeon General’s warnings have successfully been displayed for decades.” Comment Letter 24. Plaintiffs’ comments necessarily acknowledged that the statute precluded this course of action, but made the extraordinary suggestion that the agency should assert the Executive Branch’s constitutional duty to take care that the law shall be faithfully executed “to

¹⁴ <http://www.lorillard.com/responsibility/smoking-and-health/addiction>.

eliminate constitutional and other infirmities.” *Ibid.*

It is thus unsurprising that plaintiffs’ APA arguments challenging the rulemaking add nothing to their constitutional claim that the size and placement of the health warnings, as well as the inclusion of images, violate the First Amendment. Plaintiffs’ objections to the rulemaking generally condemn the agency for faithfully implementing the statute or for not amassing additional evidence in support of the judgment already made by Congress.

1. The Regulatory Impact Statement

The errors besetting plaintiffs’ analysis are epitomized in their discussion of the regulatory impact statement conducted pursuant to Executive Orders 12,866 and 13,563. They urge that FDA should not have implemented the statutorily mandated warnings because the regulatory impact statement did not demonstrate to a statistical certainty that the new warnings will reduce the rate of smoking. Pl. S.J. Br. 7–10, 25.

This argument has no bearing on the validity of the regulation. Congress did not ask FDA to determine the costs and benefits of including warnings of a particular size and format with specified text and accompanying graphics—Congress itself had made that judgment, and, as discussed above, had ample basis for doing so. FDA had no authority to second-guess that legislative determination, and was statutorily precluded from accepting plaintiffs’ recommendation to order that the Act’s “new textual warnings be displayed in the same manner in which the Surgeon General’s warnings have been displayed for years.” Comment Letter 3-4. In contrast, the decisions on which plaintiffs rely involved statutes that specifically directed an agency to consider costs and benefits in determining *whether* to promulgate a regulation. *See, e.g., Pub. Citizen v. Fed. Motor Carrier Safety Admin.*, 374 F.3d 1209, 1212 (D.C. Cir. 2004) (considering rule promulgated under a statute that mandated that “[b]efore prescribing or revising any . . . requirement, [the agency] shall

consider the costs and benefits of the requirement” (quoting 49 U.S.C. § 31506(d)).

The Executive Orders that require a regulatory impact analysis do not permit FDA to second-guess congressional judgments. The orders apply generally to all federal rulemaking and are designed to “improve the internal management of the Federal Government.” Executive Order 12,866, § 10, 58 Fed. Reg. 51,735, 51,744 (1993). They include the requirement that agency rulemaking be accompanied by a regulatory impact statement, but they explicitly declare that they do “not create any right or benefit, substantive or procedural, enforceable at law or equity by a party against the United States, its agencies or instrumentalities, its officers or employees, or any other person.” *Ibid.*; see also Executive Order 13,563, § 7(d), 76 Fed. Reg. 3821, 3823 (2011) (similar language). Plaintiffs’ misunderstanding of the purpose of the impact statement is illustrated by their assertion that FDA’s statement in this instance improperly failed to account for the “the healthcare, social security, and other cost *increases* caused by increased longevity.” Compl. ¶ 46. For the limited purpose of complying with the Executive Orders, FDA did consider the rule’s indirect effects on such costs. See 76 Fed. Reg. at 36,714. But that analysis is irrelevant to the issues before the Court. Congress legislated on the premise that keeping people alive is a good thing. The Constitution does not require Congress to adopt plaintiffs’ accounting standards and to treat the achievement of that goal as a “cost” rather than a “benefit.”

Plaintiffs’ discussion of the Regulatory Impact Statement also provides no support for their constitutional claims. First, as already discussed, *supra* 31–34, the constitutionality of the statute does not turn on statistical predictions of the impact of warnings on national smoking rates. Second, the impact analysis does not, in fact, predict that the new warnings will have little if any impact on smoking rates. The impact analysis compared data from Canada for the years 2000 to 2009 with data from the United States for the same period. Between 2000 (prior to the effective date of the

Canadian warnings) and 2010, the smoking rate dropped 7 percentage points, from 24 percent to 17 percent. Over the same period, the smoking rate in the United States dropped less than 3 percentage points, from 23 percent to 20.5 percent. 76 Fed. Reg. at 36,720.

The impact statement observed that it could not be assumed that “the introduction of graphic warning labels in the United States will cause the U.S. smoking rate to fall by seven, or even the three percentage points needed to reach the Canadian rate.” *Ibid.* The reasons for some uncertainty are evident. The federal and state governments, as well as public health organizations, have taken a variety of measures to increase public awareness of the risks of tobacco use. Attempting to quantify the extent to which any one measure, acting alone, will contribute to a decline, or avoid an increase, in smoking rates poses major challenges. Thus, although the impact statement sought to “isolate the impact of graphic warning labels on the Canadian smoking rate,” it recognized that its analysis was no more than a “rudimentary approach” that “may be producing results that are off by one or more orders of magnitude.” *Ibid.*¹⁵

With these major caveats, the impact statement estimated that the updated warnings will have the effect of reducing the United States’ adult smoking population by more than 200,000 people, an 0.088-percentage-point drop in the smoking rate from what could be expected without the updated warnings. *Id.* at 36,721.

Plaintiffs repeatedly quote the sentence fragment that this estimate is “not statistically distinguishable from zero,” without reference to the rest of the sentence in which that statement

¹⁵ Plaintiffs point out that FDA could not account for certain “confounding factors” other than the presence of graphic warnings that contributed to the trends in smoking rates in the United States and Canada. Pl. S.J. Br. 9–10. As FDA explained, the effects of these factors were difficult to quantify, and plaintiffs suggest no means of doing so. Moreover, accounting for some such factors would tend to increase the estimate of the effect of the warnings while others would tend to decrease it, and thus FDA’s “estimates could as easily be underestimates as overestimates.” 76 Fed. Reg. at 36,711. Plaintiffs offer no response to this conclusion.

appears. *See, e.g.*, Pl. S.J. Br. 8, 24, 33; Comment Letter exh. B, Statement of Robert S. Maness, at 2. The sentence does not declare that the likely impact on smoking rates is zero. It is, instead, an acknowledgment that the parameters of the economic analysis required by the Executive Orders inject enormous uncertainty into its quantitative conclusions. The full sentence declares: “Although both of the estimation methods” discussed in the statement “lead to the conclusion that graphic warning labels will reduce smoking rates, FDA has had access to very small data sets, so our effectiveness estimates are in general not statistically distinguishable from zero; we therefore cannot reject, in a statistical sense, the possibility that the rule will not change the U.S. smoking rate.” 76 Fed. Reg. at 36,776. The agency explained that the proper approach to uncertain estimates is *not* to “set[] estimates of effects equal to zero when their estimates are statistically insignificant,” but rather to present the best estimate along with an analysis of the uncertainty. *Id.* at 36,712.

2. The Consumer Research Study

Plaintiffs offer various criticisms of the study of 18,000 consumers that FDA conducted in to determine the relative effectiveness of the proposed warnings. These criticisms are both inaccurate and immaterial.

Plaintiffs note that, as to some of the warnings, the study did not find “a statistically significant effect on consumers’ awareness of smoking risks.” Pl. S.J. Br. 7. The study was not designed to make an assessment of the kind suggested by plaintiffs. Instead, as FDA explained, the study simply provided one means of assessing the *relative* impact of different pictorial warnings based on participants’ exposure to one warning on one occasion. 76 Fed. Reg. at 36,639. The warning did so by comparing the effects of images on several different variables—including the salience metrics discussed above. As explained, *supra* 34–37, these salience metrics provided an appropriate basis for distinguishing among potential images because they predict the likelihood that

viewers will notice and process the information contained in the text. *See* FDA Study Report at 1-2, 4-1 (citing studies); 76 Fed. Reg at 36,639 (same). And, of course, plaintiffs themselves have never suggested that some warnings have greater salience than others or that any would, in their view, be constitutionally permissible.

Moreover, the impact of warnings on consumer awareness results not from a single viewing, as in FDA's study, but from repeated exposure to multiple warnings over an extended time. FDA emphasized that a pack-a-day smoker will be exposed to a package warning "more than 7,000 times per year." 76 Fed. Reg. at 36,682. In recognition of this fact, the study specified that it was not intended to furnish conclusions about "longer-term outcomes" that will be achieved by multiple viewings of the warnings. FDA Study Report at 1-2. As explained above, studies that have examined the long-term impact of pictorial warnings concluded that such warnings increase consumers' understanding of the health effects of smoking. *See supra* 16–18.

Plaintiffs are equally wide of the mark in claiming that the survey design—in which FDA studied the reactions of three different populations to the 36 prospective pictorial health warnings—created the likelihood that the study results were the result of "random error." Pl. S.J. Br. 13–14. The study was designed in this manner because scientific research demonstrated that the "effectiveness of health warnings in communicating the health risks of smoking may vary according to the audience" and that "[a] variety of health warnings facilitates better targeting of specific groups whose primary concerns about smoking tend to vary." 75 Fed. Reg. at 69,534. Because FDA considered a finding to be statistically significant if there was only a 5% chance that it was coincidence, 76 Fed. Reg. at 36,648, by definition, one would expect only 5% of the total number of findings to be statistically significant if random error were the only contributing factor. As the data from the study demonstrates, however, the actual number of significant findings was greater

by an order of magnitude. *See generally* FDA Study Report, app. C, at C-1. In addition, many of the findings were significant at the .001 confidence level, meaning that “there is less than one chance in a thousand that the finding happened by coincidence.” 76 Fed. Reg. at 36,648.

Plaintiffs also argue that the consumer study (as well as other studies in the record) “suffer from the methodological flaw of ‘social desirability bias,’” because survey participants systematically over-report their intention to quit smoking. Pl. S.J. Br. 12–13, 27. FDA directly addressed that point during the rulemaking, explaining that “[t]he more recent scientific literature shows that statements by smokers concerning their intentions to quit smoking are predictive of their making subsequent quit attempts.” 75 Fed. Reg. 52,352, 52,354 (Aug. 25, 2010). Plaintiffs offer no basis for finding this conclusion to be arbitrary or capricious.

3. Other APA Challenges

Plaintiffs summarize their APA claims as follows: “(1) the stated purpose of the Rule—to decrease smoking—is not supported by the administrative record; (2) FDA’s cost-benefit analysis exaggerated the Rule’s benefits while ignoring obvious costs; (3) FDA rejected comments based on the absence of empirical support even though it ignored a similar lack of empirical support in favor of the Rule; (4) FDA failed to assess numerous less burdensome alternatives . . . ; and (5) FDA failed to disclose numerous studies and other data on which the Rule is predicated.” P.I. Reply 17.

We have already addressed many of these arguments. *First*, plaintiffs’ arguments regarding the warnings’ likely impact on smoking rates is incorrect and offers no basis for setting aside the rule. *See supra* 31–34. *Second*, the cost-benefit calculations in FDA’s regulatory impact analysis were not meant to justify the graphic warnings requirement, and plaintiffs’ claims regarding supposed errors in those calculations are irrelevant to any APA challenge. *See supra* 46–49. *Third*, plaintiffs’ claim that FDA “failed to assess numerous less burdensome alternatives” to the mandated

warnings fails to appreciate that it was Congress, not FDA, that required the inclusion of images with the warning statements. *See supra* 21.

Plaintiffs' remaining arguments require little discussion. Plaintiffs fault the FDA for rejecting a comment that some of the graphic images would cause a so-called "rebound" or "boomerang" effect, *i.e.*, they would "increase cigarette use by causing consumers to avoid the warnings or increasing the appeal of cigarettes to some young people." Pl. S.J. Br. 40. But as FDA explained, the companies relied on studies that were dated and that "did not specifically address graphic warnings on cigarette packages and advertisements." 76 Fed. Reg. at 36,634. Recent empirical research studying graphic warnings in other countries has found no such "boomerang" effect. *Ibid.* (citing studies). Nor did FDA apply a "different standard[] of analysis" to comments addressing studies that supported the proposed pictorial warnings. Pl. S.J. Br. 39–40. Unlike the evidence presented by the tobacco companies, these comments were not directly contradicted by newer scientific research. *See* 76 Fed. Reg. at 36,645–46.

Nor can plaintiffs plausibly claim on this record that FDA "failed to provide a meaningful opportunity to comment" on the proposed rule by failing to disclose certain internal studies and reports. Pl. S.J. Br. 41–42. FDA went to great lengths to ensure that the rule was subject to exhaustive public notice and comment. Eight months after the passage of the Tobacco Control Act (a full sixteen months before the congressionally mandated deadline for issuing pictorial warnings), FDA issued a notice describing the design of its consumer research study and seeking public comment. *See* 75 Fed. Reg. 7,604 (Feb. 22, 2010). The agency responded to those comments on August 25, 2010, and sought further comment. *See* 75 Fed. Reg. 52,352. Then on November 12, 2010, FDA issued its notice of proposed rulemaking, unveiling 36 prospective warning images and a preliminary regulatory impact analysis. *See* 75 Fed. Reg. 69,524. Following issuance of the

proposed rule, FDA placed the results of its consumer study on the public docket of the pending rulemaking, and announced that fact in a Federal Register notice to allow public comment on the results. *See* 75 Fed. Reg. 75,936 (Dec. 7, 2010). In these circumstances, there is no basis for plaintiffs' claim that they were not afforded a "reasonable opportunity to participate in the rulemaking process." *WJG Tel. Co., Inc. v. FCC*, 675 F.2d 386, 389 (D.C. Cir. 1982).

In any event, the information that plaintiffs identify as missing from the record did not in any respect prevent plaintiffs from commenting on matters before the agency. Plaintiffs' claim that FDA "failed to disclose key technical data and assumptions it used" in the regulatory impact analysis is incorrect and, in any event, beside the point. As explained above, FDA's cost-benefit analysis played no role in justifying the rule, and so there is no reason why plaintiffs would have needed this information. Dr. Viscusi's assertion that FDA "neglected to describe . . . in meaningful detail" the process by which FDA selected the warning text and the 36 prospective images is similarly mistaken. Pl. S.J. Br. 42 (quoting Viscusi Statement at 37–38). The warning text was required by Congress, and plaintiffs do not explain why knowledge of the process by which the prospective images were selected would have aided their ability to participate in the rulemaking: once FDA revealed the prospective images, plaintiffs were free to (and did) comment on them before FDA promulgated its final rule.

IV. There Is No Authority To Issue an Injunction that Would Delay Enforcement of the Warning Requirements Established by Statute.

The effective date of the updated health warnings was established by Congress in the Tobacco Control Act. Congress provided that, "[n]ot later than 24 months after June 22, 2009, the Secretary shall issue regulations that require color graphics depicting the negative health consequences of smoking to accompany the label statements specified in the statute." 15 U.S.C. § 1333 Note. Congress further provided that the Act's amendment to the pre-existing warning

requirements “shall take effect 15 months after the issuance of the regulations.” *Ibid.* Consistent with Congress’s directive, FDA issued its graphics regulations on June 22, 2011. *See* 76 Fed. Reg. 36,628. Accordingly, the updated health warnings will take effect on September 22, 2012.

In their motion for a preliminary injunction, plaintiffs asked the Court to delay the effective date for 15 months if it *rejects* their challenges. We explained in our opposition to that motion that this relief cannot properly be awarded as a “preliminary injunction,” and there would likewise be no basis for issuing final judgment sustaining the validity of the statute and regulation but postponing the effective date established by Congress.

Plaintiffs’ summary judgment motion does not argue that the Court could disregard the effective date established by Congress if their challenge to the warning requirements is unsuccessful. Instead, they ask the Court to issue a “declaration invalidating and setting aside the Rule,” Pl. S.J. Mot. iii ¶ 1, and, further, to enjoin FDA from enforcing the warning requirements established by statute “until 15 months after issuance by FDA of regulations . . . that are substantively and procedurally valid and permissible.” *See id.* ¶¶ 2, 3.

Because plaintiffs’ challenge to the rule has no merit, their request for further relief is moot. Even assuming, however, that some aspect of the rule were ultimately declared invalid, there would be no basis for the relief that plaintiffs seek. Plaintiffs’ assertion that Congress itself foreclosed “multiple . . . overhauls of their packaging and advertising” (Pl. S.J. Br. 44-45) is belied by the plain terms of the Tobacco Control Act, which expressly authorizes the Secretary to make further adjustments to the warning requirements through rulemaking. *See* 15 U.S.C. § 1333(b)(4) (authorizing the Secretary to “adjust the format and type sizes for the label statements”); *see also* 21 U.S.C. § 387f(d)(1) (authorizing restrictions on advertising and promotion of tobacco products to protect public health). Thus, Congress expressly contemplated that there would be multiple

rounds of changes to the warnings.

Assuming *arguendo* that some aspect of the rule were ultimately declared invalid, the proper course would be a remand to FDA to determine in the first instance whether the particular provision is severable from other warning requirements, whether additional rule-making proceedings are necessary or appropriate, and when any revised rule should take effect. In any such rulemaking, plaintiffs and other interested parties would have the opportunity to submit their views regarding the revised rule as well as its effective date, and plaintiffs could attempt to show that an additional lengthy delay is appropriate even though they implemented the Canadian warning requirements over the course of 180 days. *See Tobacco Products Information Regulations, SOR/2000-272 (Can.)*.¹⁶

FDA's final determinations on such matters would be subject to judicial review on the basis of the administrative record. The APA authorizes judicial review of final agency action, *see* 5 U.S.C. § 706; it does not permit a court to address in advance the contours or effective date of action not yet taken by an agency. *Cf. Nat'l Petrochemical & Refiners Ass'n v. EPA*, 630 F.3d 145, 164 (D.C. Cir. 2010) ("when Congress has delegated 'a determination of policy or judgment which the agency alone is authorized to make and *which it has not made*, a judicial judgment cannot be made to do service for an administrative judgment") (quoting *SEC v. Chenery Corp.*, 318 U.S. 80, 88, 63 S.Ct. 454, 87 L.Ed. 626 (1943) (emphasis in *Nat'l Petrochemical*)).

CONCLUSION

For the foregoing reasons, plaintiffs' motion for summary judgment should be denied, and the government's motion for summary judgment should be granted.

¹⁶ <http://www.canlii.org/en/ca/laws/regu/sor-2000-272/latest/sor-2000-272.html>.

Respectfully submitted,

Dated: October 21, 2011

Of Counsel:

WILLIAM B. SCHULTZ
Acting General Counsel

ELIZABETH H. DICKINSON
Acting Associate General Counsel
Food and Drug Division

ERIC M. BLUMBERG
Deputy Chief Counsel, Litigation

KAREN E. SCHIFTER
Senior Counsel
U.S. Department of Health & Human Services
Office of the General Counsel
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002

TONY WEST
Assistant Attorney General

BETH S. BRINKMANN
Deputy Assistant Attorney General

MAAME EWUSI-MENSAH FRIMPONG
Acting Deputy Assistant Attorney General


/s/
DRAKE CUTINI
DANIEL K. CRANE-HIRSCH
Attorneys, Consumer Protection Branch
PO Box 386
Washington, DC 20044
202-307-0044 (Cutini)
drake.cutini@usdoj.gov

/s/
MARK B STERN
ALISA B. KLEIN
SARANG V. DAMLE
DANIEL TENNY
LINDSEY POWELL
Attorneys, Appellate Staff
Civil Division, Room 7217
U.S. Department of Justice
950 Pennsylvania Ave., NW
Washington, DC 20530
202-514-5735 (Damle)
Fax: 202-514-9405
sarang.damle@usdoj.gov

CERTIFICATE

Pursuant to the provisions of Rule 44 of the Federal Rules of Civil Procedure, I hereby certify that Kristin Inez Davis, Senior Regulatory Counsel, Office of Regulations, Center for Tobacco Products, United States Food and Drug Administration, whose declaration is attached, has custody of official records of the United States Food and Drug Administration.

In witness whereof, I have, pursuant to the provision of Title 42, United States Code, Section 3505, and FDA Staff Manual Guide 1410.23(1)(A)(19), hereto set my hand and caused the seal of the Department of Health and Human Services to be affixed this 18th day of October, 2011.



Karen Kennard
Director
Division of Dockets Management
Office of the Commissioner
United States Food and Drug
Administration

By direction of the Secretary of
Health and Human Services




Kristin Inez Davis

DECLARATION OF KRISTIN INEZ DAVIS

Kristin Inez Davis declares as follows:

1. I am a Senior Regulatory Counsel, Office of Regulations, Center for Tobacco Products, United States Food and Drug Administration (FDA).


2. In this capacity, I have custody of official records of FDA relating to FDA's issuance of a Proposed Rule, "Required Warnings for Cigarette Packages and Advertisements," Docket No. FDA-2010-N-0568, 75 Fed. Reg. 69524 (November 12, 2010) and Final Rule, "Required Warnings for Cigarette Packages and Advertisements," Docket No. FDA-2010-N-0568, 76 Fed. Reg. 36628 (June 22, 2011) ("Proposed Rule" and "Final Rule," respectively).

3. Attached are copies of two indices. The first is a list of the documents referenced in the Proposed Rule, the documents referenced in the Final Rule, and internal FDA memoranda drafted in the course of considering the Proposed and Final Rule. The second is a list of comments submitted by the public on the Proposed Rule. The second list was compiled and is maintained by FDA's Division of Dockets Management.

4. The documents listed in the attached indices comprise the administrative record for the Proposed and Final Rule, and are official records of FDA.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on October 13, 2011



Kristin Inez Davis

Index to References and Memos in Proposed and Final Rule, "Required Warnings for Cigarette Packages and Advertisements", Docket No. FDA-2010-N-0568, 75 Fed. Reg. 69524 (November 12, 2010), 76 Fed. Reg. 36628 (June 22, 2011)		
Name	Title	Bates
Proposed Rule References		
Reference 1	Centers for Disease Control and Prevention, "Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses--United States, 2000-2004," Morbidity and Mortality Weekly Report, 57(45); 1226-1228, Nov. 14, 2008, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5745a3.htm .	000001-000005
Reference 2	U.S. Department of Health and Human Services, "The Health Consequences of Smoking," A Report of the Surgeon General; 2004, available at http://www.surgeongeneral.gov/library/smokingconsequences/index.html .	000006-000961
Reference 3	U.S. Department of Health and Human Services, "Youth & Tobacco; Preventing Tobacco Use Among Young People," A Report of the Surgeon General; 1994, available at http://www.surgeongeneral.gov/library/reports/ .	000962-001180
Reference 4	H.R. 1108, Family Smoking Prevention And Tobacco Control Act: Hearing Before the House Subcommittee on Health of the 110th Cong. Committee on Energy and Commerce.	001181-001399
Reference 5	Institute of Medicine (IOM) of the National Academies, "Ending the Tobacco Problem: A Blueprint for the Nation," 2007, available at http://www.iom.edu/Reports/2007/Ending-the-Tobacco-Problem-A-Blueprint-for-the-Nation.aspx .	001400-002132
Reference 6	Centers for Disease Control and Prevention, "Vital Signs: Current Cigarette Smoking Among Adults Aged > 18 Years--United States, 2009," Morbidity and Mortality Weekly Report, 59(35); 1135-1140, Sept. 10, 2010, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5935a3.htm .	002133-002144
Reference 7	Centers for Disease Control and Prevention, "Surveillance for Cancers Associated with Tobacco Use--United States, 1999-2004," Morbidity and Mortality Weekly Report, 57(SS08); 1-33, Sept. 5, 2008, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5708a1.htm .	002145-002193
Reference 8	Substance Abuse and Mental Health Services Administration, "Results from the 2008 National Survey on Drug Use and Health: National Findings," Rockville, MD: 2009, available at http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf .	002194-002497
Reference 9	Centers for Disease Control and Prevention, "Tobacco Use Among Middle and High School Students--United States, 2000-2009," Morbidity and Mortality Weekly Report, 59(33); 1063-1068, Aug. 27, 2010, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5933a2.htm .	002498-002508
Reference 10	Centers for Disease Control and Prevention, "Trends in Smoking Initiation Among Adolescents and Young Adults--United States, 1980-1989," Morbidity and Mortality Weekly Report, 44(28); 521-525, July 21, 1995, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/00038190.htm .	002509-002514
Reference 11	Centers for Disease Control and Prevention, "Youth Risk Behavior Surveillance – United States, 2009," Morbidity and Mortality Weekly Report 2010, 59 (No. SS-5); June 4, 2010, available at http://www.cdc.gov/mmwr/pdf/ss/ss5905.pdf .	002515-002659

Name	Title	Bates
Reference 12	Johnston, L.D., O'Malley P.M., Bachman J.G., and Schulenberg, J.E., "Smoking Continues Gradual Decline Among U.S. Teens, Smokeless Tobacco Threatens a Comeback." University of Michigan News Service: Ann Arbor, MI, Dec. 14, 2009, available at http://www.monitoringthefuture.org/data/09data.html#2009data-cigs .	002660-002663
Reference 13	Centers for Disease Control and Prevention, "Cigarette Use Among High School Students--United States, 1991--2009," Morbidity and Mortality Weekly Report, 59(26); 797-801, July 9, 2010, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5926a1.htm .	002664-002701
Reference 14	Taioli, E., and Wynder, E.L., "Effect of the Age at Which Smoking Begins on Frequency of Smoking in Adulthood," The New England Journal of Medicine, 325(13); 968-969, 1991.	002702-002703
Reference 15	Chen, J. and Millar, W, "Age of Smoking Initiation: Implications for Quitting," Health Reports (Statistics Canada, Catalogue 82-003-XPB), 9(4); 39-46, 1998.	002704-002711
Reference 16	Breslau, N., and Peterson, E., "Smoking Cessation in Young Adults: Age at Initiation of Cigarette Smoking and Other Suspected Influences," American Journal of Public Health, 86(2); 214-20, 1996.	002712-002718
Reference 17	Benowitz, N., "Nicotine Addiction," The New England Journal of Medicine, 362(24); 2295-303, 2010.	002719-002727
Reference 18	Centers for Disease Control and Prevention, "Cigarette Smoking-Attributable Morbidity--United States, 2000," Morbidity and Mortality Weekly Report, 52(35); 842-844, Sept. 5, 2003, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5235a4.htm .	002728-002731
Reference 19	Fiore M.C., Jaen C.R., Baker T.B., et al., "Treating Tobacco Use and Dependence: 2008 Update," Rockville, MD: US Department of Health and Human Services, Public Health Service, 2008, available at http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf .	002732-003005
Reference 20	U.S. Department of Health and Human Services, "Reducing the Health Consequences of Smoking--25 Years of Progress," A Report of the Surgeon General; 1989, available at http://www.surgeongeneral.gov/library/reports/ .	003006-003718
Reference 21	U.S. Department of Health and Human Services, "The Health Consequences of Smoking: Nicotine Addiction," A Report of the Surgeon General; 1988, available at http://www.surgeongeneral.gov/library/reports/ .	003719-004361
Reference 22	Berg, C., et al., "Failure to Report Attempts to Quit Smoking," Addictive Behaviors, 35; 900-904, 2010.	004362-004366
Reference 23	Centers for Disease Control and Prevention, "Cigarette Smoking Among Adults and Trends in Smoking Cessation--United States, 2008," Morbidity and Mortality Weekly Report, 58(44); 1227-1232, Nov. 13, 2009, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5844a2.htm .	004367-004374
Reference 24	DiFranza, J., et al., "Initial Symptoms of Nicotine Dependence in Adolescents," Tobacco Control, 9; 313-319, 2000.	004375-004382
Reference 25	Centers for Disease Control and Prevention, "High School Students Who Tried to Quit Smoking Cigarettes--United States, 2007." Morbidity and Mortality Weekly Report, 58(16); 428-431, May 1, 2009, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5816a4.htm .	004383-004387
Reference 26	U.S. Department of Health and Human Services, "The Health Benefits of Smoking Cessation," A Report of the Surgeon General; 1990, available at http://www.surgeongeneral.gov/library/reports/ .	004388-005014

Name	Title	Bates
Reference 27	Hammond, D., "Tobacco Labelling & Packaging Toolkit: A guide to FCTC Article 11," Feb. 2009, available at www.tobaccolabels.ca/download/tobaccolab/uatldtook?attachment=1 .	005015-005146
Reference 28	Hammond, D., Fong, G.T., and McDonald, P.W., et al., "Impact of the Graphic Canadian Warning Labels on Adult Smoking Behaviour," <i>Tobacco Control</i> , 12; 391-5, 2003.	005147-005151
Reference 29	Hammond, D., McDonald, P.W., and Fong, G.T., et al. "The Impact of Cigarette Warning Labels and Smoke-free Bylaws on Smoking Cessation--Evidence from Former Smokers," <i>Canadian Journal of Public Health/Revue Canadienne de Sante Publique</i> , 95(3); 201-204, May-June 2004.	005152-005155
Reference 30	Centers for Disease Control and Prevention, "Health Warnings on Tobacco Products--Worldwide, 2007," <i>Morbidity and Mortality Weekly Report</i> , 58(19); 528-9, May 22, 2009, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5819a3.htm .	005156-005160
Reference 31	Lorillard et al., 80 F.T.C. 455, 460-65 (1972) (consent orders).	005161-005171
Reference 32	Federal Trade Commission, "Staff Report on the Cigarette Advertising Investigation," ch. 4, May 1981, available at http://tobaccodocuments.org/lor/03607752-7763.html .	005172-005207
Reference 33	Fischer, P.M., Richards, J.W., and Berman, E.F., et al., "Recall and Eye Tracking Study of Adolescents Viewing Tobacco Advertisements," <i>Journal of the American Medical Association</i> , 261; 84-89, 1989.	005208-005213
Reference 34	Robinson, T.N. Killen, J.D., "Do Cigarette Warning Labels Reduce Smoking?: Paradoxical Effects Among Adolescents," <i>Archives of Pediatrics & Adolescent Medicine</i> , 151(3); 267-72, 1997.	005214-005220
Reference 35	Davis, R.M. and Kendrick, J.S., "The Surgeon General's Warnings in Outdoor Cigarette Advertising," <i>Journal of the American Medical Association</i> , 261(1); 90-94, 1989.	005221-005225
Reference 36	Hammond, D., Fong, G.T., and Borland, R., et al., "Text and Graphic Warnings on Cigarette Packages: Findings from the International Tobacco Control Four Country Study," <i>American Journal of Preventive Medicine</i> , 32(3); 202-209, 2007.	005226-005233
Reference 37	Hammond, D., Fong, G.T. and McNeill, A., et al., "Effectiveness of Cigarette Warning Labels in Informing Smokers about the Risks of Smoking: Findings from the International Tobacco Control (ITC) Four Country Survey," <i>Tobacco Control</i> , 15(III); iii19-iii25, 2006, available at http://tc.bmjournals.com/cgi/content/full/15/suppl_3/iii19 .	005234-005241
Reference 38	Peters, E., Romer, D. and Slovic, P., et al., "The Impact and Acceptability of Canadian-Style Cigarette Warning Labels Among U.S. Smokers and Nonsmokers," <i>Nicotine & Tobacco Research</i> , 9(4); 473-481, April 2007.	005242-005251
Reference 39	Federal Trade Commission, "Cigarette Report for 2006," 2009, available at http://www.ftc.gov/os/2009/8/090812cigarettereport.pdf .	005252-005278
Reference 40	National Cancer Institute, "The Role of the Media in Promoting and Reducing Tobacco Use," NCI Tobacco Control Monograph Series, Monograph 19, NIH Publication No. 07-6242, 2008, available at cancercontrol.cancer.gov/TCRB/monographs/19/index.html .	005279-005942
Reference 41	Millar, W.J., "Reaching Smokers with Lower Educational Attainment," <i>Health Reports (Statistics Canada)</i> , 8(2); 11-19, 1996.	005943-005951

Name	Title	Bates
Reference 42	Fong, G.T., Hammond, D., and Hitchman, S.C., "The Impact of Pictures on the Effectiveness of Tobacco Warnings," Bulletin of the World Health Organization, 87; 640-43, 2009, available at www.who.int/bulletin/volumes/87/8/09-069575.pdf .	005952-005955
Reference 43	Canadian Cancer Society, Evaluation of New Warnings on Cigarette Packages. Prepared by Environics, Focus Canada 2001-3, 2001, available at http://www.cancer.ca/Canada-wide/How%20you%20can%20help/Take%20action/Advocacy%20what%20were%20doing/Tobacco%20control%20advocacy/Progress%20in%20tobacco%20control/Evaluation%20of%20new%20warnings%20on%20cigarette%20packages.aspx?sc_lang=en .	005956-006021
Reference 44	Morrison, W., Doucet, C., and Diener, A., "Knowledge of Health Risks," Health Canada, 2002 Youth Smoking Survey-Technical Report; 197-228, 2004, available at http://www.hc-sc.gc.ca/hc-ps/pubs/tobac-tabac/yss-etj-2002/index-eng.php .	006022-006369
Reference 45	Koval, J.J., Aubut, J.A., et al., "The Potential Effectiveness of Warning Labels on Cigarette Packages: The Perceptions of Young Adult Canadians," Canadian Journal of Public Health/Revue Canadienne de Sante Publique, 96(5); 353-6, 2005.	006370-006373
Reference 46	Borland, R., Wilson, N., et al., "Impact of Graphic and Text Warnings on Cigarette Packs: Findings from Four Countries over Five Years," Tobacco Control, 18(5); 358-364, 2009.	006374-006381
Reference 47	White, V., Webster, B., and Wakefield, M., "Do Graphic Health Warning Labels Have an Impact on Adolescents' Smoking-Related Beliefs and Behaviours?" Addiction, 103; 1562-71, 2008.	006382-006391
Reference 48	Elliott & Shanahan Research, "Developmental Research for New Australian Health Warnings on Tobacco Products Stage 2," prepared for Population Health Division, Department of Health and Ageing, Commonwealth of Australia, August 2003, available at http://www.health.gov.au/internet/main/publishing.nsf/Content/4FA9E17EB0A1FB6ECA25776900054914/\$File/warnres2.pdf .	006392-006457
Reference 49	Kempf, D.S. and Harmon, S.K., "Examining the Effectiveness of Proposed Cigarette Package Warning Labels with Graphic Images Among U.S. College Students," Academy of Marketing Studies Journal, 10(2); 77-93, 2006.	006458-006474
Reference 50	O'Hegarty, M., Pederson, L.L., et al., "Young Adults' Perceptions of Cigarette Warning Labels in the United States and Canada," Preventing Chronic Disease, 4(2); 1-9, 2007.	006475-006483
Reference 51	Hammond, D., Fong, G.T., et al., "Graphic Canadian Cigarette Warning Labels and Adverse Outcomes: Evidence from Canadian Smokers," American Journal of Public Health, 94(8); 1442-5, 2004.	006484-006487
Reference 52	Shanahan, P. and Elliot, D., "Evaluation of the Effectiveness of the Graphic Health Warnings on Tobacco Product Packaging 2008," Canberra: Australian Government Department of Health and Ageing, 2009.	006488-006729
Reference 53	Miller, C.L., Hill, D.J., Quester, P.G., et al., "Response of Mass Media, Tobacco Industry and Smokers to the Introduction of Graphic Cigarette Pack Warnings in Australia," European Journal of Public Health, 19(6); 644-49, 2009.	006730-006735
Reference 54	Vardavas, C.I., Connolly, G., et al., "Adolescents Perceived Effectiveness of the Proposed European Graphic Tobacco Warning Labels," European Journal of Public Health, 19(2); 212-17, 2009.	006736-006741

Name	Title	Bates
Reference 55	O'Hegarty, M., Pederson, L.L., et al., "Reactions of Young Adult Smokers to Warning Labels on Cigarette Packs," American Journal of Preventive Medicine, 30(6); 467-73, 2006.	006742-006748
Reference 56	Health Canada, "Canadian Tobacco Use Monitoring Survey (CTUMS)," available at http://hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_ctums-esutc_prevalence/prevalence-eng.php .	006749-006763
Reference 57	Elliott & Shanahan Research, "Literature Review: Evaluation of the Effectiveness of the Graphic Health Warnings on Tobacco Product Packaging 2008," prepared for Department of Health and Ageing, Commonwealth of Australia, 2009.	006764-006830
Reference 58	Danaei, G., Ding, E.L., and Mozaffarian, E., et al., "The Preventable Causes of Death in the United States: Comparative Risk Assessment of Dietary, Lifestyle and Metabolic Risk Factors," PLoS Medicine 6(4), April 28, 2009.	006831-006853
Reference 59	Tobacco Labelling Resource Centre, "Country Information: Canada," available at http://www.tobaccolabels.ca/currentl/canada (accessed August 3, 2010).	006854-006861
Reference 60	Eastern Research Group, Inc., "Baseline of State and International Tobacco Laws," June 25, 2010.	006862-006950
Reference 61	Health Canada, "Overview of Historical Data, Wave 1, 1999-2009," available at http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_ctums-esutc_2009/w-p-1_histo-eng.php (accessed August 3, 2010).	006951-006957
Reference 62	National Center for Health Statistics (U.S. Department of Health and Human Services), "National Health Interview Survey: Questionnaires, Datasets and Related Documentation, 1997 to the Present," available at http://www.cdc.gov/nchs/nhis/quest_data_related_1997_forward.htm (accessed July 23, 2010).	006958-006962
Reference 63	Health Canada, Tobacco Directorate, "Long-Term Trends in the Prevalence of Current Smokers," Mimeo, May 14, 2009.	006963-006964
Reference 64	National Center for Biotechnology Information, "Health, United States, 2005: Table 63," available at http://www.cdc.gov/nchs/data/hus/hus05.pdf .	006965-006974
Reference 65	U.S. Census Bureau, Population Division, Interim State Population Projections, 2005, available at http://www.census.gov/population/www/projections/projectionsagesex.html .	006975-006992
Reference 66	Sloan, F.A., Ostermann, J., and Conover, C., et al., The Price of Smoking, Cambridge MA: MIT Press (2004).	006993-007034
Reference 67	Taylor, Donald H., Jr., et al., "Benefits of Smoking Cessation for Longevity," American Journal of Public Health, 92(6): 990-996, 2002.	007035-007042
Reference 68	OMB Circular A-4, 11-12.	007043-007090
Reference 69	Cutler, D. 2008, "Are We Finally Winning the War on Cancer?" Journal of Economic Perspectives, 22:3-26.	007091-007114
Reference 70	Murphy, K.M. and Topel, R.H., "The Value of Health and Longevity," Journal of Political Economy, 114(5): 871-904, 2006.	007115-007149
Reference 71	Sullivan, P.W. and Gushchyan, V., "Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States," Medical Decision-Making, 26: 410-420, July-Aug. 2006.	007150-007161
Reference 72	Hall, John R., Jr., "The Smoking-Material Fire Problem," Quincy, MA: National Fire Protection Association, March 2010.	007162-007207
Reference 73	National Fire Protection Association, News Release, July 16, 2004.	007208-007209

Name	Title	Bates
Reference 74	ABC News/Associated Press, Fire-Safe Cigarette Law Yields Results, February 13, 2006.	007210-007211
Reference 75	U.S. Environmental Protection Agency, National Center for Environmental Economics, "Frequently Asked Questions on Mortality Risk Valuation," 2010, available at http://yosemite.epa.gov/ee/epa/eed.nsf/pages/MortalityRiskValuation.html .	007212-007217
Reference 76	U.S. Department of Commerce, Bureau of Economic Analysis, 2010a, National Economic Accounts: Current-dollar and "real" GDP, available at http://www.bea.gov/national/index.htm .	007218-007220
Reference 77	U.S. Census Bureau, Statistics of U.S. Businesses (SUSB), Latest SUSB Annual Data, U.S., All Industries, 2007, available at http://www.census.gov/econ/susb/ (accessed July 2010).	007221-007481
Reference 78	U.S. Census Bureau, 2005c, Product Lines: 2002, 2002 Economic Census, Accommodation and Food Services, Subject Series, available at http://www.census.gov/prod/ec02/ec0272sllst.pdf .	007482-007504
Reference 79	U.S. Census Bureau, 2005d, Product Lines: 2002, 2002 Economic Census, Retail Trade, Subject Series, available at http://www.census.gov/prod/ec02/ec0244sllst.pdf .	007505-007764
Reference 80	U.S. Census Bureau, Nonemployer Statistics, U.S., All Industries, 2008, Retail Trade, Accommodation and Food Services, available at http://censtats.census.gov/cgi-bin/nonemployer/nonsect.pl (accessed July 2010).	007765-007783
Reference 81	RTI: Muth, Mary K., Melanie J. Ball, Michaela C. Coglaiti, and Shawn A. Karns. "Model to Estimate Costs of Using Labeling as a Risk-Reduction Strategy for Consumer Products Regulated by the Food and Drug Administration," Methodology Report, RTI International, Research Triangle Park, NC: May 2010.	007784-007915
Reference 82	RTI Spreadsheet: Preliminary Estimates from the Forthcoming FDA Labeling Cost Model, August 2010.	007916-007918
Reference 83	RTI Spreadsheet: Preliminary Estimates from the Forthcoming FDA Labeling Cost Model, August 2010. RTI: Muth, Mary K., Erica C. Gledhill, and Shawn A. Karns, "FDA Labeling Cost Model." RTI Health, Social, and Economics Research, Research Triangle Park, NC: January 2003.	007919-008051
Reference 84	California Directory of Compliant Cigarettes and Roll-Your-Own Brand Families Listed by Manufacturer, available at http://ag.ca.gov/tobacco/pdf/CompliantManufacturers.pdf (accessed July 2, 2010).	008052-008061
Reference 85	"District of Columbia Tobacco Directory," Office of the Chief Financial Officer, available at http://cfo.dc.gov/cfo/cwp/view,A,1324,Q,616374.asp (accessed Aug. 6, 2010).	008062-008066
Reference 86	Hawaii, State of, Department of the Attorney General, Criminal Justice Division Tobacco Enforcement Unit "Directory: Cigarettes and Roll-Your-Own Tobacco," available at http://hawaii.gov/ag/tobacco/Directory%2010-28-10.pdf .	008067-008125
Reference 87	Nebraska Department of Revenue, "Nebraska Directory of Certified Tobacco Product Manufacturers and Brands," August 2010, available at http://www.revenue.ne.gov/cig/manufacturer.html .	008126-008130
Reference 88	"South Carolina Tobacco Directory," Office of the Attorney General, November 1, 2010, available at http://www.scattorneygeneral.org/civil/pdf/sc_tobacco_directory.pdf .	008131-008139
Reference 89	"Utah Approved Tobacco Manufacturers and Cigarette/RYO Brands," Utah State Tax Commission Publication 51, 11/01/2010, available at http://tax.utah.gov/forms/pubs/pub-51.pdf .	008140-008143

Name	Title	Bates
Reference 90	Flynn, Jennifer D, "Characteristics of Home Fire Victims Fact Sheet," NFPA Fire Analysis and Research, March 2010.	008144-008145
Reference91	Arias, E., "United States Life Tables, 2006," National Vital Statistics Reports 58(21), June 28, 2010, available at http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf .	008146-008185
Reference 92	U.S. Census Bureau, American FactFinder, "2006 Annual Survey of Manufacturers," available at http://factfinder.census.gov/servlet/lBQTable?_bm=y&-ds_name=AM0631GS101 .	008186-008188
Reference 93	Thrasher, James F. et al. "Estimating the Impact of Different Cigarette Package Warning Label Policies: The Auction Method," Addictive Behaviors, 32: 2916-2925, 2007.	008189-008198
Reference 94	U.S. Department of Agriculture, "2007 Census of Agriculture: United States Summary and State Data: Volume 1, Geographic Area Series, Part 51," December 2009, available at http://www.agcensus.usda.gov/Publications/2007/Full_Report/usv1.pdf .	008199-008937
Reference 95	Chaloupka, F., and Warner, K, "The Economics of Smoking," Handbook of Health Economics, ed., Holland: Newhouse.Amsterdam, 2000.	008938-009071
Reference 96	Warner, K.E., et al., "Employment Implications of Declining Tobacco Product Sales for the Regional Economies of the United States," Journal of the American Medical Association, 1996.	009072-009077
Reference 97	U.S. Bureau of Economic Analysis, National Economic Accounts. "Table 3.5. Taxes on Production and Imports," available at http://www.bea.gov/national/nipaweb/SelectTable.asp (accessed October 13, 2010).	009078-009079
Reference 98	U.S. Department of the Treasury, Alcohol and Tobacco Tax and Trade Bureau, "Federal Excise Tax Increase and Related Provisions," available at http://www.ttb.gov/main_pages/schip-summary.shtml (accessed August 18, 2010).	009080-009085
Reference 99	Tax Foundation, "State Sales, Gasoline, Cigarette and Alcohol Tax Rates by State, 2000-2010," available at http://www.taxfoundation.org/publications/show/245.html .	009086-009088
Reference 100	U.S. Department of Commerce, Census Bureau 2008, National Cancer Institute and Centers for Disease Control and Prevention co-sponsored Tobacco Use Supplement to the Current Population Survey 2006-2007, available at http://www.nber.org/data/current-population-survey-data.html .	009089-009093
Reference 101	U.S. Department of Commerce, Bureau of Economic Analysis, 2010b, National Income and Product Accounts Table 2.5.5, available at http://www.bea.gov/national/nipaweb/TableView.asp?SelectedTable=74&Freq=Year&FirstYear=2008&LastYear=2009 (accessed August 26, 2010).	009094-009099
Reference 102	U.S. Census Bureau, 2010, International Trade Statistics.	009100-009101
Reference 103	U.S Department of Agriculture, Foreign Agricultural Service, Global Agricultural Trade System Online, available at http://www.fas.usda.gov/ustrade/usthome.asp (accessed August 9, 2010).	009102-009103
Reference 104	AC Nielsen, 2010.	009104

Name	Title	Bates
Reference 105	Maxwell, J.C., The Maxwell Report: Year-End and Fourth Quarter 2008 Sales Estimates for the Cigarette Industry, Richmond, VA: John C. Maxwell, Jr., February 2009.	009105-009119
Reference 106	U.S. Small Business Administration, 2008, Table of Size Standards, available at http://www.sba.gov/contractingopportunities/officials/size/table/index.html (accessed August 2010).	009120-009161
Reference 107	U.S. Census Bureau, 2005a, Establishment and Firm Size: 2002, 2002 Economic Census, Accommodation and Food Services, Subject Series, available at http://www.census.gov/prod/ec02/ec0272ssszt.pdf .	009162-009212
Reference 108	U.S. Census Bureau, 2005b, Establishment and Firm Size: 2002, 2002 Economic Census, Retail Trade, Subject Series, available at http://www.census.gov/prod/ec02/ec0244ssszt.pdf .	009213-009429
	Cigarette Required Warnings - English and Spanish. U.S. Food and Drug Administration. PROPOSED Edition 1.0, November 2010.	009430-009437
	Cigarette Required Warnings - Other Foreign Language Advertisements. U.S. Food and Drug Administration. PROPOSED Edition 1.0, November 2010.	009438-009440
	Health warnings for U.S. Food and Drug Administration proposed regulation "Required Warnings for Cigarette Packages and Advertisements".	009441-009517
Final Rule References		
Reference 1	Centers for Disease Control and Prevention, "Smoking-Attributable Mortality, Years of Potential Life Lost, and Productivity Losses--United States, 2000-2004," Morbidity and Mortality Weekly Report, 57(45); 1226-1228, Nov. 14, 2008, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5745a3.htm .	009518-09522
Reference 2	U.S. Department of Health and Human Services, "The Health Consequences of Smoking," A Report of the Surgeon General; 2004, available at http://www.surgeongeneral.gov/library/smokingconsequences/index.html .	09523-010477
Reference 3	Institute of Medicine of the National Academies, "Ending the Tobacco Problem: A Blueprint for the Nation," 2007, available at http://www.iom.edu/Reports/2007/Ending-the-Tobacco-Problem-A-Blueprint-for-the-Nation.aspx .	010478-0111200
Reference 4	Centers for Disease Control and Prevention, "Vital Signs: Current Cigarette Smoking Among Adults Aged > 18 Years--United States, 2009," Morbidity and Mortality Weekly Report, 59(35), 1135-40, Sept. 10, 2010, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5935a3.htm .	011201-011212
Reference 5	Centers for Disease Control and Prevention, "Youth Risk Behavior Surveillance--United States, 2009," Morbidity and Mortality Weekly Report 2010, 59 (No. SS-5); June 4, 2010, available at http://www.cdc.gov/mmwr/pdf/ss/ss5905.pdf .	011213-011357
Reference 6	Centers for Disease Control and Prevention, "Tobacco Use Among Middle and High School Students--United States, 2000-2009," Morbidity and Mortality Weekly Report, 59(33); 1063-68, Aug. 27, 2010, available at http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5933a2.htm .	011358-011368

Name	Title	Bates
Reference 7	Substance Abuse and Mental Health Services Administration, "Results from the 2008 National Survey on Drug Use and Health: National Findings," Rockville, MD: 2009, available at http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.pdf .	011369-011672
Reference 8	Taioli, E., and Wynder, E.L., "Effect of the Age at Which Smoking Begins on Frequency of Smoking in Adulthood," <i>The New England Journal of Medicine</i> , 325(13); 968-69, 1991.	011673-011674
Reference 9	Chen, J., and Millar, W., "Age of Smoking Initiation: Implications for Quitting," <i>Health Reports (Statistics Canada, Catalogue 82-003-XPB)</i> , 9(4); 39-46, 1998.	011675-011682
Reference 10	Breslau, N., and Peterson, E., "Smoking Cessation in Young Adults: Age at Initiation of Cigarette Smoking and Other Suspected Influences," <i>American Journal of Public Health</i> , 86(2); 214-20, 1996.	011683-011689
Reference 11	Hammond, D., "Tobacco Labelling & Packaging Toolkit: A guide to FCTC Article 11," Feb. 2009, available at http://www.tobaccolabels.ca/download/tobaccolab/iatatldtook?attachment=1 .	011690-011821
Reference 12	Max, W., et al., "The Disproportionate Cost of Smoking for African Americans in California," <i>American Journal of Public Health</i> , 100(1); 152-58, 2010.	011822-011828
Reference 13	Lee, J.G.L., Griffin, G.K., and Melvin, C.L., "Tobacco use Among Sexual Minorities in the USA, 1987 to May 2007: a Systematic Review," <i>Tobacco Control</i> , 18; 275-82, 2009.	011829-011837
Reference 14	Helyer, A.J., et al., "Economic Consequences of Tobacco Use for the Department of Defense, 1995" <i>Military Medicine</i> , 163(4); 217-21, 1998.	011838-011842
Reference 15	Bray, R.M., et al., "Substance Use and Mental Health Trends Among U.S. Military Active Duty Personnel: Key Findings From the 2008 DoD Health Behavior Survey," <i>Military Medicine</i> , 175(6); 390-99, 2010.	011843-011852
Reference 16	U.S. Department of Health and Human Services, "The Health Consequences of Smoking: Nicotine Addiction," A Report of the Surgeon General; 1988, available at http://www.surgeongeneral.gov/library/reports/ .	011853-012495
Reference 17	U.S. Department of Health and Human Services, "The Health Consequences of Involuntary Exposure to Tobacco Smoke," A Report of the Surgeon General; 2006, available at http://www.surgeongeneral.gov/library/secondhandsmoke/report/fullreport.pdf .	012496-013220
Reference 18	U.S. Department of Health and Human Services, "Youth & Tobacco; Preventing Tobacco Use Among Young People," A Report of the Surgeon General; 1994, available at http://www.surgeongeneral.gov/library/reports/ .	013221-013440
Reference 19	Institute of Medicine, <i>Growing Up Tobacco Free: Preventing Nicotine Addiction in Children and Youths</i> , Washington, DC: National Academy Press (1994).	013441-013462
Reference 20	Hammond, D., et al., "Text and Graphic Warnings on Cigarette Packages: Findings from the International Tobacco Control Four Country Study," <i>American Journal of Preventive Medicine</i> , 32(3); 202-209, 2007.	013463-013470
Reference 21	Strecher, V.J., et al., "Do Cigarette Smokers Have Unrealistic Perceptions of Their Heart Attack, Cancer, and Stroke Risks?," <i>Journal of Behavioral Medicine</i> , 18; 45-54, 1995.	013471-013480
Reference 22	Slovic, P., "Do Adolescent Smokers Know the Risks?," <i>Duke Law Journal</i> , 47; 1133-41, 1998.	013481-013487

Name	Title	Bates
Reference 23	Survey of 900 Adult Smokers in the U.S. Conducted by American Legacy Foundation and GlaxoSmithKline Consumer Healthcare, August 2007. http://www.americanlegacy.org/304.aspx .	013488-013493
Reference 24	Finney Rutten, L.J., et al., "Smoking Knowledge and Behavior in the United States: Sociodemographic, Smoking Status, and Geographic Patterns," <i>Nicotine & Tobacco Research</i> , 10 (10); 1559-70, 2008.	013494-013506
Reference 25	Ayanian, J.Z., and Cleary, P.D., "Perceived Risks of Heart Disease and Cancer Among Cigarette Smokers," <i>Journal of the American Medical Association</i> , 281(11); 1019-21, 1999.	013507-013509
Reference 26	Hammond, D., Fong, G.T. and McNeill, A., et al., "Effectiveness of Cigarette Warning Labels in Informing Smokers about the Risks of Smoking: Findings from the International Tobacco Control (ITC) Four Country Survey," <i>Tobacco Control</i> , 15(III); iii19-iii25, 2006, available at http://tc.bmjournals.com/cgi/content/full/15/suppl_3/iii19 .	013510-013516
Reference 27	Oncken, C., et al, "Knowledge and Perceived Risk of Smoking-Related Conditions: a Survey of Cigarette Smokers," <i>Preventive Medicine</i> , 40(6); 779-84, 2005.	013517-013522
Reference 28	Weinstein ND, et al., "Public Understanding of the Illnesses Caused by Cigarette Smoking," <i>Nicotine & Tobacco Research</i> , 6(2); 349-55, April 2004.	013523-013530
Reference 29	Cummings, K.M., et al. "Are Smokers adequately Informed about the Health Risks of Smoking and Medicinal Nicotine?," <i>Nicotine & Tobacco Research</i> , 6 (Supp. 3); S333-40, December 2004.	013531-013539
Reference 30	Johnston, LD, et al., National Survey Results on Drug Use from the Monitoring the Future Study, 1975-1997, Volume I: Secondary School Students, National Institute on Drug Abuse, Rockville, MD, NIH Publication No. 98-4345, 1998.	013540-013986
Reference 31	Romer, D., Jamieson, P, "The Role of Perceived Risk in Starting and Stopping Smoking," in Slovic, P. (Ed.), <i>Smoking: Risk, Perception and Public Policy</i> , Thousand Oaks, CA: Sage Publications, Inc. (2001).	013987-014001
Reference 32	Davis, T.C., et al., "Low Literacy Impairs Comprehension of Prescription Drug Warning Labels," <i>Journal of General Internal Medicine</i> , 21(8); 847-51, 2006.	014002-014006
Reference 33	Wolf, M.S., et al., "Misunderstanding of Prescription Drug Warning Labels Among Patients with Low Literacy," <i>American Journal Health-System Pharmacy</i> , 63(11); 1048-55, 2006.	014007-014015
Reference 34	Haddock, C.K., et al., "Modified Tobacco Use and Lifestyle Change in Risk-Reducing Beliefs about Smoking," <i>American Journal of Preventive Medicine</i> , 27(1); 35-41, 2004.	014016-014022
Reference 35	Jamieson, P.E., et al., "Sure Smoking Causes Cancer but it won't Happen to me." Robert Wood Johnson Foundation, July 2001, available at http://www.rwjf.org/reports/grr/037045.htm .	014023-014028
Reference 36	Weinstein, N.D., "Accuracy of Smoker's Risk Perception," <i>Nicotine & Tobacco Research</i> , 1(Supp. 1); S123-S130, 1999.	014029-014037
Reference 37	U.S. Department of Health and Human Services, "How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease," A Report of the Surgeon General; 2010, available at http://www.surgeongeneral.gov/library/tobaccosmoke/report/index.html .	014038-014829

Name	Title	Bates
Reference 38	Farber, H.J., et al., "Secondhand Tobacco Smoke in Children with Asthma: Sources of and Parental Perceptions about Exposure in Children and Parental Readiness to Change," Chest, 133(6); 1367-74, 2008.	014830-014844
Reference 39	Hyland, A, et al., "Attitudes and Beliefs about Secondhand Smoke and Smoke-Free Policies in Four Countries: Findings from the International Tobacco Control Four Country Survey," Nicotine & Tobacco Research, 11(6); 642-49, 2009.	014845-014853
Reference 40	Elliott & Shanahan Research, "Literature Review: Evaluation of the Effectiveness of the Graphic Health Warnings on Tobacco Product Packaging 2008," prepared for Department of Health and Ageing, Commonwealth of Australia, 2009.	014854-014920
Reference 41	Borland, R., Wilson, N., Fong, G.T., et al., "Impact of Graphic and Text Warnings on Cigarette Packs: Findings from Four Countries over Five Years," Tobacco Control, 18(5); 358-64, 2009.	014921-014928
Reference 42	European Health Research Partnership and Centre for Tobacco Control Research, "Research into the Labelling of Tobacco Products in Europe," report submitted to the European Commission; Sept. 15, 2001, available at http://www.ashaust.org.au/pdfs/EuroWarns0306.pdf .	014929-014993
Reference 43	Baxter, L.A. & Babbie, E. 2004. The Basics of Communication Research. Toronto, ON: Thomson Wadsworth.	014994-014998
Reference 44	Hammond, D., Fong, G.T., et al., "Graphic Canadian Cigarette Warning Labels and Adverse Outcomes: Evidence from Canadian Smokers," American Journal of Public Health, 94(8); 1442-5, 2004.	014999-015002
Reference 45	Peters, E., et al., "The Impact and Acceptability of Canadian-Style Cigarette Warning Labels Among U.S. Smokers and Nonsmokers," Nicotine & Tobacco Research, 9(4); 473-481, April 2007.	015003-015013
Reference 46	Fong, G.T., Hammond, D., and Hitchman, S.C., "The Impact of Pictures on the Effectiveness of Tobacco Warnings," Bulletin of the World Health Organization, 87; 640-43, 2009, available at http://www.who.int/bulletin/volumes/87/8/09-069575.pdf .	015014-015017
Reference 47	Vardavas, C.I., Connolly, G., et al., "Adolescents Perceived Effectiveness of the Proposed European Graphic Tobacco Warning Labels," European Journal of Public Health, 19(2); 212-17, 2009.	015018-015023
Reference 48	Elliott & Shanahan Research, "Developmental Research for New Australian Health Warnings on Tobacco Products Stage 2," prepared for Population Health Division, Department of Health and Ageing, Commonwealth of Australia, August 2003, available at http://www.health.gov.au/internet/main/publishing.nsf/Content/4FA9E17EB0A1FB6ECA25776900054914/\$File/warnres2.pdf .	015024-015089
Reference 49	Nonnemaker, J., et al., "Experimental Study of Graphic Cigarette Warning Labels: Final Results Report Prepared for Center for Tobacco Products, Food and Drug Administration," Contract No. HHSF-223-2009-10135G, Dec. 2010.	015090-015606
Reference 50	RTI International, "Errata to Experimental Study of Graphic Cigarette Warning Labels," Contract No. HHSF-223-2009-10135G, May 2011.	015607-015613
Reference 51	Dillard, J.P., Weber, K.M., and Vail, R.G., "The Relationship Between the Perceived and Actual Effectiveness of Persuasive Messages: A Meta-Analysis With Implications for Formative Campaign Research," Journal of Communication, 57; 613-631, 2007.	015614-015637

Name	Title	Bates
Reference 52	Kees, J., et al., "Understanding How Graphic Pictorial Warnings Work on Cigarette Packaging," Journal of Public Policy & Marketing, 29(2); 265-76, 2010.	015638-015650
Reference 53	Goodall, C., and Appiah, O., "Adolescents' Perceptions of Canadian Cigarette Package Warning Labels: Investigating the Effects of Message Framing," Health Communications, 23; 117-27, 2008.	015651-015661
Reference 54	National Cancer Institute, "The Role of the Media in Promoting and Reducing Tobacco Use," NCI Tobacco Control Monograph Series, Monograph 19, NIH Publication No. 07-6242, 2008, available at http://cancercontrol.cancer.gov/TCRB/monographs/19/index.html .	015662-016344
Reference 55	Strahan E.J., et al., "Enhancing the Effectiveness of Tobacco Package Warning Labels: a Social Psychological Perspective," Tobacco Control, 11(3); 183-90, 2002.	016345-016352
Reference 56	"The International Language of ISO Graphical Symbols," 2010, available at http://www.iso.org/iso/graphical-symbols_booklet.pdf .	016353-016388
Reference 57	Wogalter, M.S., Kalsher, M.J., and Rashid, R., "Effect of Signal Word and Source Attribution on Judgments of Warning Credibility and Compliance Likelihood," International Journal of Industrial Ergonomics, 24(2); 185-92, 1999.	016389-016396
Reference 58	Shaw, G.M., et al., "Orofacial Clefts, Parental Cigarette Smoking, and Transforming Growth Factor-Alpha Gene Variants," American Journal of Human Genetics, 58; 551-61, 1996.	016397-016408
Reference 59	Guttman, N. and Peleg, H., "Public Preferences for an Attribution to Government or to Medical Research Versus Unattributed Messages in Cigarette Warning Labels in Israel," Health Communication, 15(1); 1-25, 2003.	016409-016433
Reference 60	Framework Convention on Tobacco Control, adopted May 21, 2003, available at http://whqlibdoc.who.int/publications/2003/9241591013.pdf .	016434-016477
Reference 61	Hammond D., "Health Warnings on Tobacco Packages: Summary of Evidence and Legal Challenges," January 2008, available at http://tobaccofreecenter.org/files/pdfs/en/India-study-warningLabels-DHammond-Jan08.pdf .	016478-016508
Reference 62	Wogalter, M.S., Conzola, V.C., and Smith-Jackson, T.L., "Research-Based Guidelines for Warning Design and Evaluation," Applied Ergonomics, 33; 219-30, 2002.	016509-016520
Reference 63	Borland, R. and Hill, D., "Initial Impact of the New Australian Tobacco Health Warnings on Knowledge and Beliefs," Tobacco Control, 6(4); 317-25, 1997.	016521-016529
Reference 64	U.S. Food and Drug Administration, "Cigarette Required Warnings--PDF Files," June 2011. Required Warning 1	016530-016863
Reference 65	Centers for Disease Control and Prevention, "Cigarette Smoking Among Adults--United States, 2007," Morbidity and Mortality Weekly Report, 57(45); 1221-26, 2008.	016864-016870
Reference 66	Fiore, M.C., Jaen C.R., Baker T.B., et al., "Treating Tobacco Use and Dependence: 2008 Update," Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, 2008, available at http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf .	016871-017146
Reference 67	Miller, C., Hill, D., and Quester, P., "Impact on the Australian Quitline of the New Graphic Cigarette Pack Warnings Including the Quitline Number," Tobacco Control, 18; 235-237, 2009.	017147-017149

Name	Title	Bates
Reference 68	Wilson, N., Li, J., Hoek, J. et. al., "Long-Term Benefit of Increasing the Prominence of a Quitline Number on Cigarette Packaging: 3 years of Quitline Call Data," New Zealand Medical Journal, 123(1321); 109-11, Aug. 2010.	017150-017152
Reference 69	Wilson, N., Weerasekera, D., Hoek, J., et al., "Increased Smoker Recognition of a National Quitline Number Following Introduction of Improved Pack Warnings: ITC Project New Zealand," Nicotine & Tobacco Research, 12 (Supp.); S72-7, Oct. 2010.	017153-017158
Reference 70	UK Department of Health, "Consultation on the Introduction of Picture Warnings on Tobacco Packs," August 2007, available at http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_077962.pdf .	017159-017183
Reference 71	Bot, S., et al., "Impact of Telephone Numbers on Cigarette Packets on Call Volumes to Quitlines," STIVIRO, den Haag, the Netherlands, 2007, available at http://enqonline.org/presentations/Impact_of_Quitline_Telephone_Numbers_on_Cigarette_Packets_final.pdf .	017184-017218
Reference 72	Willemsen, M.C., Simons, C., and Zeeman, G., "Impacts of the New EU Health Warnings on the Dutch Quit Line," Tobacco Control, 11; 381-82, 2002.	017219-019222
Reference 73	Cavalcante, T.M., "Labelling and Packaging in Brazil," available at http://www.who.int/tobacco/training/success_stories/en/best_practices_brazil_labelling.pdf .	017223-017238
Reference 74	Showing the Truth, Saving Lives: the Case for Pictorial Health Warnings (2009). Washington, DC, PAHO: Pan American Health Organization.	017239-017270
Reference 75	Brown J.H., D'Emidio-Caston, M., and Pollard, J.A., "Students and Substances: Social Power in Drug Education," Educational Evaluation and Policy Analysis, 19; 65-82, 1997.	017271-017294
Reference 76	Keller, P.A., and Block, L.G., "Increasing the Persuasiveness of Fear Appeals: The Effect of Arousal and Elaboration," Journal of Consumer Research, 22; 448-59, 1996.	017295-017307
Reference 77	Moscato, S., et al., "Evaluating a Fear Appeal Message to Reduce Alcohol Use Among 'Greeks'," American Journal of Health Behavior, 25(5); 481-91, 2001.	017308-017324
Reference 78	Pechmann, C., et al., "What to Convey in Antismoking Advertisements for Adolescents: The Use of Protection Motivation Theory to Identify Effective Message Themes," Journal of Marketing for Mental Health, 67; 1-18, 2003.	017325-017342
Reference 79	Gore, T.D., and Bracken, C.C., "Testing the Theoretical design of a Health Risk Message: Reexamining the Major Tenets of the Extended Parallel Process Model," Health Education & Behavior, 32(1); 27-41, Feb. 2005.	017343-017357
Reference 80	Ruiter, R.A.C., et al., "Danger and Fear Control in Response to fear Appeals: The Role of Need for Cognition," Basic and Applied Social Psychology, 26; 13-24, 2004.	017358-017370
Reference 81	Witte, K., and Allen, M., "A Meta-Analysis of Fear Appeals: Implications for Effective Public Health Campaigns," Health Education & Behavior, 27(5); 591-615, Oct. 2000.	017371-017395
Reference 82	Ossip-Klein, D., Giovino, G.A., Megahed, N., et al., "Effects of a Smokers' Hotline: Results of a 10-County Self-Help Trial," Journal of Consulting and Clinical Psychology, 59(2); 325-32, 1991.	017396-017403

Name	Title	Bates
Reference 83	Li, J., and Grigg, M., "New Zealand: New Graphic Warnings Encourage Registrations with the Quitline," <i>Tobacco Control</i> , 18(1); 72, 2009.	017404
Reference 84	Avery, R., et al., "Private Profits and Public Health: Does Advertising of Smoking Cessation Products Encourage Smokers to Quit?" <i>Journal of Political Economy</i> , 115(3); 447-81, 2007.	017405-017440
Reference 85	Farrelly, M.C., et al., "Getting to the Truth: Evaluating National Tobacco Countermarketing Campaigns," <i>American Journal of Public Health</i> , 92(6); 901-07, 2002.	017441-017448
Reference 86	Wakefield, M., et al., "Effect of Televised Tobacco Company-Funded Smoking Prevention Advertising on Youth Smoking-Related Beliefs, Intentions, and Behavior," <i>American Journal of Public Health</i> , 96(12); 2154-60, 2006.	017449-017456
Reference 87	Cokkinides, V.E., et al., "Racial and Ethnic Disparities in Smoking-Cessation Interventions: Analysis of the 2005 National Health Interview Survey," <i>American Journal of Preventive Medicine</i> , 34(5); 404-12, 2008.	017457-017465
Reference 88	Stead, L.F., Perera, R., and Lancaster, T., "Telephone Counselling for Smoking Cessation (Review)," <i>Cochrane Database of Systematic Reviews</i> , Issue 3, 2009.	017466-017560
Reference 89	U.S. Department of Health and Human Services, "Ending the Tobacco Epidemic: A Tobacco Control Strategic Action Plan for the U.S. Department of Health and Human Services," Nov. 10, 2010, available at http://www.hhs.gov/ash/initiatives/tobacco/tobaccostrategicplan2010.pdf .	017561-017625
Reference 90	Centers for Disease Control and Prevention, "Telephone Quitlines: A Resource for Development, Implementation, and Evaluation," U.S. Department of Health and Human Services; 2004, available at http://www.cdc.gov/tobacco/quit_smoking/cessation/quitlines/pdfs/quitlines.pdf .	017626-017767
Reference 91	Universal Service Monitoring Report, CC Docket No. 98-202, Section 6, 2010, available at http://hraunfoss.fcc.gov/edocs_public/attachmatch/DOC-303886A1.pdf .	017768-018364
Reference 92	NTIA Research Preview, Digital Nation: Expanding Internet Usage, U.S. Department of Commerce: National Telecommunications and Information Administration, February 2011, available at http://www.ntia.doc.gov/reports/2011/NTIA_Internet_Use_Report_February_2011.pdf .	018365-018392
Reference 93	Sheffer, M.A., et al., "Creating a Perfect Storm to Increase Consumer Demand for Wisconsin's Tobacco Quitline," <i>American Journal of Preventive Medicine</i> , 38(3S); S343-46, 2010.	018393-018396
Reference 94	Lancaster, T., and Stead, L.F., "Physician Advice for Smoking Cessation," <i>Cochrane Database of Systematic Reviews</i> 2004, Issue 4. Art. No.: CD000165.	018397-018438
Reference 95	Brotherton, S.E., and Etzel, S.I., "Graduate Medical Education, 2007-2008," <i>Journal of the American Medical Association</i> , 300(10); 1228-43, 2008.	018439-018454
Reference 96	Schnoll, R.A., et al., "Smoking Cessation Treatment by Primary Care Physicians: An Update and Call for Training," <i>American Journal of Preventive Medicine</i> , 31(3); 233-39, 2006.	018455-018461

Name	Title	Bates
Reference 97	Kempf, D.S., and Harmon, S.K., "Examining the Effectiveness of Proposed Cigarette Package Warning Labels with Graphic Images Among U.S. College Students," <i>Academy of Marketing Studies Journal</i> , 10(2); 77-93, 2006.	018462-018478
Reference 98	Centers for Disease Control and Prevention, Office on Smoking and Health Web site, available at http://www.cdc.gov/tobacco/index.htm .	018479-018482
Reference 99	Hammond, D., Fong, G.T., and McDonald, P.W., et al., "Impact of the graphic Canadian warning labels on adult smoking behaviour," <i>Tobacco Control</i> , 12(4); 391-95, 2003.	018483-018487
Reference 100	Hammond, D., McDonald, P.W., and Fong, G.T., et al., "The Impact of Cigarette Warning Labels and Smoke-free Bylaws on Smoking Cessation--Evidence from Former Smokers," <i>Canadian Journal of Public Health/Revue Canadienne de Sante Publique</i> , 95(3); 201-04, May-June 2004.	018488-018491
Reference 101	Thrasher, James F. et al. "Estimating the Impact of Different Cigarette Package Warning Label Policies: The Auction Method," <i>Addictive Behaviors</i> , 32; 2916-25, 2007.	018492-018501
Reference 102	U.S. Census Bureau, "Language Use and English-Speaking Ability: 2000," October 2003, available at http://www.census.gov/prod/2003pubs/c2kbr-29.pdf .	018502-018512
Reference 103	OMB Circular A-4.	018513-018560
Reference 104	Gruber, J. and Köszegi, B., "Is Addiction 'Rational'? Theory and Evidence," <i>Quarterly Journal of Economics</i> , 116(4); 1261-1303, November 2001.	018561-018604
Reference 105	Bernheim, B. D. and Rangel, A., "Addiction and Cue-Triggered Decision Processes," <i>American Economic Review</i> 94(5); 1558-90, December 2004.	018605-018637
Reference 106	Schelling, T., "Economics, or the Art of Self-Management," <i>American Economic Review</i> , 68; 290-94, 1978.	018638-018643
Reference 107	Schelling, T., "The Intimate Contest for Self-Command," <i>The Public Interest</i> , 60; 94-113, 1980.	018644-018668
Reference 108	Schelling, T., "Self-Command in Practice, Policy and in a Theory of Rational Choice," <i>American Economic Review</i> , 74; 1-11, 1984.	018669-018680
Reference 109	Laux, F.L., "Addiction as a Market Failure: Using Rational Addiction Results to Justify Tobacco Regulation," <i>Journal of Health Economics</i> , 19; 421-437, 2000.	018681-018697
Reference 110	Gul, F. and Pesendorfer, W., "Harmful Addiction," <i>Review of Economic Studies</i> , 74; 147-172, 2007.	018698-018724
Reference 111	O'Hegarty, M., Pederson, L.L., et al., "Young Adults' Perceptions of Cigarette Warning Labels in the United States and Canada," <i>Preventing Chronic Disease</i> , 4(2); 1-9, 2007.	018725-018733
Reference 112	Khwaja, A., Sloan, F. and Chung, S., "The Relationship between Individual Expectations and Behaviors: Mortality Expectations and Smoking Decisions," <i>Journal of Risk and Uncertainty</i> , 35; 179-201, September 2007.	018734-018756
Reference 113	National Center for Education Statistics, "National Assessment of Adult Literacy (NAAL)," available at http://nces.ed.gov/naal/kf_demographics.asp .	018757-018759
Reference 114	Carr, T., "State Legislated Actions on Tobacco Issues, 2009," New York, NY: American Lung Association, 2009, available at http://www.lungusa2.org/slati/reports/SLATI_2009_Final_Web.pdf .	018760-019148

Name	Title	Bates
Reference 115	Vining, A. and Weimer, D.L., "An Assessment of Important Issues Concerning the Application of Benefit-Cost Analysis to Social Policy," Journal of Benefit-Cost Analysis, 1(1); Article 6, 2010, available at http://www.bepress.com/jbca/vol1/iss1/6 .	019149-019187
Reference 116	Sloan F.A., Ostermann, J., Conover, C., et al., The Price of Smoking, Cambridge, MA: MIT Press, 2004.	019188-019241
Reference 117	Taylor, D.H., Hassenblad, V., Henley, S.J., et al., "Benefits of Smoking Cessation for Longevity," American Journal of Public Health, 92(6); 990-996, June 2002.	019242-019248
Reference 118	Doll, R., Peto, R., Boreham, J., et al., "Mortality in Relation to Smoking: 50 Years' Observations on Male British Doctors," British Medical Journal, 328(7455); 1519 Epub, June 2004.	019249-019257
Reference 119	Strandberg, A.Y., Strandberg, T.E., Pitkälä, K., et al., "The Effect of Smoking in Midlife on Health-Related Quality of Life in Old Age: A 26-Year Prospective Study," Archives of Internal Medicine, 168(18); 1968-1974, October 13, 2008.	019258-019264
Reference 120	Hodgson, T.A. "Cigarette Smoking and Lifetime Medical Expenditures." The Milbank Quarterly, 70(1); 81-125, 1992.	019265-019307
Reference 121	Warner, K.E. and Mendez, D., "Tobacco Control Policy in Developed Countries: Yesterday, Today and Tomorrow," Nicotine & Tobacco Research, 12(9); 876-87, September 2010.	019308-019319
Reference 122	Warner, K.E., et al., "Employment Implications of Declining Tobacco Product Sales for the Regional Economies of the United States," Journal of the American Medical Association, 275(16); 1241-6, 1996.	019320-019325
Reference 123	Maxwell, J.C., The Maxwell Report: Year-End and Fourth Quarter 2008 Sales Estimates for the Cigarette Industry, Richmond, VA: John C. Maxwell, Jr., February 2009.	019326-019341
Reference 124	Tobacco Labelling Resource Centre, "Country Information: Canada," available at http://www.tobaccolabels.ca/currentl/canada .	019342-019349
Reference 125	Eastern Research Group, Inc., "Baseline of State and International Tobacco Laws," June 25, 2010.	019350-019438
Reference 126	Health Canada, "Overview of Historical Data, Wave 1, 1999-2009," available at http://www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/_ctums-esutc_2009/w-p-1_histo-eng.php .	019439-019445
Reference 127	Health Canada, Tobacco Directorate, "Long-Term Trends in the Prevalence of Current Smokers," Mimeo, May 14, 2009.	019446-019447
Reference 128	National Center for Health Statistics (U.S. Department of Health and Human Services), "National Health Interview Survey: Questionnaires, Datasets and Related Documentation, 1997 to the Present," available at http://www.cdc.gov/nchs/nhis/quest_data_related_1997_forward.htm (accessed July 23, 2010).	019448-019452
Reference 129	National Center for Health Statistics, "Health, United States, 2005, (Table 63)," Hyattsville, MD: National Center for Health Statistics, 2005, available at http://www.cdc.gov/nchs/data/hus/hus05.pdf .	019453-019463
Reference 130	U.S. Census Bureau, Population Division, Interim State Population Projections, 2005, File 4: Interim State Projections of Population by Single Year of Age and Sex: July 1, 2004 to 2030, available at http://www.census.gov/population/www/projections/projectionsagesex.html .	019464-019481
Reference 131	Warner, K.E., Mendez, D., and Smith D.G., "The Financial Implications of Coverage of Smoking Cessation Treatment by Managed Care Organizations," Inquiry 41; 57-69, Spring 2004.	019482-019494

Name	Title	Bates
Reference 132	U.S. Department of Commerce, Bureau of Economic Analysis, 2010, National Economic Accounts: Current-dollar and "real" GDP, available at http://www.bea.gov/national/index.htm .	019495-019497
Reference 133	Gruber, J., "Smoking's 'Internalities,'" Regulation, 25(4); 52-57, Winter 2002-2003.	019498-019504
Reference 134	Cutler, D., "Are We Finally Winning the War on Cancer?" Journal of Economic Perspectives, 22; 3-26, 2008.	019505-019528
Reference 135	Murphy, K.M. and Topel, R.H., "The Value of Health and Longevity," Journal of Political Economy, 114(5); 871-904, 2006.	019529-019563
Reference 136	Arias, E., "United States Life Tables, 2006," National Vital Statistics Reports, 58(21); June 28, 2010, available at http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf .	019564-019603
Reference 137	Giovino, G.A., Chaloupka, F.J., Hartman, A.M., et al., Cigarette Smoking Prevalence and Policies in the 50 States: An Era of Change--The Robert Wood Johnson Foundation ImpacTeen Tobacco Chart Book, Buffalo, NY: University at Buffalo, State University of New York, 2009.	019604-019836
Reference 138	Nyman, J.A., Barleen, N.A., Dowd, B.E., et al., "Quality-of-Life Weights for the U.S. Population: Self-Reported Health Status and Priority Health Conditions, by Demographic Characteristics," Medical Care, 45(7); 618-28, July 2007.	019837-019847
Reference 139	Stewart, S.T., Cutler, D.M., and Rosen, A.B., "Forecasting the Effects of Obesity and Smoking on U.S. Life Expectancy," The New England Journal of Medicine, 361(23); 2252-60, December 3, 2009.	019848-019856
Reference 140	U.S. Department of Labor, Bureau of Labor Statistics. Consumer Price Index Detailed Report, (complete text and tables), December 2010, available at http://www.bls.gov/cpi/cpid1012.pdf .	019857-019979
Reference 141	Hall, J.R., Jr., "The Smoking-Material Fire Problem," Quincy, MA: National Fire Protection Association, March 2010.	019980-020026
Reference 142	U.S. Department of Commerce, Census Bureau 2008, National Cancer Institute and Centers for Disease Control and Prevention co-sponsored Tobacco Use Supplement to the Current Population Survey 2006-2007, available at http://www.nber.org/data/current-population-survey-data.html .	020027-020031
Reference 143	Federal Trade Commission, "Cigarette Report for 2006," 2009, available at http://www.ftc.gov/os/2009/8/090812cigarettereport.pdf .	020032-020058
Reference 144	Markowitz, S., "Where There's Smoking, There's Fire: The Effects of Smoking Policies on the Incidence of Fires in the United States," National Bureau of Economic Research, Working Paper 16625, December 2010, available at http://www.nber.org/papers/w16625 .	0200059-0200096
Reference 145	National Fire Protection Association, News Release, July 16, 2004.	0200097-0200098
Reference 146	Coalition for Fire-Safe Cigarettes, "The New York Experience," available at http://firesafecigarettes.org/itemDetail.asp?categoryID=107&itemID=1512&URL=In+the+news%2FThe+New+York+Experience&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+firesafecigarettes+%28Fire+Safe+Cigarettes%29 , accessed February 14, 2011.	0200099-020100
Reference 147	Flynn, J.D., "Characteristics of Home Fire Victims Fact Sheet," NFPA Fire Analysis and Research, March 2010.	020101-020102
Reference 148	U.S. Census Bureau, Statistics of U.S. Businesses (SUSB), Latest SUSB Annual Data, U.S., All Industries, 2007, available at http://www.census.gov/econ/susb/ (accessed July 2010).	020103-020397

Name	Title	Bates
Reference 149	U.S. Census Bureau, 2005c, Product Lines: 2002, 2002 Economic Census, Accommodation and Food Services, Subject Series, available at http://www.census.gov/prod/ec02/ec0272sllst.pdf .	020398-020420
Reference 150	U.S. Census Bureau, 2005d, Product Lines: 2002, 2002 Economic Census, Retail Trade, Subject Series, available at http://www.census.gov/prod/ec02/ec0244sllst.pdf .	020421-020680
Reference 151	U.S. Census Bureau, Nonemployer Statistics, U.S., All Industries, 2008, Retail Trade, Accommodation and Food Services, available at http://censtats.census.gov/cgi-bin/nonemployer/nonsect.pl (accessed July 2010).	020681-020699
Reference 152	Muth, M.K., Gledhill, E.C., and Karns, S.A., "FDA Labeling Cost Model," Research Triangle Park, NC: Research Triangle Institute (RTI), January 2003.	020700-020832
Reference 153	California Directory of Compliant Cigarettes and Roll-Your-Own Brand Families Listed by Manufacturer, available at http://ag.ca.gov/tobacco/pdf/CompliantManufacturers.pdf (accessed July 2, 2010).	020833-020842
Reference 154	Office of the Chief Financial Officer, "District of Columbia Tobacco Directory," available at http://cfo.dc.gov/cfo/cwp/view,A,1324,Q,616374.asp (accessed Aug. 6, 2010).	020843-020847
Reference 155	State of Hawaii, Department of the Attorney General, Criminal Justice Division Tobacco Enforcement Unit "Directory: Cigarettes and Roll-Your-Own Tobacco," available at http://hawaii.gov/ag/tobacco .	020848-020906
Reference 156	Nebraska Department of Revenue, "Nebraska Directory of Certified Tobacco Product Manufacturers and Brands," August 2010.	020907-020911
Reference 157	State of South Carolina, Office of the Attorney General, "South Carolina Tobacco Directory," November 1, 2010.	020912-020920
Reference 158	Utah State Tax Commission, "Utah Approved Tobacco Manufacturers and Cigarette/RYO Brands," Utah State Tax Commission Publication 51, November 2010.	020921-020924
Reference 159	Braithwaite, R.S., Meltzer, D.O., King, J.T., et al., "What Does the Value of Modern Medicine Say About the \$50,000 per Quality-Adjusted Life-Year Decision Rule?," <i>Medical Care</i> , 46(4): 349-56, April 2008.	020925-020932
Reference 160	U.S. Census Bureau, American FactFinder, "2006 Annual Survey of Manufacturers," 2008, available at http://factfinder.census.gov/servlet/IBQTable?_bm=y&-ds_name=AM0631GS101 .	020933-020935
Reference 160	U.S. Department of Agriculture, "2007 Census of Agriculture: United States Summary and State Data: Volume 1, Geographic Area Series, Part 51," December 2009, available at http://www.agcensus.usda.gov/Publications/2007/Full_Report/usv1.pdf .	020936-021674
Reference 162	Chaloupka, F., and Warner, K, "The Economics of Smoking," in A.J. Culyer and J.P. Newhouse (eds.), <i>Handbook of Health Economics</i> , vol. 1B, Amsterdam: Elsevier, 2000.	021675-021808
Reference 163	U.S. Bureau of Economic Analysis, National Economic Accounts, "Table 3.5. Taxes on Production and Imports," available at http://www.bea.gov/national/nipaweb/SelectTable.asp (accessed October 13, 2010).	021809-021810
Reference 164	U.S. Department of the Treasury, Alcohol and Tobacco Tax and Trade Bureau, "Federal Excise Tax Increase and Related Provisions," available at http://www.ttb.gov/main_pages/schip-summary.shtml (accessed August 18, 2010).	021811-021816

Name	Title	Bates
Reference 165	Tax Foundation, "State Sales, Gasoline, Cigarette and Alcohol Tax Rates by State, 2000-2010," available at http://www.taxfoundation.org/publications/show/245.html .	021817-021819
Reference 166	Joint Committee on Taxation, "Overview of Revenue Estimating Procedures and Methodologies Used by the Staff of the Joint Committee on Taxation," (JCX-1-05), February 2, 2005, available at http://jct.gov/publications.html?func=startdown&id=1181 .	021820-021855
Reference 167	U.S. Department of the Treasury, Daily Treasury Long-Term Rate Data, Daily Treasury Real Long-Term Rates, available at http://www.treasury.gov/resource-center/data-chart-center/interest-rates/Pages/default.aspx (accessed February 11, 2011).	021856-021857
Reference 168	U.S. Department of Commerce, Bureau of Economic Analysis, 2010, National Income and Product Accounts Table 2.5.5, available at http://www.bea.gov/national/nipaweb/TableView.asp?SelectedTable=74&Freq=Year&FirstYear=2008&LastYear=2009 (accessed August 26, 2010).	021858-021863
Reference 169	U.S. Census Bureau, 2010, International Trade Statistics.	021864-021865
Reference 170, Part 1	U.S. Department of Agriculture, Foreign Agricultural Service, Global Agricultural Trade System Online, available at http://www.fas.usda.gov/ustrade/usthome.asp (accessed August 9, 2010).	021866
Reference 170, Part 2	U.S. Department of Agriculture, Foreign Agricultural Service, Global Agricultural Trade System Online, available at http://www.fas.usda.gov/ustrade/usthome.asp (accessed August 9, 2010).	021867
Reference 171	U.S. Small Business Administration, 2008, Table of Size Standards.	021868-021909
Reference 172	U.S. Census Bureau, 2005a, "Establishment and Firm Size: 2002," 2002 Economic Census, Accommodation and Food Services, Subject Series, available at http://www.census.gov/prod/ec02/ec0272ssst.pdf .	021910-021960
Reference 173	U.S. Census Bureau, 2005b, "Establishment and Firm Size: 2002," 2002 Economic Census, Retail Trade, Subject Series, available at http://www.census.gov/prod/ec02/ec0244ssst.pdf .	021961-022177
Reference 174	The Ontario Flue-Cured Tobacco Growers' Marketing Board, Annual Report 2009, Tillsonburg, ON: The Ontario Flue-Cured Tobacco Growers' Marketing Board, June 25, 2009, available at http://www.ontarioflue-cured.com/uploads/General/2009AnnualReport.pdf .	022178-022201
Reference 175	Statistics Canada, "Population by Year, by Province and Territory," 2010, available at http://www40.statcan.gc.ca/l01/cst01/demo02a-eng.htm (accessed February 7, 2011).	022202
Reference 176	Bank of Canada, "Consumer Price Index, 1995 to Present," available at http://www.bankofcanada.ca/en/cpi.html (accessed February 7, 2011).	022203-022208
Reference 177	Centers for Disease Control and Prevention, State Tobacco Activities Tracking and Evaluation (STATE) System, State Comparison Report, available at http://apps.nccd.cdc.gov/statesystem/ComparisonReport/ComparisonReports.aspx (accessed February 7-8, 2011), 1995.	022209-022236

Name	Title	Bates
Reference 178	Jamison, N., et al., "Federal and State Cigarette Excise Taxes--United States, 1995-2009," Morbidity and Mortality Weekly Report, 58(19); 524-27, May 22, 2009.	022237-022244
Reference 179	U.S. Census Bureau Population Division, "Table CO-EST2001-12-00--Time Series of Intercensal State Population Estimates: April 1, 1990 to April 1, 2000," April 11, 2002, available at http://www.census.gov/popest/archives/2000s/vintage_2001/CO-EST2001-12/CO-EST2001-12-00.xls (accessed February 8, 2011).	022245-022246
Reference 180	U.S. Census Bureau, Population Division, "Table 1--Annual Estimates of the Resident Population for the United States, Regions, States and Puerto Rico: April 1, 2000 to July 1, 2009," (NST-EST2009-01), December 2009, available at http://www.census.gov/popest/states/tables/NST-EST2009-01.xls (accessed February 7, 2011).	022247-022248
Reference 181	Weimer, D.L., Vining, A.R., and Thomas, R.K., "Cost-Benefit Analysis Involving Addictive Goods: Contingent Valuation to Estimate Willingness-to-Pay for Smoking Cessation," Health Economics, 18; 181-202, 2009.	022249-022270
Reference 182	Gruber, J.H. and Mullainathan, S., "Do Cigarette Taxes Make Smokers Happier?" Advances in Economic Analysis & Policy, 5(1); Article 4, 2005.	022271-022316
Reference 183	Smith, V.K., Taylor, D.H., Jr., Sloan, F.A., et al., "Do Smokers Respond to Health Shocks?," The Review of Economics and Statistics, 83(4); 675-87, November 2001.	022317-022329
	Miscellaneous Memos	
	Memo to File: Required Warnings for Cigarette Packages and Advertisements Final Rule – Electronic Files for Images.	022330
	NEPA Memo: Required Warnings for Cigarette Packages and Advertisements Proposed Regulation.	022331-022334
	Memo to File: Tribal Consultation and the Proposed Rule "Required Warnings for Cigarette Packages and Advertisements".	022335-022337
	Nielsen Updated Weekly Scanner Data.	022338-022339

Index to Comments on Proposed Rule, "Required Warnings for Cigarette Packages and Advertisements," Docket No. FDA-2010-N-0568, 75 Fed. Reg. 69524 (November 12, 2010)

Document ID	Title	Date Received	Phase
PUBLIC SUBMISSIONS			
FDA-2010-N-0568-DRAFT-0004	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0005	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0006	Norman Beck - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0007	Vanessa Payne - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0008	Denise Morrissette - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0009	Craig Hibner - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0010	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0011	B. R. - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0012	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0013	Herman Todd - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0014	Meagan - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0015	Rachel Mahon Bosman - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0016	Laura Culp - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0017	Marco Schad - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0018	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0019	Mark Maxwell - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0020	William Todd Gunter - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0022	Cameron Dekany - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0023	Amy - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0024	William M. McManus - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0028	James Bryan Mason - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0030	James T. Simmon - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0031	Philip William Young - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0032	Sonya Walters - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0033	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0035	Deborah Moran - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0036	Suanne Sines - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0039	Sara Jordan - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0040	R. Recla - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0041	Charles Ward - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0045	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0047	Ted Steichen - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0051	William V. - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0052	Kristie Nauman - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0053	Bridget Townsley - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0056	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0057	Kevin J O'Conner - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0058	Jonathan David - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0059	A.R. - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0060	James Robert Farmer - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0061	Douglas Paul Huffaker - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0062	Anthony B. McClure - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0063	Carol Louise Hardin - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0066	Kim Anne Schechter - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0070	Adriane Beatrice Miller - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0071	Theresa Verret - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0072	Mary Louise Hirzel - Comment	11/12/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0073	Jim Wilson - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0074	Patricia Waugh - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0075	Cheri L Brown - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0076	James Oliver Henry Niermann, Junior - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0077	Yvonne Watts - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0078	Jamie Elizabeth Perkins - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0079	Robert Ray Gabriel - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0080	Elinor Schwartz - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0081	Paul Jarrod Blonsky - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0082	Dana A. Pintago - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0083	Thomas Krepshaw - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0084	Cameron W. Schnur - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0086	Charles Lineberg Jr. - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0087	Debra Nester - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0088	Howard C. Brown - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0090	Martha Cifuentes - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0091	Joseph Edward Stringer - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0092	Jamison Loos - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0093	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0094	Kimberly Kirsten Gregersen - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0097	Matt Althage - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0098	David Arthur Nelson - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0099	Jacquelynne - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0100	Al Cates - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0101	Bill Burt - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0102	Stephen H Smith - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0103	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0104	Wendy Hays - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0107	Jim Funk - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0109	Edward Charles Middleton - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0111	James Arthur Gould - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0112	Jason Merrell - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0113	Lisa A. Porter - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0114	Christine E. Leitham - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0119	Anonymous - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0120	David Paul Shrader - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0122	Scott D. - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0124	Linda Britton - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0125	John Mark Florence - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0126	E.K. Cobb - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0128	Lily Jun Betz - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0129	Anonymous - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0130	Shirley A. Bryant - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0131	Maggie - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0132	John Lewis Lostetter II - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0134	Barry Lynn Townsend - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0135	David R. Stephens - Comment	11/13/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0136	Karen Janeen Jersvig - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0137	Brian Odonoghue - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0138	Harry Dennis - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0139	Michael Timothy Rodgers - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0140	Dan Tepper - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0143	Anonymous - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0145	Susan Varner - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0147	Erin Janoso - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0148	Eric Newlon - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0150	Brian Eugene Dixon - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0151	Charles H. Smith - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0152	Anonymous - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0154	Gary Hall - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0155	R.S. - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0157	Richard C. Tyll - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0158	Timothy Van Harlin - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0159	Richard Franklin - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0160	Sarah Rudeen - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0161	Anonymous - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0163	Hannah Leigh Young - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0166	Dan Locklair - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0167	Gloria Jean Pierce - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0168	Edward J. Farrell - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0170	Hiltrud Jones - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0171	Therese Martin - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0173	Cheryl A. Merrill - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0174	Janet Ditzer - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0176	William Landgraf, Jr. - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0177	Anonymous - Comment	11/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0178	Sue Chance - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0179	Anonymous - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0181	W. John Martius Jr. - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0182	Andrea G. Leonardi - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0184	Gail Maureen Delaney - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0185	Cindi Williamson - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0186	John B. - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0187	Amber Stivers - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0188	Anonymous - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0189	Lynn T. Henagan - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0191	Michael T. Jones - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0192	Robert L. Texidor - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0194	Dianne A. Hays - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0196	Randal M. Vicars - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0197	Johnny Neil Hays - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0198	Michael L. Bauchan - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0199	John Jay Lyon - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0201	Susan R. Stolburg - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0202	Anonymous - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0203	Robert Scott - Comment	11/14/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0204	Kelly Ebel - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0205	Leonard Rapoport - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0206	James Sidney Ketchum - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0207	Anonymous - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0208	Donia D. Cullison - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0209	A. Combs - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0210	Mary Hatch - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0211	Hoffman - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0213	Peter Murray - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0215	Susan June Felter - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0217	Michael Joseph Boone - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0218	Ryan Jacob Lederman - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0219	Daniel Bethoney - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0220	Julian S. West - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0221	Heather Ann Smithson - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0223	Mary Lee Cole - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0224	James W. Schmus - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0225	Erik Folch - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0226	Anonymous - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0227	John - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0228	Dave Ferree - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0229	Sherry Levitt - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0230	Nora Marie McDowell - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0231	Kevin Mulholland - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0232	Dick Lang - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0233	Daniel Jaimés - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0234	Margierose Salerno - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0235	Louise Fulton - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0236	Gregory Robert Howard - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0237	Sandy J. Floyd - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0238	Beverly Karen Spencer - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0239	Michael Foust - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0240	Marilyn J. Carver - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0242	Harry Edward Baird, Jr. - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0243	Judy Suarez - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0244	Anthony Joseph Sanders - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0246	Anonymous - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0247	Robert Douglas Jones - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0250	John Brown - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0251	Steven Ray Croy - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0252	Carl T. Raff - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0253	Scott M Wiesman - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0254	Lee Dale Smith - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0255	Glenn Russell Smith - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0256	Thomas H. Smallwood, Sr. - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0257	Varun Sastry - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0259	Sheryl - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0260	Steve - Comment	11/14/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0261	Sherry Black - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0262	Anonymous - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0263	Laurie Jean Grina - Comment	11/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0265	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0266	Cheryl Driscoll - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0267	Derek Suchard - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0268	Christina M. Licina - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0269	Ron Roskos - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0273	Mary George - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0274	Diane Paul - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0275	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0278	Angela M. Hoedt - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0279	Tracie - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0288	Jacinda - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0289	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0291	Linda Luciano - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0292	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0294	Scott Ronald Haese - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0295	V.M. Oakley - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0296	Terry L. Hammett - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0297	Patricia Anne Stewart - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0298	Sheral A. Thomas - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0299	Carma Simmons Wise - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0301	Caile E. Spear - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0303	John Vinson - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0306	Michael Renaldo Pedro - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0307	Debbie Byrd - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0308	I. Jamison - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0310	Mark J. Kovasity - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0311	Timothy Allen Urban - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0312	Rick Brovelli - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0313	Don Adams - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0315	Jean Brook - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0317	John Myers - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0318	Roger D. Hale - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0320	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0322	Elaine Rebecca Hinchee - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0324	Jane Savides - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0326	Elaine Yasenia Hernandez Wilson - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0328	Sky Christopherson - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0329	Jennifer L. McArdle - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0330	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0332	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0333	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0336	Erik Bryer - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0337	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0340	Carolyn Durbin - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0343	Miche'le G. Lipari - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0344	Sandra L. Grasley - Comment	11/15/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0345	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0346	Jackie Ann Puvalowski - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0347	Randall Stephens - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0348	Filippo C. Vitale - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0353	Felicia Barnes - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0354	Jesse Derouen - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0355	Charles Lynn Grubbs - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0356	Matthew Hancock - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0357	James Elwood Quinn - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0358	Marlene Cartaina - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0360	Katherine Rosch - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0362	Gwen Miller, RN, COHN - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0363	Marty Horton Ramirez - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0365	Jena Nylec - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0366	Peggy J. Morris - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0367	Stacy K. Williams - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0368	Kevin McCullough - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0369	Daniel Barth - Comment	11/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0370	Karen B. Hortman - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0372	C.M. Springer - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0373	Kevin Fruchey - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0374	Shawn Robert Gertken - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0376	Nancy Hinsdale Poole - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0377	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0379	Elizabeth Trapp - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0380	Bob Rudd - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0383	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0386	Karen Stump - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0387	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0388	David Strunk - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0392	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0393	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0394	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0395	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0396	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0397	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0399	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0400	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0401	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0402	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0403	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0404	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0405	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0406	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0407	Calvin Quigley Cerrone - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0410	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0411	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0412	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0413	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0414	Anonymous - Comment	11/16/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0415	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0416	Tria Vang - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0417	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0421	Jean Barilla - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0426	Charles A. Carlsen - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0427	Martha A. Stamper - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0430	Anonymous - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0431	Marianne Alpha Schroer - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0433	Barbara Lynn FRancesco - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0434	John G. Ellis - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0435	Jenna Cline - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0436	Jenna Cline - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0438	Christie Lynne Goodman - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0439	James R. Kane - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0440	Erin Theisen - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0442	Patricia J. McDulin - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0444	Anonymous - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0447	Michele Renaud - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0448	Vicki Reed - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0450	Betty Jean Robinson - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0453	Linda - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0454	Hannah Walker - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0459	George Eric Forsen - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0462	Anonymous - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0463	Robert Joseph Spellman - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0464	Marilyn Elder - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0465	J.W. - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0468	Jan Alkire - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0469	Jennifer Harrell - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0470	Adam Miller - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0472	Robert E. Morton, Jr. - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0474	T.A. Cover - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0475	Emily Orlikowski - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0478	Barbara Slack - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0479	Anas Brown - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0480	Charles Dolder - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0520	Danielle - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0521	Danielle - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0522	Ayla Marquez - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0523	Stephen McMillen - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0524	Meagan Sierens - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0525	Jessica Cook - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0526	James Fish - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0527	Richard Reis - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0528	William Santagata - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0529	Michael Pallack - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0530	Anne F. Long - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0531	Ann Holterman - Comment	11/18/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0532	Judith Cornelius - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0533	Nedra Dokes - Comment	11/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0534	Anonymous - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0535	Mary Baker - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0536	Clarence D. Bowers - Comment	11/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0548	Chris Stauber - Comment	11/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0550	Barbara Oberman - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0551	Corey Barron - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0552	Richard Edmund Ferry - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0553	Anonymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0554	Katie Fulks - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0558	Anonymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0562	Jenna Cline - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0563	Joseph Conley - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0564	Aaron Faw - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0569	Shontia Griffin - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0573	Paul Lewis - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0577	Bronte Root - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0581	Brent Ray - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0582	Lauren Ambrozic - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0583	Thomas Foeller - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0584	David Hagen - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0585	Annymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0586	Anonymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0588	Anonymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0589	Sue Sayne - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0590	Tim Dougherty - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0591	Anonymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0594	Angel Studebaker - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0595	Heather Cowen-Wilson - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0596	David Hasenauer - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0598	Justin Robertson - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0599	Nora Ferguson - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0600	Anonymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0602	Anonymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0603	Kassie Kronenberger - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0604	Morgan Lederman - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0605	Awais Hussain - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0606	Amber Shipman - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0608	Alex Meffert - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0609	Anonymous - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0610	Ben Weiman - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0611	Beth Bland - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0612	Chris Fletcher - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0613	Judy Sarayda Shapiro - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0614	Christina Carter - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0616	Clarence D. Bowers - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0617	Scott Wohlers - Comment	11/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0618	Karie Newman - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0621	Mary Ann Hartnett - Comment	11/19/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0622	Steve Stout - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0623	Marjorie Carter - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0626	Jennifer Wathen - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0628	Porche Franklin - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0630	Stephanie Steel - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0635	Mary Boyd - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0636	Jane O'Toole - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0637	Colin Rigsby - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0638	Joan Woodcock - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0640	Lindsey Bein - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0641	Gino Rampolla - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0643	Anonymous - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0644	Sara Gonzalez - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0646	Shon Hathcock - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0647	McKenzie Walker - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0648	Robin Moon - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0650	Shelley Nasello - Comment	11/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0652	Sheyda Irani - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0653	Grace E Ekstrom - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0656	T. - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0657	Martin Minemier - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0658	Linda Roberts - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0659	Alan Quackenbush - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0663	Anonymous - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0664	Anonymous - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0665	Cherlyn - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0666	Dianne McNally - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0667	Sherri Bayer - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0668	Edward Merrell - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0670	Gloria J Williams - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0671	Nicole Wagoner - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0672	Anonymous - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0673	Barbara Jones - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0674	Anonymous - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0675	Fernando Almeida - Comment	11/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0676	Charlene Dolos - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0677	Kenneth Sutherland III - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0679	William Cunningham Jr - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0680	Anonymous - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0681	Donna Ipema - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0682	Lindsey - Comment L	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0683	Kelley Briggs - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0684	Roberto Luciano - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0686	Ronald Schoenherr - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0687	Anonymous - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0688	Marilyn Sanders - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0690	Sheena Tomar - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0691	Ronald Henry - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0694	Ronald Rombough - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0695	Terry Pentz - Comment	11/21/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0696	Bibi Prindle - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0697	Mark Pinson - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0699	Tanya Wyatt - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0700	Anonymous - Comment	11/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0703	Anne Field - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0707	Gina Livorsi - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0708	Linda Treglia - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0709	Anonymous - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0710	Jeff Slattery - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0711	Emily Gorenson - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0712	Josie Ceselski - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0713	Theresa Welt - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0714	Vickie Brown - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0716	Jennifer Roche - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0718	Rachel Ciccarone - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0719	Gary Keene - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0720	Nancy Hadley - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0721	Joyce Faltis - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0722	Devon Sanders - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0723	Karen Thompson - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0724	Molly Marks - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0725	Kenyetta Watkins - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0726	Samantha Ross - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0728	Jordan Kantner - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0729	James Smith - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0730	Teddy Sloan - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0731	Anonymous - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0732	Anonymous - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0735	Anonymous - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0736	Ian Durkee - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0740	Joseph Stelzer - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0741	Alec McKenna - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0742	Carolyn Hilde - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0743	Marta Kowal - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0745	Miranda Linco - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0746	Jasmine Paige - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0747	Jack Church - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0750	Mary Bryant - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0751	Deanna Cooley - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0753	Linda Hawkins - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0755	Gregg Cayce - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0756	Diana Verdick - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0757	Lauren Kostrzeski - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0758	Andrew Miller - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0760	Thomas Gabriel - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0761	Yamini Patel - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0762	Kay Adefuye - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0763	Juliet Dlugokecki - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0765	Matt Nadzam - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0767	Keturah Nowak - Comment	11/23/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0768	Fuwad Ogunedina - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0769	Logan Thompson - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0770	Nathan Reynolds - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0772	Anonymous - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0777	Garrett Potterton - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0778	Kelly Bitsilly - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0779	Mark Luger - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0780	Mark Luger - Comment	11/24/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0784	Marissa Villaluna - Comment	11/24/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0788	Jennie Rhoades - Comment	11/24/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0791	Anonymous - Comment	11/24/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0792	Meredith Lindsay Milewicz - Comment	11/24/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0793	Helen Ogden - Comment	11/25/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0794	Anonymous - Comment	11/25/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0795	Todd Burnell Settle - Comment	11/26/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0796	Sarah B. Semon - Comment	11/26/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0797	Richard Draper - Comment	11/26/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0798	Vickie Susan Barrett - Comment	11/26/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0799	Michelle L Sykes - Comment	11/26/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0801	Eileen Bowen - Comment	11/27/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0803	Jeffrey Todd Kinkle - Comment	11/27/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0805	Bennett Myron Spence - Comment	11/27/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0806	Anonymous - Comment	11/27/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0807	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0810	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0811	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0812	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0813	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0814	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0815	Christine Lisiecki - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0816	Michelle Chang - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0817	Jack H. - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0818	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0819	Jamie Mustful - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0820	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0821	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0822	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0824	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0826	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0827	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0829	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0830	Anonymous - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0831	Lane Foster Mobley - Comment	11/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0832	Alexander Meffert-Nelson - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0833	Anonymous - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0836	Lee Vogtman - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0837	Cathy T Moore - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0843	Lorien Smyer - Comment	11/29/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0845	Cal D. Rains - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0848	Tierrilee Adrienne Robb - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0849	Dennis Radecky - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0851	B.H. - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0852	Bovy - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0853	Sobette Anna Sissi - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0854	Sophie Sissi - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0855	Anonymous - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0856	Anonymous - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0857	Thoms Rhoades - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0859	James Edward Arntz - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0861	Anonymous - Comment	11/30/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0862	Anonymous - Comment	11/30/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0868	Anonymous - Comment	11/30/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0869	Anonymous - Comment	11/30/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0870	Anonymous - Comment	11/30/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0873	Tim Pishdad - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0876	Kathy E. Figiel - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0877	Amber Brister - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0878	Mami Dittmar - Comment	11/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0881	Dee Bura - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0883	Anonymous - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0884	Spencer M. - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0885	Wade Austin Perry - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0886	Anonymous - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0888	Anonymous - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0893	Richard Edmund Ferry - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0894	Nikquan Lewis - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0895	Carla Johnson - Comment	11/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0896	Mike Harrison - Comment	11/24/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0901	James Allen Zorns - Comment	12/2/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0903	Lynda Wilson, R.N. - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0904	Unknown - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0905	Ronald T. Schoenherr - Comment	11/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0906	J.P. Cochran - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0907	Patrick Ewalt - Comment	12/3/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0908	J.F. Somers - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0909	Tammy Larson - Comment	12/1/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0912	Amy Roberts - Comment	12/3/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0913	Anonymous - Comment	12/3/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0917	Courtney Elbert - Comment	12/3/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0918	Anonymous - Comment	12/3/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0920	Jack Marrion - Comment	12/4/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0921	Gary Lyndon Simons - Comment	12/4/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0922	Sean Robert Desrochers - Comment	12/4/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0924	Robin L. Bettencourt - Comment	12/5/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0930	Keli Marie Hall - Comment	12/6/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0932	Anonymous - Comment	12/6/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0933	Megan Multack - Comment	12/6/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0942	Shea Marie Evans - Comment	12/6/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-0944	Richard J. Smith III - Comment	12/6/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0952	Marlet Jones - Comment	12/6/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0955	George Perry Hoskin - Comment	12/6/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0958	Samuel C. Ingraham - Comment	12/6/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0963	Danielle S. Mills - Comment	12/7/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0966	Anonymous - Comment	12/7/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0974	Anonymous - Comment	12/7/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0982	Marnie Schilken - Comment	12/7/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0991	Yolanda Dixon - Comment	12/7/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0992	Sven E. Rodenbeck - Comment	12/7/2010	DoNotPost
FDA-2010-N-0568-DRAFT-0995	Amanda Yong - Comment	12/7/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1001	Pamela Kathleen Reynolds - Comment	12/8/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1004	Anonymous - Comment	12/8/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1005	Anonymous - Comment	12/8/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1006	Janice Mercer - Comment	12/8/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1010	Daniel Taharlev - Comment	12/9/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1013	Julie J. Kessler - Comment	12/9/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1019	David Steinmetz, No Butts About It Litter Campaign - Comment	12/10/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1020	Samuel Ikenberry - Comment	12/10/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1026	Anonymous - Comment	12/10/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1031	Dominick Splendorio - Comment	12/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1034	Alan W. Siemering - Comment	12/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1035	Victor Isarraraz - Comment	12/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1036	Victor Isarraraz - Comment	12/12/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1038	Antoinette Kelleher-Raynes - Comment	12/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1047	Sachin Desai - Comment	12/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1048	Nirdesh K. Gupta - Comment	12/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1051	David Steinmetz, No Butts About It Litter Campaign - Comment	12/13/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1052	Jeff Murray - Comment	12/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1057	Mitchell Glass - Comment	12/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1058	Lisa Delaney - Comment	12/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1059	Madeline Jean Akeley - Comment	12/14/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1060	Karen R. Hinkle - Comment	12/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1061	Kristine Marie Villanueva - Comment	12/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1066	Jacqueline M. Vanier - Comment	12/15/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1071	Jonathan Matthew Holland - Comment	12/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1072	Jeffery Don House - Comment	12/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1073	Lovely M. Bayani - Comment	12/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1074	William Taylor - Comment	12/16/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1076	Susan Stein, Ph.D. - Comment	12/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1082	Malu Misilao - Comment	12/17/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1087	Barbara Lou Rushmore - Comment	12/18/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1089	L. Aguilar - Comment	12/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1090	Jeffry Larson - Comment	12/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1091	Kristen Carteret - Comment	12/19/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1092	Corwin D. Strong - Comment	12/19/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1099	Charles Joseph Alley III - Comment	12/20/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1103	Samantha - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1104	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1105	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1106	Justice D. - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1107	Samantha - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1108	Kylee Hetherington - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1109	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1110	Samantha - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1111	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1112	Jason Daniel Bond - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1113	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1114	Samantha - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1115	Austin - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1116	Kendra H. - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1117	Samantha - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1118	Samantha - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1119	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1120	Alexander - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1121	Noah - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1122	Rebecca C. - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1123	Samantha - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1124	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1125	Trevor - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1126	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1127	Austin - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1128	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1129	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1130	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1131	Brandon - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1134	Rick - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1135	Joshua - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1136	Colin - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1137	Taylor - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1138	Teal - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1139	Suzie Ryder - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1140	Aaron - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1141	Derek - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1142	Jahzaya - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1143	Andrew - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1144	Tanner - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1145	Amber - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1146	Elias - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1147	Joshua Mickle Ryan - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1148	Brenda - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1150	Kenneth Woodard - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1151	Anonymous - Comment	12/21/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1152	Ronald Adam Zdrojewski - Comment	12/21/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1153	Anonymous - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1154	David - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1155	Ben Blasier - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1156	Paul - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1157	Joe Gardner - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1158	David - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1159	Shantel - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1160	Demi - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1161	Danielle - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1162	Travis - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1163	Peyton - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1164	Timothy Plaza - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1165	Emmyz Bean - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1166	Ashley - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1167	Monica Wlodarski - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1168	Matayaa - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1169	Demi - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1170	Molly - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1171	Megan - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1172	Lexer - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1173	Mlra - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1175	Austin - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1176	Anonymous - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1178	Anonymous - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1179	Shannon Ann Mary S. - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1180	Josh - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1181	Amanda - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1182	Josh - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1183	Nick - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1184	Josh - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1185	Sarah Ketchup Mustard - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1186	Alexander Douglas Hammer - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1187	Brent - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1188	John - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1189	Ember - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1190	Lizzie - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1191	Trey - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1192	Lilly - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1193	Rachael - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1194	Hunter - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1195	Hunter - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1196	Nathan - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1197	Breana - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1198	Christian Prior - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1199	Shelby Lee Buffham - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1203	Anonymous - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1204	Stephen Ulbricht - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1205	Celia Gooch - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1206	Michael Shaw - Comment	12/23/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1207	Anonymous - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1208	Anne Kisly - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1211	Christy Ann Onufer - Comment	12/26/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1212	Edward Greene - Comment	12/26/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1213	Cameron Lowell Palmer - Comment	12/26/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1214	Anonymous - Comment	12/27/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1215	Joan Blackwood Davis - Comment	12/27/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1217	Jonathan Mark Ball - Comment	12/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1218	Carol McNamara - Comment	12/28/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1222	Catherine Ann Champion - Comment	12/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1223	Jaime Marie Price - Comment	12/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1225	Ann Keysor - Comment	12/30/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1227	Anonymous - Comment	12/31/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1228	Nick Mancini - Comment	1/1/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1229	Patricia Broderick - Comment	1/1/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1230	Kim L. Byers - Comment	1/1/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1234	Stephen Helfer - Comment	1/3/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1236	Bruce Turner - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1237	Diane Rudebock - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1238	Harvey Hild - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1239	Wayne Truax - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1240	Jennifer Watson - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1241	Thomas Tenner - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1242	Alma Sahli - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1243	Bob Elling - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1244	Christine Lisiecki - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1245	James Swan - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1246	Bill Daly - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1247	Molly Henderson - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1248	Judy Mahaffey - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1249	Shely Taylor - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1250	Richard Adams - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1251	Pamela Woodard - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1252	Anthony Capobianco - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1253	Denee D. Chmiel - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1254	Allan Figot - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1255	Alison Beck - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1256	Valorie Snyder - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1258	Coletta Barrett - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1259	John Harvey - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1261	Martha Vennes - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1262	Tony Elliott - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1263	James Ottinger - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1264	Paula Gjerstad - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1265	Rosalie Sudowski - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1266	Corey E. Olsen - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1267	Lilly Keller - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1268	Cherish Hart - Comment	12/22/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1269	Doug Bogan - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1270	Marilyn Ritsky - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1271	Christine Marquette - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1272	Sharleen Ackley - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1273	Nel Curtiss - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1275	Jessica Kraskian - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1276	James Dunford - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1277	Roy Coleman - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1278	Eugene Shaffer - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1279	Norm Petrik - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1280	Delwin Goss - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1281	Mark Olson - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1282	Nicole Orr - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1283	Lillian Billingsley - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1284	Betty Matthews - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1286	Rebecca C. Knight - Comment	1/4/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1288	Mark Reback - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1289	Deborah Stucklen - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1290	Angela Clark - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1294	Stephen Helfer - Comment	1/4/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1295	Maureen Margaret - Comment	1/4/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1300	Mary Anna Evans - Comment	1/4/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1303	Anna M. Todd - Comment	1/4/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1306	Kim Golden - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1307	Renee Verspoor - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1308	Janice Reagan - comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1309	Joleen Chambers - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1310	Phillip Crabill - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1311	Miriam Iosupovici - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1312	Marge Walsh - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1313	Susan Hons - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1314	Sylvia Watson-Chambers - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1315	Mary Wells - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1316	Kathleen Marble - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1317	Claire Gayley - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1318	Tim Hayes - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1319	Amy Figot - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1320	Judy Richards - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1321	Dennis Ledden - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1323	Katie Taylor - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1325	Lawrence Abramson - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1326	Sandra Pieschel - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1327	Sharon Goodwin - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1328	George Waterhouse - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1329	Jacqueline Morales - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1330	John Viacrusis - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1331	Beverly Davis - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1332	Ruby Foster - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1333	Miriam Plitt - Comment	12/22/2010	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1334	John Galindo - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1335	Anne Devillier - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1336	Dan Eposito - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1337	Flo Morgenstein - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1338	Matthew Palo - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1340	Chris Ellis - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1342	Rita Taylor - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1344	Yvette M. Jones - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1345	Ronald Douglas Davis - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1347	Dirk Rogers - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1348	Linda Yates - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1349	Pam Massey - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1351	Robert Dorman - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1352	William Lee Kohler - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1353	Katherine Repanich - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1355	Heather Lopardo - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1357	G. Preuss - Comment	12/23/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1358	Linda Kay Bourne - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1360	Donna M. FSM - Comment	12/27/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1362	Write-In Campaign 2 - [Multiple Submitters=381] - Form Letter Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1363	Shelon Barker - Comment	12/27/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1366	William Kimber - Comment	12/29/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1367	Mary Boutain - Comment	12/30/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1368	Ball - Comment	1/3/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1369	Ceil Ann Sperzel - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1371	Laura Elizaeth Reed - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1373	Ian Brooks - Comment	12/22/2010	DoNotPost
FDA-2010-N-0568-DRAFT-1374	Regina Wilkerson - Comment	1/3/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1375	Anonymous - Comment	1/3/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1379	Reuben Bahar - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1382	Lori Greenstein Bremner - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1383	Danila Oder - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1390	Nancy Green - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1400	Amber Marko - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1406	Elizabeth Dubravcic - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1408	Willie Ericson - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1409	Marissa Amy Wilkin - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1410	Deb Campbell - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1411	Whitney Bowman - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1412	Randi Denice McIntyre - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1413	Eric James Moser - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1414	Heather Prince - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1415	Carrie King - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1416	Bonnie Fried - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1419	Jodi Kenworthy - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1420	Francis Louis Wootton - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1421	Bob Holder - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1422	David E. Gott, Esq. - Comment	1/6/2011	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1423	Ruth Carlin - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1424	Terrence F. Sinclair - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1425	Norman Wasserman - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1427	Paulette Cecile Martinez - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1429	Anonymous - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1430	B.B. - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1431	Patricia Salenius - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1432	Anonymous - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1433	Evelyn S. Heller - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1434	Mary Katherine Kates - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1435	Scott Benford - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1436	Andree J. Wells - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1437	Tedi Siminowsky - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1438	Thomas Michael Heller - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1441	E. Michael D. Scott - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1442	Andrew G. Cano - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1443	Sarah Quinn Rowland - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1446	Sharon Golden - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1447	Jeffrey Simon - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1448	Tammy Phillips - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1450	Mark L. Ryckman - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1452	Sabina Zolot - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1453	Lani K. Welborn - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1454	Doris M. Berko - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1456	Kenneth Lloyd Stone - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1457	Nancy Rogers Lindsey - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1458	Anita Greenlee - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1460	Donna L. Webb - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1462	Charlotte Koppe - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1464	Edward Merrell - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1465	Tara Ann Lange - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1466	Judith C Anderson - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1467	Marilyn S. Prehm - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1468	Barbara C. C. Holladay-Vernon - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1469	Anonymous - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1470	James Robert Bailey - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1473	Carol Lee Collins - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1474	Chip Henneman - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1475	Bobbie Dee Flowers - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1476	Charles J. McCall - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1477	Rael Nidess, M.D. - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1478	Donn Walter Leatherman - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1479	Hank - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1484	C. Kleymeyer - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1485	John S. McPeek - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1488	Rachel Lindstrom - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1490	Anne Schulthess - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1491	Jill Manske - Comment	1/7/2011	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1492	Sriram Madhusoodanan - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1494	Anthony Angelo Capobianco - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1496	Paul Moss - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1497	Diane Hart - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1499	Lee Stanfield - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1500	Gregory Esteve - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1501	Philip Lewis Joffe - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1502	Jennifer DeLeeuw Lindquist - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1503	Aaron Ucko - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1504	Deb Brown - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1505	Anthony David Albert - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1506	Melissa Vatterott - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1507	Mary Leitch - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1508	Dorothy C. Chamberlin - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1509	Leah Margulies, Esq. - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1511	Thomas Tizard - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1512	Sally Small - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1514	Kathleen H Hayes - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1515	Robert Rose - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1518	Maradel K Gale - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1520	Meredith Alexander - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1521	Janet A. Holden - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1522	Bob Segal - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1524	Lucille Teresa Boss - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1525	Lucille Teresa Boss - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1526	Lucille Teresa Boss - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1527	Lucille Teresa Boss - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1528	Brad Jones - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1529	Alex Woolery - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1530	Chris M. Candell - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1531	Jason G. Berteotti - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1532	Melissa McCool - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1535	Ralph Louis Shenker - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1536	Paul - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1537	Sarah Woodside Gallagher - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1538	Dirk Faegre - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1540	Mary L. Mutch - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1541	Elaine Becker - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1542	Brian Allen Houser - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1544	Harriet C. McCleary - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1545	Carla - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1546	Laurie Ann de Jong - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1547	Anonymous - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1548	William Schmidt - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1550	Bill Anderson - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1551	Mark Reback - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1552	Francis Hagan - Comment	1/7/2011	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1553	Dudley & Candace Campbell - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1555	Leslie Marie Sheridan - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1556	Sherri J. Carlson - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1557	Ron J. McGill - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1558	Holly Kukkonen - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1559	Megan Rising - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1560	Stephen W. Couche - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1561	Allan B. Jones - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1562	Gabriel Steinfeld - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1563	Mark M. Giese - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1564	Harold T. Hodes - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1565	Ephraim Olani - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1566	Corey E. Olsen - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1567	Holly Garland - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1568	Brenda Page Troup - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1570	James Schall - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1571	Jim Flynn - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1573	Justin Sweet - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1575	Misty T. - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1576	Maura Kelly Leib - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1579	M.E. Buckner - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1580	Mary Suda - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1581	Mike Hansen - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1582	Nancy Wall - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1583	Connie K Raper - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1584	Lynn Elliott - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1585	Ruth Elaine Smith - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1586	Simon Jonsson - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1590	N. Refes - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1593	Douglas C. Estes - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1594	Mike Vanlandingham - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1595	Ari Meyer - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1599	Larry Andrews - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1600	Norman Conrad - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1601	Doug Landau - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1602	Debra J. Saude - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1603	Martha White - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1604	Gerritt and Elizabeth Baker-Smith - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1605	Diana Lisa Andres - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1606	Denise Romesburg - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1607	Edith G. Montgomery - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1608	Gordon John Gerbitz - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1609	Anonymous - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1610	Marcia J. Bailey - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1611	Greg Sells - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1612	Evelyn Stern - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1613	Mannon Hubbard - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1614	Art Hanson - Comment	1/7/2011	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1615	Mary K. Mataja - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1616	Patricia - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1617	Anthony Martin - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1618	Cheryl Ann Dzubak - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1619	Natalie Hanson - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1620	Lynne M. Taylor - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1621	Lisa Anthony - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1622	Betsy A. Aller - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1623	Deborah Reynolds Pendrey - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1625	Karen McNay Bauerle - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1626	Linda K. Clarey - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1627	Marian Claire di Piazza - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1628	Mary Lou Mortimer - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1629	Eric Scheihagen - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1630	Alicia Campbell - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1631	Frank D. FitzPatrick - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1633	Carol Rosskam - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1634	Gene Ulmer - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1638	Laura Anne Meek - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1641	Michael W Evans - Comment	1/8/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1642	Angelo J. Feldkamp - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1643	Sharon A. Mulgrwe - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1644	Joshua Bud Maizel - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1645	Anonymous - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1647	Janet E. Mclver - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1648	Patricia A. Young - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1649	Hollie Rinoul - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1650	Barbara Jean Stewart - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1651	Kristiana Dahl - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1653	James C. Roberts - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1654	J. Lasahn - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1656	Valerie Foy - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1657	Durango Mendoza - Comment	1/9/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1658	Francisco Jose Costa - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1659	Carol Danoff - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1660	Ben Zachary Heller - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1664	Clayton Vern Griffith - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1666	Pat and Gary Gover - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1667	Erika E. DeCarlo - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1672	Christine Sparks - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1676	Emanuel Magid - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1677	Anonymous - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1680	Belinda J. Isham - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1682	Donna M. Ayerst - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1686	Richard Charles Wheeler - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1688	Ronald Baltzer Brooks - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1689	Diane - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1691	Karen Bernhardt - Comment	1/10/2011	DoNotPost

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-DRAFT-1692	Sarah Michele Vassello - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1693	Keith Andrew Fry - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1694	Keith Andrew Fry - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1695	Keith Andrew Fry - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1696	Keith Andrew Fry - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1698	Keith and Kyle Fluegge - Comment	1/10/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1700	Charles Otter McSweeney - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1701	Jacqueline Nalls - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1704	Ryan Arruda - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1705	George Gaffney, M.D. - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1713	Milbrey E. - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1717	Richard Paul Fehr - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1723	Victoria F. Warren - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1757	Christopher Lish - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1758	Christopher Lish - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1759	Elaine Barbara Lubetsky - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1760	Monica McQueen - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1761	Sachi Uyesugi - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1770	Anonymous - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1776	Mary P. Farley, R.N., M.N. - Comment	1/11/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1790	Theresa Eckstein - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1791	Carla Compton - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1792	Marianne Duke - Comment	1/6/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1793	Christine Shelley - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1794	Holly Thompson - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1795	Margo Perkins - Comment	1/5/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1796	Cresha Auck - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1797	Cynthia Shambley - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1798	Cathy Savage - Comment	1/7/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1801	Terry Sunderlin - Comment	1/13/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1805	Keltcie Delamar - Comment	1/13/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1806	Lorie McKellar - Comment	1/14/2011	DoNotPost
FDA-2010-N-0568-DRAFT-1817	Charlotte Fellers, et al - Comment	3/8/2011	DoNotPost
FDA-2010-N-0568-0004	Life or Death Playing Cards, Mickey Weedon - Comment	11/12/2010	Posted
FDA-2010-N-0568-0005	Julia McFarlane [Vancouver Island Health Authority] - Comment	11/17/2010	Posted
FDA-2010-N-0568-0010	Christopher Saldivar (108 6th Grade Students From Ralston Middle School) - Comment	12/3/2010	Posted
FDA-2010-N-0568-0011	George Cromer, III., Aleuttans East Borough School District (AEBSD) Sand Point School - Comment	11/23/2010	Posted
FDA-2010-N-0568-0012	Gail Ellis; Health & Physical Education Educator - (45, 10th Grade Students, Jasper-Troupsburg Central School) - Comment	12/10/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0013	Wayne Keene, R.N., B.S.N., MS., Northern Navajo Medical Center - Comment	12/9/2010	Posted
FDA-2010-N-0568-0014	Bianca Aniski, Ethel Jacobsen Elerntaiy School - Comment	11/12/2010	Posted
FDA-2010-N-0568-0015	Sharon Jarchin, Jarchin Group, Inc. - Comment	11/12/2010	Posted
FDA-2010-N-0568-0016	Anje Van Berckelaer, M.D., MS., Robert Wood Johnson Clinical Scholars, University of Pennsylvania - Comment	11/12/2010	Posted
FDA-2010-N-0568-0018	Arlington Citizen for Clean Air - Comment	11/15/2010	Posted
FDA-2010-N-0568-0019	Stanislaus County TOPS (Tobacco-Control Outreach and Prevention Services) - Comment	12/23/2010	Posted
FDA-2010-N-0568-0020	McConnell Heart Health Center Ohio Health - Comment	1/3/2011	Posted
FDA-2010-N-0568-0021	California Family Health Council, Inc. (CFHC) - Comment	1/3/2011	Posted
FDA-2010-N-0568-0022	Troy School District Troy Community Coalition - Comment	11/17/2010	Posted
FDA-2010-N-0568-0023	Traci Galinsky - Comment	12/1/2010	Posted
FDA-2010-N-0568-0024	Ronald Hall - Comment	12/1/2010	Posted
FDA-2010-N-0568-0025	Sacred Heart Rehabilitation Center - Comment	12/20/2010	Posted
FDA-2010-N-0568-0026	National Latino Tobacco Control Network (NLTCN) - Comment	1/11/2011	Posted
FDA-2010-N-0568-0027	Albert Ortiz (Artist) - Comment	11/22/2010	Posted
FDA-2010-N-0568-0028	Clallam County Board of Health - Comment	1/4/2011	Posted
FDA-2010-N-0568-0029	Johns Hopkins Bloomberg School of Public Health (JHSPH) - Comment	1/5/2011	Posted
FDA-2010-N-0568-0030	Ohio Department of Health Tobacco Program - Comment	1/5/2011	Posted
FDA-2010-N-0568-0031	Clark County Tobacco Prevention and Cessation Coalition - Comment	1/5/2011	Posted
FDA-2010-N-0568-0032	University of Detroit Mercy School of Dentistry - Comment	1/6/2011	Posted
FDA-2010-N-0568-0033	Penn State University College of Medicine - Comment	1/6/2011	Posted
FDA-2010-N-0568-0034	S.A.F.E. Smokefree Air for Everyone - Comment	1/6/2011	Posted
FDA-2010-N-0568-0035	Bladder Cancer Advocacy Network (BCAN) - comment	1/6/2011	Posted
FDA-2010-N-0568-0036	ClearWay Minnesota - Comment	1/7/2011	Posted
FDA-2010-N-0568-0037	University of Massachusetts Medical School - Comment	1/7/2011	Posted
FDA-2010-N-0568-0038	Nebraska Department of Health and Human Services - Comment	11/15/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0039	Tobacco Control & Prevention Program - Comment	11/10/2010	Posted
FDA-2010-N-0568-0040	Anonymous - Comment	11/12/2010	Posted
FDA-2010-N-0568-0041	Write-In Campaign 1 - (Surgeon General's Warning) - [Multiple Submitters Total Count=69 - Form Letter Comment	12/6/2010	Posted
FDA-2010-N-0568-0042	Action on Smoking and Health (ASH) - Comment	1/10/2011	Posted
FDA-2010-N-0568-0043	La Clinica de Raza, Inc. - Comment	1/10/2011	Posted
FDA-2010-N-0568-0044	Allison Johnson, United General Hospital - Comment	1/11/2011	Posted
FDA-2010-N-0568-0045	Democracy Institute - Comment	1/11/2011	Posted
FDA-2010-N-0568-0046	Association of National Advertisers, Inc., and American Advertising Federation (AAF), (Davis Wright Tremaine, LLP) - Comment	1/11/2011	Posted
FDA-2010-N-0568-0047	Dosal Tobacco Corporation - Comment	1/11/2011	Posted
FDA-2010-N-0568-0048	NATO - Comment	1/12/2011	Posted
FDA-2010-N-0568-0049	Pasadena Tobacco Prevention Coalition - Comment	1/12/2011	Posted
FDA-2010-N-0568-0050	Wendy Max, Institute for Health & Aging, University of California, San Francisco - Comment	1/12/2011	Posted
FDA-2010-N-0568-0051	Jessica Apodaca, Office of Student Wellness, Santa Fe Public Schools - Comment	1/12/2011	Posted
FDA-2010-N-0568-0052	Canadian Cancer Society - Comment	1/12/2011	Posted
FDA-2010-N-0568-0059	California Department of Public Health (CDPH) - Comment	1/12/2011	Posted
FDA-2010-N-0568-0060	University of California San Francisco - Comment	1/13/2011	Posted
FDA-2010-N-0568-0061	Peripheral Arterial Disease (PAD) - Comment	1/14/2011	Posted
FDA-2010-N-0568-0062	Canadian Cancer Society - Comment	1/18/2011	Posted
FDA-2010-N-0568-0063	Association of National Advertisers, Inc., (ANA) and American Advertising Federation (AAF) - Comment	1/19/2011	Posted
FDA-2010-N-0568-0064	State of California-Health and Human Services Agency California Department of Health - Comment	1/19/2011	Posted
FDA-2010-N-0568-0065	American Wholesale Marketers Association (AWMA) - Comment	2/4/2011	Posted
FDA-2010-N-0568-0066	Pennsylvania Department of Health - Comment	1/21/2011	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0067	Kathryn Keister and Prashant Patel - Comment	2/23/2011	Posted
FDA-2010-N-0568-0068	George Croomer, III., (Sand Point School) - Comment	2/23/2011	Posted
FDA-2010-N-0568-0069	Rodney D Barekman - Comment	11/12/2010	Posted
FDA-2010-N-0568-0070	Jim Elsesser - Comment	11/12/2010	Posted
FDA-2010-N-0568-0071	Evette Marie Olszyk - Comment	11/12/2010	Posted
FDA-2010-N-0568-0072	Sam Phillips - Comment	11/12/2010	Posted
FDA-2010-N-0568-0073	Dale Klabacha - Comment	11/12/2010	Posted
FDA-2010-N-0568-0074	Kathi K. Elkins - Comment	11/12/2010	Posted
FDA-2010-N-0568-0075	Michael G. Sell - Comment	11/12/2010	Posted
FDA-2010-N-0568-0076	Mariela Gonzalez - Comment	11/12/2010	Posted
FDA-2010-N-0568-0077	Kay M. Kreklau - Comment	11/12/2010	Posted
FDA-2010-N-0568-0078	Madeline Ronne - Comment	11/12/2010	Posted
FDA-2010-N-0568-0079	Amanda Halford - Comment	11/12/2010	Posted
FDA-2010-N-0568-0080	Holly M-Z - Comment	11/12/2010	Posted
FDA-2010-N-0568-0081	Erin G. Johnson - Comment	11/12/2010	Posted
FDA-2010-N-0568-0082	Teresa Ann Toombs - Comment	11/12/2010	Posted
FDA-2010-N-0568-0083	Sharon marie Day - Comment	11/12/2010	Posted
FDA-2010-N-0568-0084	Daniel Robert Pea - Comment	11/12/2010	Posted
FDA-2010-N-0568-0085	Anonymous - Comment	11/12/2010	Posted
FDA-2010-N-0568-0086	Nicole Marie Kogowski - Comment	11/12/2010	Posted
FDA-2010-N-0568-0087	Andrew Scott - Comment	11/12/2010	Posted
FDA-2010-N-0568-0088	Deena Jean Martin - Comment	11/12/2010	Posted
FDA-2010-N-0568-0089	Arlene K. Stoller - Comment	11/12/2010	Posted
FDA-2010-N-0568-0090	Marcia Brown-Machen - Comment	11/12/2010	Posted
FDA-2010-N-0568-0091	Reggie J. Labat - Comment	11/12/2010	Posted
FDA-2010-N-0568-0092	Juan Antonio Flores - Comment	11/12/2010	Posted
FDA-2010-N-0568-0093	Gavin Brown - Comment	11/12/2010	Posted
FDA-2010-N-0568-0094	David Berry - Comment	11/12/2010	Posted
FDA-2010-N-0568-0095	Eric Hansen - Comment	11/12/2010	Posted
FDA-2010-N-0568-0096	Raymond Rose - Comment	11/12/2010	Posted
FDA-2010-N-0568-0097	JoAnne Zito-Brause - Comment	11/12/2010	Posted
FDA-2010-N-0568-0098	Kristina - Comment	11/12/2010	Posted
FDA-2010-N-0568-0099	JoAnne Zito-Brause - Comment	11/12/2010	Posted
FDA-2010-N-0568-0100	Michelle Jeanette-Toupin Bielecki - Comment	11/12/2010	Posted
FDA-2010-N-0568-0101	Lauren Kelsey - Comment	11/12/2010	Posted
FDA-2010-N-0568-0102	Charlotte Marie Aborn - Comment	11/12/2010	Posted
FDA-2010-N-0568-0103	Zoe Melisa Kipping - Comment	11/12/2010	Posted
FDA-2010-N-0568-0104	Joshua Dyme - Comment	11/13/2010	Posted
FDA-2010-N-0568-0106	Regina Marie Moore - Comment	11/13/2010	Posted
FDA-2010-N-0568-0107	Charles Yingling - Comment	11/13/2010	Posted
FDA-2010-N-0568-0108	Lauren Frances LaBelle - Comment	11/13/2010	Posted
FDA-2010-N-0568-0109	Denise Raphaelle Eavers - Comment	11/13/2010	Posted
FDA-2010-N-0568-0110	Bre-Ann Slay - Comment	11/13/2010	Posted
FDA-2010-N-0568-0111	Mary Barba - Comment	11/13/2010	Posted
FDA-2010-N-0568-0112	Rachel E Mossey - Comment	11/13/2010	Posted
FDA-2010-N-0568-0113	Henry Carole Hambel - Comment	11/13/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0114	Deborah Leader - Comment	11/13/2010	Posted
FDA-2010-N-0568-0115	Anonymous - Comment	11/13/2010	Posted
FDA-2010-N-0568-0116	Joseph Bonneau - Comment	11/13/2010	Posted
FDA-2010-N-0568-0117	Alex Linenberger - Comment	11/13/2010	Posted
FDA-2010-N-0568-0118	Matthew S. White - Comment	11/13/2010	Posted
FDA-2010-N-0568-0119	Larry Lamarr Jordan - Comment	11/14/2010	Posted
FDA-2010-N-0568-0120	Patricia Joan Taylor - Comment	11/14/2010	Posted
FDA-2010-N-0568-0121	Susan Joan Forton - Comment	11/14/2010	Posted
FDA-2010-N-0568-0122	Steve J. Rohosky - Comment	11/14/2010	Posted
FDA-2010-N-0568-0123	Eric Crum - Comment	11/14/2010	Posted
FDA-2010-N-0568-0124	Margie Katherine Barry - Comment	11/14/2010	Posted
FDA-2010-N-0568-0125	William Balcer - Comment	11/14/2010	Posted
FDA-2010-N-0568-0126	Bridgette Collado - Comment	11/14/2010	Posted
FDA-2010-N-0568-0127	Patricia Ann Pelham - Comment	11/14/2010	Posted
FDA-2010-N-0568-0128	Sima Parsai - Comment	11/14/2010	Posted
FDA-2010-N-0568-0129	Ferris Sydney Whitfield - Comment	11/14/2010	Posted
FDA-2010-N-0568-0130	Paul Mayer - Comment	11/14/2010	Posted
FDA-2010-N-0568-0131	Cory Hunt - Comment	11/14/2010	Posted
FDA-2010-N-0568-0132	Samantha Jo Beck - Comment	11/14/2010	Posted
FDA-2010-N-0568-0133	Anonymous - Comment	11/14/2010	Posted
FDA-2010-N-0568-0134	Legacy - Comment	1/11/2011	Posted
FDA-2010-N-0568-0135	Michele N. Vaught - Comment	11/15/2010	Posted
FDA-2010-N-0568-0136	Chris Novrocki - Comment	11/15/2010	Posted
FDA-2010-N-0568-0137	Cheryl Uzdarwin - Comment	11/15/2010	Posted
FDA-2010-N-0568-0138	Tony Perez - Comment	11/15/2010	Posted
FDA-2010-N-0568-0139	Robert L. Daly - Comment	11/15/2010	Posted
FDA-2010-N-0568-0140	Erica A. Danos - Comment	11/15/2010	Posted
FDA-2010-N-0568-0141	Suzanne Mary Binau - Comment	11/15/2010	Posted
FDA-2010-N-0568-0142	Wendy Crespi Morgan - Comment	11/15/2010	Posted
FDA-2010-N-0568-0143	Pamela Minx Pollard - Comment	11/15/2010	Posted
FDA-2010-N-0568-0144	R.K. Teague - Comment	11/15/2010	Posted
FDA-2010-N-0568-0145	Becky L. Lamb - Comment	11/15/2010	Posted
FDA-2010-N-0568-0146	Stacy Marie Harris - Comment	11/15/2010	Posted
FDA-2010-N-0568-0147	Florence Dallo - Comment	11/15/2010	Posted
FDA-2010-N-0568-0148	Denise Catherine Zock - Comment	11/15/2010	Posted
FDA-2010-N-0568-0149	Kathryn L. Mitchell-Healey - Comment	11/15/2010	Posted
FDA-2010-N-0568-0150	Lora Stott - Comment	11/15/2010	Posted
FDA-2010-N-0568-0151	Crystal Samantha Kherkher - Comment	11/15/2010	Posted
FDA-2010-N-0568-0152	Kim M. Downing - Comment	11/15/2010	Posted
FDA-2010-N-0568-0153	Ryan Claire Reikowsky - Comment	11/15/2010	Posted
FDA-2010-N-0568-0154	Chris Hollenback - Comment	11/15/2010	Posted
FDA-2010-N-0568-0155	Karen S. Thompson - Comment	11/15/2010	Posted
FDA-2010-N-0568-0156	Veronica Maldonado - Comment	11/15/2010	Posted
FDA-2010-N-0568-0157	Rose Marie Davis - Comment	11/15/2010	Posted
FDA-2010-N-0568-0158	Nancy Jo Sauerma - Comment	11/15/2010	Posted
FDA-2010-N-0568-0159	Jen Brown - Comment	11/15/2010	Posted
FDA-2010-N-0568-0160	Tim J. Nelson - Comment	11/15/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0161	Laurena Leigh-Charlotte White - Comment	11/15/2010	Posted
FDA-2010-N-0568-0162	Joyce Nelle Adkins - Comment	11/15/2010	Posted
FDA-2010-N-0568-0163	Gayle Davidson - Comment	11/15/2010	Posted
FDA-2010-N-0568-0164	Debbie McDonald - Comment	11/15/2010	Posted
FDA-2010-N-0568-0165	Amanda - Comment	11/15/2010	Posted
FDA-2010-N-0568-0166	Anonymous - Comment	11/15/2010	Posted
FDA-2010-N-0568-0167	Jane Branscomb - Comment	11/15/2010	Posted
FDA-2010-N-0568-0168	Amanda - Comment	11/15/2010	Posted
FDA-2010-N-0568-0169	Casey K. Oskey - Comment	11/15/2010	Posted
FDA-2010-N-0568-0170	Anonymous - Comment	11/15/2010	Posted
FDA-2010-N-0568-0171	Aisatou Diallo - Comment	11/16/2010	Posted
FDA-2010-N-0568-0172	Nicolas Alexander Mauro - Comment	11/16/2010	Posted
FDA-2010-N-0568-0173	Erica L Smith - Comment	11/16/2010	Posted
FDA-2010-N-0568-0174	Michael Scott Steves - Comment	11/16/2010	Posted
FDA-2010-N-0568-0175	Anonymous - Comment	11/16/2010	Posted
FDA-2010-N-0568-0176	Daniel C. Rutz - Comment	11/16/2010	Posted
FDA-2010-N-0568-0177	Christina Marie Hamilton - Comment	11/16/2010	Posted
FDA-2010-N-0568-0178	Brian TenHopen - Comment	11/16/2010	Posted
FDA-2010-N-0568-0179	Carol - Comment	11/16/2010	Posted
FDA-2010-N-0568-0180	Robin Ellis - Comment	11/16/2010	Posted
FDA-2010-N-0568-0181	Elizabeth Bryanna Crose - Comment	11/16/2010	Posted
FDA-2010-N-0568-0182	Muhammad Thaakier Salie - Comment	11/16/2010	Posted
FDA-2010-N-0568-0183	Anonymous - Comment	11/16/2010	Posted
FDA-2010-N-0568-0184	Jordyn Lempert - Comment	11/16/2010	Posted
FDA-2010-N-0568-0185	Dennis James Martin - Comment	11/16/2010	Posted
FDA-2010-N-0568-0186	Derek Brett Sulpizio - Comment	11/16/2010	Posted
FDA-2010-N-0568-0187	Danielle Sylvester - Comment	11/16/2010	Posted
FDA-2010-N-0568-0188	Jake Harlick - Comment	11/16/2010	Posted
FDA-2010-N-0568-0189	Matt E. Phelan - Comment	11/16/2010	Posted
FDA-2010-N-0568-0190	Rebecca Rene Keating - Comment	11/16/2010	Posted
FDA-2010-N-0568-0191	Tyler James Bryant - Comment	11/16/2010	Posted
FDA-2010-N-0568-0192	Jim T. Funk - Comment	11/16/2010	Posted
FDA-2010-N-0568-0193	Amanda Mazurek - Comment	11/16/2010	Posted
FDA-2010-N-0568-0194	Lauren Nicole Stakey - Comment	11/16/2010	Posted
FDA-2010-N-0568-0195	Rachel H. Watson - Comment	11/16/2010	Posted
FDA-2010-N-0568-0196	Anonymous - Comment	11/17/2010	Posted
FDA-2010-N-0568-0197	Renee Hoffinger - Comment	11/17/2010	Posted
FDA-2010-N-0568-0198	Jenny R. Ostien - Comment	11/17/2010	Posted
FDA-2010-N-0568-0199	Linda Cahn - Comment	11/17/2010	Posted
FDA-2010-N-0568-0200	Kim Randell Aanderud - Comment	11/17/2010	Posted
FDA-2010-N-0568-0201	Shirley Kathleen Chaney - Comment	11/17/2010	Posted
FDA-2010-N-0568-0202	Dori Khakpour - Comment	11/17/2010	Posted
FDA-2010-N-0568-0203	Mary Ann Martin - Comment	11/17/2010	Posted
FDA-2010-N-0568-0204	Anonymous - Comment	11/17/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0205	Beverly J. Tafoya-Dominguez - Comment	11/17/2010	Posted
FDA-2010-N-0568-0206	Beverly Tafoya-Dominguez - Comment	11/17/2010	Posted
FDA-2010-N-0568-0207	Dr. Sam Schwartz - Comment	4/14/2011	Posted
FDA-2010-N-0568-0208	BIC Corporation - Comment	4/26/2011	Posted
FDA-2010-N-0568-0209	Anthony Lamont - Comment	11/17/2010	Posted
FDA-2010-N-0568-0210	Chris Morin - Comment	11/17/2010	Posted
FDA-2010-N-0568-0211	Julie A. Marders - Comment	11/17/2010	Posted
FDA-2010-N-0568-0212	Laura Culp - Comment	11/17/2010	Posted
FDA-2010-N-0568-0213	Adriana Christina Badalamenti - Comment	11/17/2010	Posted
FDA-2010-N-0568-0214	Nicholas Reusch - Comment	11/18/2010	Posted
FDA-2010-N-0568-0215	Judith Anne Labdik - Comment	11/18/2010	Posted
FDA-2010-N-0568-0216	Richard Spiegel - Comment	11/18/2010	Posted
FDA-2010-N-0568-0217	Victor Manzon - Comment	11/18/2010	Posted
FDA-2010-N-0568-0218	Anthony Scott Kostrzewa - Comment	11/18/2010	Posted
FDA-2010-N-0568-0219	Sandra Farley - Comment	11/18/2010	Posted
FDA-2010-N-0568-0220	Aubrey K. - Comment	11/18/2010	Posted
FDA-2010-N-0568-0221	Rita Shapiro - Comment	11/18/2010	Posted
FDA-2010-N-0568-0222	Sage - Comment	11/18/2010	Posted
FDA-2010-N-0568-0223	Wendy Smith - Comment	11/18/2010	Posted
FDA-2010-N-0568-0224	Janel Meriam Ayar - Comment	11/18/2010	Posted
FDA-2010-N-0568-0225	Christopher James Lounsbery - Comment	11/18/2010	Posted
FDA-2010-N-0568-0226	Freya Andrukitas Zork - Comment	11/18/2010	Posted
FDA-2010-N-0568-0227	Kara Ann Grauf - Comment	11/18/2010	Posted
FDA-2010-N-0568-0228	Lauren S. Kallabat - Comment	11/18/2010	Posted
FDA-2010-N-0568-0229	Nathan S. Zachar - Comment	11/18/2010	Posted
FDA-2010-N-0568-0230	Symone Sterling - Comment	11/18/2010	Posted
FDA-2010-N-0568-0231	Reed Hall - Comment	11/18/2010	Posted
FDA-2010-N-0568-0232	Jessica Lauren Minicuci - Comment	11/18/2010	Posted
FDA-2010-N-0568-0233	Amanda M. Fernandez - Comment	11/18/2010	Posted
FDA-2010-N-0568-0234	Ariel Cason - Comment	11/18/2010	Posted
FDA-2010-N-0568-0235	Dennis James Martin - Comment	11/18/2010	Posted
FDA-2010-N-0568-0236	Casey Lynn Curnutte - Comment	11/18/2010	Posted
FDA-2010-N-0568-0237	Reosha' Renee Pope - Comment	11/18/2010	Posted
FDA-2010-N-0568-0238	Chris James Lounsbery - Comment	11/18/2010	Posted
FDA-2010-N-0568-0239	Zachary Frederick Sexton - Comment	11/18/2010	Posted
FDA-2010-N-0568-0240	Ellin Johnson - Comment	11/18/2010	Posted
FDA-2010-N-0568-0241	Chelsea Messina Salkeld - Comment	11/18/2010	Posted
FDA-2010-N-0568-0242	Lauren Marie Etta - Comment	11/18/2010	Posted
FDA-2010-N-0568-0243	Richard Steven Bello - Comment	11/18/2010	Posted
FDA-2010-N-0568-0244	Michael Mendelson - Comment	11/18/2010	Posted
FDA-2010-N-0568-0245	Willow McVeigh - Comment	11/18/2010	Posted
FDA-2010-N-0568-0246	Chris - Comment	11/18/2010	Posted
FDA-2010-N-0568-0247	Rana M. Parker - Comment	11/18/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0248	Wafeeza Bacchus - Comment	11/18/2010	Posted
FDA-2010-N-0568-0249	Anonymous - Comment	11/19/2010	Posted
FDA-2010-N-0568-0250	University of Wisconsin-Center for Tobacco Research and Intervention (UW-CTRI) - Comment	1/7/2011	Posted
FDA-2010-N-0568-0267	Linda Cooperstock - Comment	11/19/2010	Posted
FDA-2010-N-0568-0268	Andy Reinhard - Comment	11/19/2010	Posted
FDA-2010-N-0568-0269	Holly Martin - Comment	11/19/2010	Posted
FDA-2010-N-0568-0270	Deborah Ruth Noyes - Comment	11/19/2010	Posted
FDA-2010-N-0568-0271	Danielle Morgan Kubly - Comment	11/19/2010	Posted
FDA-2010-N-0568-0272	Walton Sumner - Comment	11/19/2010	Posted
FDA-2010-N-0568-0273	L. Wright - Comment	11/19/2010	Posted
FDA-2010-N-0568-0274	Josh - Comment	11/19/2010	Posted
FDA-2010-N-0568-0275	Jim - Comment	11/19/2010	Posted
FDA-2010-N-0568-0276	Andy Reinhard - Comment	11/19/2010	Posted
FDA-2010-N-0568-0277	Sharon Marks - Comment	11/19/2010	Posted
FDA-2010-N-0568-0278	Wanda Armstrong - Comment	11/19/2010	Posted
FDA-2010-N-0568-0279	Matt Finn - Comment	11/19/2010	Posted
FDA-2010-N-0568-0280	Mary Ann Magaw - Comment	11/19/2010	Posted
FDA-2010-N-0568-0281	Betty L Martini - Comment	11/19/2010	Posted
FDA-2010-N-0568-0282	Thurman Allen Merritt - Comment	11/20/2010	Posted
FDA-2010-N-0568-0283	Pamela Rae Welsing - Comment	11/20/2010	Posted
FDA-2010-N-0568-0284	Barbara Cindric - Comment	11/20/2010	Posted
FDA-2010-N-0568-0285	Iorraine Ruppe - Comment	11/20/2010	Posted
FDA-2010-N-0568-0286	Virginia Frances Stegall - Comment	11/20/2010	Posted
FDA-2010-N-0568-0287	Madeline Arkin - Comment	11/20/2010	Posted
FDA-2010-N-0568-0288	Sasha W. - Comment	11/21/2010	Posted
FDA-2010-N-0568-0289	Charles Bina - Comment	11/21/2010	Posted
FDA-2010-N-0568-0290	Michael Hart - Comment	11/21/2010	Posted
FDA-2010-N-0568-0291	Arnold H. Herman - Comment	11/21/2010	Posted
FDA-2010-N-0568-0292	Cliff William Rustia - Comment	11/21/2010	Posted
FDA-2010-N-0568-0293	Chiquita Cole - Comment	11/21/2010	Posted
FDA-2010-N-0568-0294	James Scott Lachapelle - Comment	11/21/2010	Posted
FDA-2010-N-0568-0295	David Ehrlich - Comment	11/22/2010	Posted
FDA-2010-N-0568-0296	Chris Peralta - Comment	11/22/2010	Posted
FDA-2010-N-0568-0297	James L. Williams - Comment	11/22/2010	Posted
FDA-2010-N-0568-0298	Gregg L. Ruppel - Comment	11/22/2010	Posted
FDA-2010-N-0568-0299	Alexander Zubenko - Comment	11/22/2010	Posted
FDA-2010-N-0568-0300	Rhonda Jane Drain - Comment	11/22/2010	Posted
FDA-2010-N-0568-0301	Nora Elizabeth Coulter - Comment	11/22/2010	Posted
FDA-2010-N-0568-0302	Bernice Gerig Carver - Comment	11/22/2010	Posted
FDA-2010-N-0568-0303	Marty L. Eckrem - Comment	11/22/2010	Posted
FDA-2010-N-0568-0304	Susan K. Bergquist - Comment	11/22/2010	Posted
FDA-2010-N-0568-0305	Andrew J. Woodruff - Comment	11/22/2010	Posted
FDA-2010-N-0568-0306	Paula J. Martel - Comment	11/22/2010	Posted
FDA-2010-N-0568-0307	Anonymous - Comment	11/22/2010	Posted
FDA-2010-N-0568-0308	Ashley V. Dzingle - Comment	11/22/2010	Posted
FDA-2010-N-0568-0309	Lynda Anne Nesbitt - Comment	11/22/2010	Posted
FDA-2010-N-0568-0310	Nick A. Mauro - Comment	11/23/2010	Posted
FDA-2010-N-0568-0311	Mary Ann Aregood - Comment	11/23/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0312	Jacqueline L. Webb - Comment	11/23/2010	Posted
FDA-2010-N-0568-0313	Beth Lisa Haley - Comment	11/23/2010	Posted
FDA-2010-N-0568-0314	Troy Michael Doetch - Comment	11/23/2010	Posted
FDA-2010-N-0568-0315	Joni Jones - Comment	11/23/2010	Posted
FDA-2010-N-0568-0316	Anonymous - Comment	11/23/2010	Posted
FDA-2010-N-0568-0317	Anonymous - Comment	11/23/2010	Posted
FDA-2010-N-0568-0318	Barbara A Armstrong - Comment	11/23/2010	Posted
FDA-2010-N-0568-0319	MSIntelligence - Comment	11/24/2010	Posted
FDA-2010-N-0568-0320	Isabel Truong - Comment	11/24/2010	Posted
FDA-2010-N-0568-0321	Patricia Lundrigan - Comment	11/24/2010	Posted
FDA-2010-N-0568-0322	Justin Daniel Hassenfeld - Comment	11/24/2010	Posted
FDA-2010-N-0568-0323	Dara Sheinker - Comment	11/24/2010	Posted
FDA-2010-N-0568-0324	Brandon John Bloom - Comment	11/24/2010	Posted
FDA-2010-N-0568-0325	Jonathan K Rash - Comment	11/24/2010	Posted
FDA-2010-N-0568-0326	Glenn D. Cormier - Comment	11/24/2010	Posted
FDA-2010-N-0568-0327	David T. - Comment	11/27/2010	Posted
FDA-2010-N-0568-0328	James R. Damon - Comment	11/27/2010	Posted
FDA-2010-N-0568-0329	Wesley Eden Helms - Comment	11/27/2010	Posted
FDA-2010-N-0568-0330	Nitteya Thompson - Comment	11/28/2010	Posted
FDA-2010-N-0568-0331	William P. Williams - Comment	11/28/2010	Posted
FDA-2010-N-0568-0332	Frank Lukas Birt - Comment	11/28/2010	Posted
FDA-2010-N-0568-0333	Anonymous - Comment	11/28/2010	Posted
FDA-2010-N-0568-0334	Natalie Grace Ringham - Comment	11/28/2010	Posted
FDA-2010-N-0568-0335	Lanell M. Perkins - Comment	11/29/2010	Posted
FDA-2010-N-0568-0336	Betty C. Jung - Comment	11/29/2010	Posted
FDA-2010-N-0568-0337	Diane Ouellette Barnaby - Comment	11/29/2010	Posted
FDA-2010-N-0568-0338	Larry P. East - Comment	11/29/2010	Posted
FDA-2010-N-0568-0339	Keri Reyburn - Comment	11/29/2010	Posted
FDA-2010-N-0568-0340	Bob Wit Jeb - Comment	11/29/2010	Posted
FDA-2010-N-0568-0341	Schnee Nicole - Comment	11/29/2010	Posted
FDA-2010-N-0568-0342	Alan W. Palmer - Comment	11/29/2010	Posted
FDA-2010-N-0568-0343	Sally Ann Dutson - Comment	11/29/2010	Posted
FDA-2010-N-0568-0344	Bill Ramsaur - Comment	11/29/2010	Posted
FDA-2010-N-0568-0345	Timothy Ashton Alexander - Comment	11/29/2010	Posted
FDA-2010-N-0568-0346	Jo DeBuhr - Comment	11/29/2010	Posted
FDA-2010-N-0568-0347	Eric Campbell - Comment	11/30/2010	Posted
FDA-2010-N-0568-0348	Shylo Dennison - Comment	11/30/2010	Posted
FDA-2010-N-0568-0349	Angel Nace - Comment	11/30/2010	Posted
FDA-2010-N-0568-0350	Aleta R. Carpenter - Comment	11/30/2010	Posted
FDA-2010-N-0568-0351	Angela Maria Martinelli - Comment	11/30/2010	Posted
FDA-2010-N-0568-0352	Vicki Barron - Comment	11/30/2010	Posted
FDA-2010-N-0568-0353	Jason Lee Ambrosino - Comment	11/30/2010	Posted
FDA-2010-N-0568-0354	Tiffany Humphrey - Comment	11/30/2010	Posted
FDA-2010-N-0568-0355	Constance Elaine Cephus - Comment	12/1/2010	Posted
FDA-2010-N-0568-0356	Denise Woods - Comment	12/1/2010	Posted
FDA-2010-N-0568-0357	Deborah Dawn Colwell - Comment	12/1/2010	Posted
FDA-2010-N-0568-0358	Ryan Barbieri - Comment	12/1/2010	Posted
FDA-2010-N-0568-0359	Jesus Perez - Comment	12/1/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0360	Abby Lynn McElligott - Comment	12/1/2010	Posted
FDA-2010-N-0568-0361	Anonymous - Comment	12/1/2010	Posted
FDA-2010-N-0568-0362	Anonymous - Comment	12/2/2010	Posted
FDA-2010-N-0568-0363	Aaron - Comment	12/2/2010	Posted
FDA-2010-N-0568-0364	Ann Quinn-Zobeck - Comment	12/2/2010	Posted
FDA-2010-N-0568-0365	Hollie Dawn Garrison - Comment	12/2/2010	Posted
FDA-2010-N-0568-0366	Anonymous - Comment	12/2/2010	Posted
FDA-2010-N-0568-0367	Dani Roesler - Comment	12/2/2010	Posted
FDA-2010-N-0568-0368	Gina Rae Ryg - Comment	12/3/2010	Posted
FDA-2010-N-0568-0369	Amy McQueen - Comment	12/3/2010	Posted
FDA-2010-N-0568-0370	Tina M. Lavy - Comment	12/3/2010	Posted
FDA-2010-N-0568-0371	Diana S. Blythe - Comment	12/4/2010	Posted
FDA-2010-N-0568-0372	Xenia A. - Comment	12/5/2010	Posted
FDA-2010-N-0568-0373	Calleagh Cecelia Brown - Comment	12/5/2010	Posted
FDA-2010-N-0568-0374	Erin M. Swaller - Comment	12/5/2010	Posted
FDA-2010-N-0568-0375	Lucille Rathier - Comment	12/5/2010	Posted
FDA-2010-N-0568-0376	Christie Pua'ala Hussey - Comment	12/6/2010	Posted
FDA-2010-N-0568-0377	Christie Pua'ala Hussey - Comment	12/6/2010	Posted
FDA-2010-N-0568-0378	Mallory Jane McPherson - Comment	12/6/2010	Posted
FDA-2010-N-0568-0379	Lauren C. Lackey - Comment	12/6/2010	Posted
FDA-2010-N-0568-0380	Brittany Keener - Comment	12/6/2010	Posted
FDA-2010-N-0568-0381	Jeff Shrifter - Comment	12/6/2010	Posted
FDA-2010-N-0568-0382	Alicia S. Hoard - Comment	12/6/2010	Posted
FDA-2010-N-0568-0383	John M. Golden - Comment	12/6/2010	Posted
FDA-2010-N-0568-0384	Jonnie D. Purify, Jr. - Comment	12/6/2010	Posted
FDA-2010-N-0568-0385	Shary M. Jones - Comment	12/6/2010	Posted
FDA-2010-N-0568-0386	Steven Randolph Tidwell - Comment	12/6/2010	Posted
FDA-2010-N-0568-0387	Shani Smith - Comment	12/6/2010	Posted
FDA-2010-N-0568-0388	Patrick C. Harper - Comment	12/6/2010	Posted
FDA-2010-N-0568-0389	Mark Miller - Comment	12/6/2010	Posted
FDA-2010-N-0568-0390	Arlan Lee Rosenbloom - Comment	12/6/2010	Posted
FDA-2010-N-0568-0391	Patricia Davison Mail - Comment	12/6/2010	Posted
FDA-2010-N-0568-0392	Dale King - Comment	12/6/2010	Posted
FDA-2010-N-0568-0393	CAPT Jooh J Bartko - Comment	12/6/2010	Posted
FDA-2010-N-0568-0394	C.K. Olson - Comment	12/6/2010	Posted
FDA-2010-N-0568-0395	Anonymous - Comment	12/6/2010	Posted
FDA-2010-N-0568-0396	Eva McLanahan - Comment	12/6/2010	Posted
FDA-2010-N-0568-0397	Ferdinand R Hassler - Comment	12/6/2010	Posted
FDA-2010-N-0568-0398	Anonymous - Comment	12/6/2010	Posted
FDA-2010-N-0568-0399	Erica Frahm - Comment	12/6/2010	Posted
FDA-2010-N-0568-0400	Alberto Moreno - Comment	12/6/2010	Posted
FDA-2010-N-0568-0401	LTJG Rebecca L. Hampton - Comment	12/7/2010	Posted
FDA-2010-N-0568-0402	Connor Steele - Comment	12/7/2010	Posted
FDA-2010-N-0568-0403	Mary F. Rossi-Coajou - Comment	12/7/2010	Posted
FDA-2010-N-0568-0404	Erin Grasso - Comment	12/7/2010	Posted
FDA-2010-N-0568-0405	Jeremy Sobel - Comment	12/7/2010	Posted
FDA-2010-N-0568-0406	Jill Hammond - Comment	12/7/2010	Posted
FDA-2010-N-0568-0407	Laura Gieraltowski - Comment	12/7/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0408	Rob Lyerla - Comment	12/7/2010	Posted
FDA-2010-N-0568-0409	Austin Lee Nichols - Comment	12/7/2010	Posted
FDA-2010-N-0568-0410	Kimberly Ruth Crocker - Comment	12/7/2010	Posted
FDA-2010-N-0568-0411	Silvia Benincaso - Comment	12/7/2010	Posted
FDA-2010-N-0568-0412	Mark A. Chen - Comment	12/7/2010	Posted
FDA-2010-N-0568-0413	Richard Michael Davidson - Comment	12/7/2010	Posted
FDA-2010-N-0568-0414	Richard Michael Davidson - Comment	12/7/2010	Posted
FDA-2010-N-0568-0415	Jolene M. Caselli - Comment	12/7/2010	Posted
FDA-2010-N-0568-0416	Laura A. Meller - Comment	12/7/2010	Posted
FDA-2010-N-0568-0417	LCDR Deborah Dee - Comment	12/7/2010	Posted
FDA-2010-N-0568-0418	Richard John Calvert - Comment	12/7/2010	Posted
FDA-2010-N-0568-0419	Nadine Marie Simons - Comment	12/7/2010	Posted
FDA-2010-N-0568-0420	Ronald Arthur Berry - Comment	12/7/2010	Posted
FDA-2010-N-0568-0421	Sara Beth Newman - Comment	12/7/2010	Posted
FDA-2010-N-0568-0422	Frank - Comment	12/7/2010	Posted
FDA-2010-N-0568-0423	Sarah Bennett - Comment	12/7/2010	Posted
FDA-2010-N-0568-0424	Charles Helmick - Comment	12/7/2010	Posted
FDA-2010-N-0568-0425	Cameron Seth Lorbiecki - Comment	12/8/2010	Posted
FDA-2010-N-0568-0426	Anonymous - Comment	12/8/2010	Posted
FDA-2010-N-0568-0427	Nicole king - Comment	12/8/2010	Posted
FDA-2010-N-0568-0428	Monique M. Connor - Comment	12/8/2010	Posted
FDA-2010-N-0568-0429	Janet Keysser - Comment	12/8/2010	Posted
FDA-2010-N-0568-0430	Lori Sugiyama - Comment	12/8/2010	Posted
FDA-2010-N-0568-0431	Amy Ray Fisher - Comment	12/9/2010	Posted
FDA-2010-N-0568-0432	Eric S. Armbrrecht - Comment	12/9/2010	Posted
FDA-2010-N-0568-0433	Andrea Bankoski - Comment	12/9/2010	Posted
FDA-2010-N-0568-0434	Patricia Nye - Comment	12/9/2010	Posted
FDA-2010-N-0568-0435	Nadine Marie Simons - Comment	12/9/2010	Posted
FDA-2010-N-0568-0436	Anonymous - Comment	12/9/2010	Posted
FDA-2010-N-0568-0437	Ashley - Comment	12/9/2010	Posted
FDA-2010-N-0568-0438	David Kristopher Glabe - Comment	12/10/2010	Posted
FDA-2010-N-0568-0439	Isabel Auerbach - Comment	12/10/2010	Posted
FDA-2010-N-0568-0440	Robert C. Williams - Comment	12/10/2010	Posted
FDA-2010-N-0568-0441	Jason McLean - Comment	12/10/2010	Posted
FDA-2010-N-0568-0442	Latoya Nicola Belgrave - Comment	12/10/2010	Posted
FDA-2010-N-0568-0443	Latonia Ford - Comment	12/10/2010	Posted
FDA-2010-N-0568-0444	Andrea Barrus - Comment	12/10/2010	Posted
FDA-2010-N-0568-0445	Caleb Hopwood - Comment	12/11/2010	Posted
FDA-2010-N-0568-0446	Alan Stuart Echt - Comment	12/11/2010	Posted
FDA-2010-N-0568-0447	Gary William Bangs - Comment	12/12/2010	Posted
FDA-2010-N-0568-0448	John T. Majewski - Comment	12/12/2010	Posted
FDA-2010-N-0568-0449	Anonymous - Comment	12/12/2010	Posted
FDA-2010-N-0568-0450	Sherry Burrer - Comment	12/12/2010	Posted
FDA-2010-N-0568-0451	Anonymous - Comment	12/13/2010	Posted
FDA-2010-N-0568-0452	Dylan Selterman - Comment	12/13/2010	Posted
FDA-2010-N-0568-0453	Cynthia Keely - Comment	12/13/2010	Posted
FDA-2010-N-0568-0454	Kevin Matthew Kunard - Comment	12/13/2010	Posted
FDA-2010-N-0568-0455	Rachelle Leong - Comment	12/13/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0456	Anonymous - Comment	12/13/2010	Posted
FDA-2010-N-0568-0457	Stephen Isaacs - Comment	12/13/2010	Posted
FDA-2010-N-0568-0458	Mitchell Wada - Comment	12/14/2010	Posted
FDA-2010-N-0568-0459	Jobana L. Perez - Comment	12/14/2010	Posted
FDA-2010-N-0568-0460	Anonymous - Comment	12/13/2010	Posted
FDA-2010-N-0568-0461	Megan Mattingly - Comment	12/14/2010	Posted
FDA-2010-N-0568-0462	Barry Sanders - Comment	12/14/2010	Posted
FDA-2010-N-0568-0463	Ashley J. Burns - Comment	12/14/2010	Posted
FDA-2010-N-0568-0464	Michelle E. Poindexter - Comment	12/15/2010	Posted
FDA-2010-N-0568-0465	Donna Sue Peros - Comment	12/15/2010	Posted
FDA-2010-N-0568-0466	Emily Nichole Stark - Comment	12/15/2010	Posted
FDA-2010-N-0568-0467	Kelly J. Jarrell - Comment	12/15/2010	Posted
FDA-2010-N-0568-0468	Alexis Bartolome Vea - Comment	12/15/2010	Posted
FDA-2010-N-0568-0469	Eric William Bradford - Comment	12/15/2010	Posted
FDA-2010-N-0568-0470	Mark Goldstein - Comment	12/16/2010	Posted
FDA-2010-N-0568-0471	Kate Heim - Comment	12/16/2010	Posted
FDA-2010-N-0568-0472	Marie Davantes - Comment	12/17/2010	Posted
FDA-2010-N-0568-0473	Claudine Samanic - Comment	12/17/2010	Posted
FDA-2010-N-0568-0474	Susan Utegg - Comment	12/17/2010	Posted
FDA-2010-N-0568-0475	Adele M. Spegman - Comment	12/17/2010	Posted
FDA-2010-N-0568-0476	Dana L. Hall - Comment	12/17/2010	Posted
FDA-2010-N-0568-0477	Marty Celis Borja - Comment	12/17/2010	Posted
FDA-2010-N-0568-0478	Al D. Paet - Comment	12/17/2010	Posted
FDA-2010-N-0568-0479	Luciano Nunes Duro - Comment	12/17/2010	Posted
FDA-2010-N-0568-0480	Thurman Allen Allen Merritt M.D., MHA - Comment	12/18/2010	Posted
FDA-2010-N-0568-0481	Anonymous - Comment	12/18/2010	Posted
FDA-2010-N-0568-0482	Lyzette Czarina Abalos - Comment	12/18/2010	Posted
FDA-2010-N-0568-0483	Mark Kane Goldstein - Comment	12/19/2010	Posted
FDA-2010-N-0568-0484	Kathryn S. Kreimer - Comment	12/19/2010	Posted
FDA-2010-N-0568-0485	Anonymous - Comment	12/19/2010	Posted
FDA-2010-N-0568-0486	Lisa D. Wallace - Comment	12/20/2010	Posted
FDA-2010-N-0568-0487	Dorothea Moll - Comment	12/20/2010	Posted
FDA-2010-N-0568-0488	Connie Lynne Bruce - Comment	12/20/2010	Posted
FDA-2010-N-0568-0489	Anonymous - Comment	12/21/2010	Posted
FDA-2010-N-0568-0490	Dan - Comment	12/21/2010	Posted
FDA-2010-N-0568-0491	Joni A. Jensen - Comment	12/21/2010	Posted
FDA-2010-N-0568-0492	Anonymous - Comment	12/21/2010	Posted
FDA-2010-N-0568-0493	American Association for Respiratory Care (AARC) - Comment	12/22/2010	Posted
FDA-2010-N-0568-0494	American Academy of Family Physicians - Comment	12/22/2010	Posted
FDA-2010-N-0568-0495	Zach Lomba Monsto - Comment	12/22/2010	Posted
FDA-2010-N-0568-0496	John E. Kroneck - Comment	12/22/2010	Posted
FDA-2010-N-0568-0497	Judith M. Metzger - Comment	12/25/2010	Posted
FDA-2010-N-0568-0498	Liatte Krueger - Comment	12/28/2010	Posted
FDA-2010-N-0568-0499	Jochim Hansen - Comment	12/29/2010	Posted
FDA-2010-N-0568-0500	Anonymous - Comment	12/29/2010	Posted
FDA-2010-N-0568-0501	Dan Werle - Comment	12/30/2010	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0502	Christopher Gibbons - Comment	12/30/2010	Posted
FDA-2010-N-0568-0503	Margie R. Arnett - Comment	1/3/2011	Posted
FDA-2010-N-0568-0504	Penny Denise Green - Comment	12/23/2010	Posted
FDA-2010-N-0568-0505	Timothy Michael Lape - Comment	1/4/2011	Posted
FDA-2010-N-0568-0506	Linn Allen Morrill - Comment	1/4/2011	Posted
FDA-2010-N-0568-0507	Robert Andersn - Comment	1/4/2011	Posted
FDA-2010-N-0568-0508	Jeremy Kees et al - Comment	1/4/2011	Posted
FDA-2010-N-0568-0509	Lynn Rose Antil - Comment	1/4/2011	Posted
FDA-2010-N-0568-0510	Vivian Lasley-Bibbs - Comment	1/4/2011	Posted
FDA-2010-N-0568-0511	Lisa Miller - Comment	1/4/2011	Posted
FDA-2010-N-0568-0512	Jane L. Jones - Comment	1/4/2011	Posted
FDA-2010-N-0568-0513	Donald J. Breece - Comment	1/4/2011	Posted
FDA-2010-N-0568-0514	Robin M. Scott - Comment	1/4/2011	Posted
FDA-2010-N-0568-0515	Stephanie M. Steinberg - Comment	1/4/2011	Posted
FDA-2010-N-0568-0516	Marsha Lynn Laflamme - Comment	1/4/2011	Posted
FDA-2010-N-0568-0517	Anonymous - Comment	1/4/2011	Posted
FDA-2010-N-0568-0518	Tracy R. Spencer - Comment	1/4/2011	Posted
FDA-2010-N-0568-0519	Edgar Lopez - Comment	1/4/2011	Posted
FDA-2010-N-0568-0520	Marvin L. Vinson - Comment	1/4/2011	Posted
FDA-2010-N-0568-0521	Robert William Ling - Comment	1/4/2011	Posted
FDA-2010-N-0568-0522	Jerry Zee - Comment	1/5/2011	Posted
FDA-2010-N-0568-0523	Jean Kelahan - Comment	1/5/2011	Posted
FDA-2010-N-0568-0524	Diana Meyers - Comment	1/5/2011	Posted
FDA-2010-N-0568-0525	Tobacco Prevention and Cessation Program, Arkansas Department of Health - Comment	1/5/2011	Posted
FDA-2010-N-0568-0526	Michael Placona - Comment	1/5/2011	Posted
FDA-2010-N-0568-0527	Linda Salzman - Comment	1/5/2011	Posted
FDA-2010-N-0568-0528	Cassandra Contreras - Comment	1/5/2011	Posted
FDA-2010-N-0568-0529	James Darrel Gregory - Comment	1/5/2011	Posted
FDA-2010-N-0568-0530	Veronica Merrell - Comment	1/5/2011	Posted
FDA-2010-N-0568-0531	catherine A mcdonald - Comment	1/5/2011	Posted
FDA-2010-N-0568-0532	Erin Lea Fletcher - Comment	1/5/2011	Posted
FDA-2010-N-0568-0533	Johnelle Claire Lamarque - Comment	1/5/2011	Posted
FDA-2010-N-0568-0534	Gabriel Arthur Cardenas - Comment	1/5/2011	Posted
FDA-2010-N-0568-0535	Rick David Watson - Comment	1/5/2011	Posted
FDA-2010-N-0568-0536	Nancy Thomas - Comment	1/5/2011	Posted
FDA-2010-N-0568-0537	Donna Repaty, CTTS - Comment	1/5/2011	Posted
FDA-2010-N-0568-0538	Kathy Spruce Garrett - Comment	1/5/2011	Posted
FDA-2010-N-0568-0539	Christine Weiss - Comment	1/5/2011	Posted
FDA-2010-N-0568-0540	Lisa Nicole Houston - Comment	1/5/2011	Posted
FDA-2010-N-0568-0541	Sandra Schulthies - Comment	1/5/2011	Posted
FDA-2010-N-0568-0542	Kirby R. Avila - Comment	1/5/2011	Posted
FDA-2010-N-0568-0543	Karlee - Comment	1/5/2011	Posted
FDA-2010-N-0568-0544	Adam T. Bramwell - Comment	1/5/2011	Posted
FDA-2010-N-0568-0545	Bob Doyle - Comment	1/6/2011	Posted
FDA-2010-N-0568-0546	Pat Moeder - Comment	1/6/2011	Posted
FDA-2010-N-0568-0547	Anonymous - Comment	1/6/2011	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0548	Jordan D. Mathis - Comment	1/6/2011	Posted
FDA-2010-N-0568-0549	David Joseph Neville - Comment	1/6/2011	Posted
FDA-2010-N-0568-0550	Jean Marie Calomeni - Comment	1/6/2011	Posted
FDA-2010-N-0568-0551	Melissa Kuhn - Comment	1/6/2011	Posted
FDA-2010-N-0568-0552	Partnership for Prevention - Comment	1/6/2011	Posted
FDA-2010-N-0568-0553	American Medical Association (AMA) - Comment	1/6/2011	Posted
FDA-2010-N-0568-0554	Lisa Wright - Comment	1/6/2011	Posted
FDA-2010-N-0568-0555	Te van Phan - Comment	1/6/2011	Posted
FDA-2010-N-0568-0556	Jonathan E. Rosenberg - Comment	1/6/2011	Posted
FDA-2010-N-0568-0557	Kathy Heitkamp - Comment	1/6/2011	Posted
FDA-2010-N-0568-0558	Mary Ann Aregood - Comment	1/6/2011	Posted
FDA-2010-N-0568-0559	David G. Smart - Comment	1/6/2011	Posted
FDA-2010-N-0568-0560	Kenneth B. McCoppen - Comment	1/6/2011	Posted
FDA-2010-N-0568-0561	Paul Rene Knoll - Comment	1/6/2011	Posted
FDA-2010-N-0568-0562	Maddie Williams - Comment	1/6/2011	Posted
FDA-2010-N-0568-0563	Mary H. Korte - Comment	1/6/2011	Posted
FDA-2010-N-0568-0564	Carol Ann Reed - Comment	1/6/2011	Posted
FDA-2010-N-0568-0565	M.F. Petersen - Comment	1/6/2011	Posted
FDA-2010-N-0568-0566	Sandra S. Tucker - Comment	1/6/2011	Posted
FDA-2010-N-0568-0567	Cindy Quick - Comment	1/6/2011	Posted
FDA-2010-N-0568-0568	Emily Doutre - Comment	1/7/2011	Posted
FDA-2010-N-0568-0569	A. Bonvouloir - Comment	1/7/2011	Posted
FDA-2010-N-0568-0570	Mark S. Artis - Comment	1/7/2011	Posted
FDA-2010-N-0568-0571	Ray Cage - Comment	1/7/2011	Posted
FDA-2010-N-0568-0572	Joan Budd - Comment	1/7/2011	Posted
FDA-2010-N-0568-0573	Howard Rau Christofersen, MD - Comment	1/7/2011	Posted
FDA-2010-N-0568-0574	Katie Johnson - Comment	1/7/2011	Posted
FDA-2010-N-0568-0575	Michael Lahey - Comment	1/7/2011	Posted
FDA-2010-N-0568-0576	Erin G. Fitzgerald - Comment	1/7/2011	Posted
FDA-2010-N-0568-0577	Julia M. Penn, LCSW - Comment	1/7/2011	Posted
FDA-2010-N-0568-0578	Susan Peirce - Comment	1/7/2011	Posted
FDA-2010-N-0568-0579	RevAntoinette Wilhemina Pezet - Comment	1/7/2011	Posted
FDA-2010-N-0568-0580	Wayne J. Stroessner - Comment	1/7/2011	Posted
FDA-2010-N-0568-0581	Todd Snyder - Comment	1/7/2011	Posted
FDA-2010-N-0568-0582	Franklin Joseph Kapustka - Comment	1/7/2011	Posted
FDA-2010-N-0568-0583	Matthew Swyers - Comment	1/7/2011	Posted
FDA-2010-N-0568-0584	Jonathon J. Singleton - Comment	1/7/2011	Posted
FDA-2010-N-0568-0585	Sarah Hafer - Comment	1/7/2011	Posted
FDA-2010-N-0568-0586	Mary Krebs - Comment	1/7/2011	Posted
FDA-2010-N-0568-0587	Frederic W. Grannis - Comment	1/7/2011	Posted
FDA-2010-N-0568-0588	Marc Pilisuk - Comment	1/7/2011	Posted
FDA-2010-N-0568-0589	Commissioned Officers Assn. of the U.S. Public Health Service - Comment	1/7/2011	Posted
FDA-2010-N-0568-0590	Rainbow Health Initiative - Comment	1/7/2011	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0591	Alex Lessin - Comment	1/7/2011	Posted
FDA-2010-N-0568-0592	Diego Itzjak Shmuels - Comment	1/7/2011	Posted
FDA-2010-N-0568-0593	Jill Ransom, RN - Comment	1/7/2011	Posted
FDA-2010-N-0568-0594	C. Everett Koop, et al. - Comment	1/7/2011	Posted
FDA-2010-N-0568-0595	LA Tobacco Control Program - Comment	1/7/2011	Posted
FDA-2010-N-0568-0596	LA Tobacco Control Program - Comment	1/7/2011	Posted
FDA-2010-N-0568-0597	Ann Manion Watters - Comment	1/7/2011	Posted
FDA-2010-N-0568-0598	Anonymous - Comment	1/7/2011	Posted
FDA-2010-N-0568-0599	Matt Slade - Comment	1/7/2011	Posted
FDA-2010-N-0568-0600	Pennsylvania Department of Health - Comment	1/7/2011	Posted
FDA-2010-N-0568-0601	Barbara Cohan - Comment	1/8/2011	Posted
FDA-2010-N-0568-0602	Marilyn Hawrylik - Comment	1/8/2011	Posted
FDA-2010-N-0568-0603	Rachel Manning - Comment	1/8/2011	Posted
FDA-2010-N-0568-0604	Gregory Marc Bentley - Comment	1/8/2011	Posted
FDA-2010-N-0568-0605	Stephen Lorin Hamann - Comment	1/8/2011	Posted
FDA-2010-N-0568-0606	Don Lee Lamm - Comment	1/8/2011	Posted
FDA-2010-N-0568-0607	Robert New - Comment	1/8/2011	Posted
FDA-2010-N-0568-0608	Tim Paul Strong - Comment	1/9/2011	Posted
FDA-2010-N-0568-0609	Guru Sonpavde - Comment	1/9/2011	Posted
FDA-2010-N-0568-0610	Michael A. O'Donnell - Comment	1/9/2011	Posted
FDA-2010-N-0568-0611	Ellen Peters - Comment	1/10/2011	Posted
FDA-2010-N-0568-0612	Anonymous - Comment	1/10/2011	Posted
FDA-2010-N-0568-0613	Stanton A. Glantz - Comment	1/10/2011	Posted
FDA-2010-N-0568-0614	Helen Sharon Campbell - Comment	1/10/2011	Posted
FDA-2010-N-0568-0615	NC Division of Public Health - Comment	1/10/2011	Posted
FDA-2010-N-0568-0616	Cheryl T. Lee - Comment	1/10/2011	Posted
FDA-2010-N-0568-0617	Walter Mulican Whineright - Comment	1/10/2011	Posted
FDA-2010-N-0568-0618	Carol Sexy Murphy - Comment	1/10/2011	Posted
FDA-2010-N-0568-0619	Micheal Brian Dutra - Comment	1/10/2011	Posted
FDA-2010-N-0568-0620	Erik Lewis - Comment	1/10/2011	Posted
FDA-2010-N-0568-0621	Jeff Bertucci - Comment	1/10/2011	Posted
FDA-2010-N-0568-0622	Martha Rose Regalado - Comment	1/10/2011	Posted
FDA-2010-N-0568-0623	Lawson A. Moyer III MD - Comment	1/10/2011	Posted
FDA-2010-N-0568-0624	Tyler Lee Long - Comment	1/10/2011	Posted
FDA-2010-N-0568-0625	Heather - Comment	1/10/2011	Posted
FDA-2010-N-0568-0626	Free & Clear - Comment	1/10/2011	Posted
FDA-2010-N-0568-0627	Public Health - Seattle & King County - Comment	1/10/2011	Posted
FDA-2010-N-0568-0628	American College of Physicians (ACP) - Comment	1/10/2011	Posted
FDA-2010-N-0568-0629	Anonymous - Comment	1/10/2011	Posted
FDA-2010-N-0568-0630	Marion R. Gaffney - Comment	1/10/2011	Posted
FDA-2010-N-0568-0631	University of South Carolina - Comment	1/11/2011	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0632	Christopher Keith Haddock - Comment	1/11/2011	Posted
FDA-2010-N-0568-0633	World Lung Foundation - Comment	1/11/2011	Posted
FDA-2010-N-0568-0634	National Association of County and City Health Officials (NACCHO) - Comment	1/11/2011	Posted
FDA-2010-N-0568-0635	Corporate Accountability International - Comment	1/11/2011	Posted
FDA-2010-N-0568-0636	Altria Client Services - Comment	1/11/2011	Posted
FDA-2010-N-0568-0637	Lorillard Tobacco Company - Comment	1/11/2011	Posted
FDA-2010-N-0568-0638	Annenberg Public Policy Center, University of Pennsylvania - Comment	1/11/2011	Posted
FDA-2010-N-0568-0639	Roswell Park Cancer Institute - Comment	1/11/2011	Posted
FDA-2010-N-0568-0640	Chris R. Doster - Comment	1/11/2011	Posted
FDA-2010-N-0568-0641	Marra Williams - Comment	1/11/2011	Posted
FDA-2010-N-0568-0642	Laura Elizabeth Crook - Comment	1/11/2011	Posted
FDA-2010-N-0568-0643	NYC Department of Health and Mental Hygiene - Comment	1/11/2011	Posted
FDA-2010-N-0568-0644	GlaxoSmithKline Consumer Healthcare - Comment	1/11/2011	Posted
FDA-2010-N-0568-0645	Anonymous - Comment	1/11/2011	Posted
FDA-2010-N-0568-0646	Elizabeth Manteuffel - Comment	1/11/2011	Posted
FDA-2010-N-0568-0647	Dosal Tobacco Corp. - Comment	1/11/2011	Posted
FDA-2010-N-0568-0648	American College of Cardiology - Comment	1/11/2011	Posted
FDA-2010-N-0568-0649	WomenHeart - Comment	1/11/2011	Posted
FDA-2010-N-0568-0650	Gloria Beth Soliz - Comment	1/11/2011	Posted
FDA-2010-N-0568-0651	COPD Foundation - Comment	1/11/2011	Posted
FDA-2010-N-0568-0652	Shelbey Miller - Comment	1/11/2011	Posted
FDA-2010-N-0568-0653	Bay County Health Dept. Tobacco Prevention Program - Comment	1/11/2011	Posted
FDA-2010-N-0568-0654	Japan Tobacco International U.S.A. - Comment	1/11/2011	Posted
FDA-2010-N-0568-0655	WomenHeart - Comment	1/11/2011	Posted
FDA-2010-N-0568-0656	WomenHeart - Comment	1/11/2011	Posted
FDA-2010-N-0568-0657	WomenHeart - Comment	1/11/2011	Posted
FDA-2010-N-0568-0658	R.J. Reynolds Tobacco Company, Lorillard Tobacco Company, and Commonwealth Brands, Inc. - Comment	1/11/2011	Posted
FDA-2010-N-0568-0659	American Cancer Society Cancer Action Network, the American Heart Association, Campaign for Tobacco-Free Kids, American Lung Association, & the American Academy of Pediatrics - Comment	1/11/2011	Posted

Document ID	Title	Date Received	Phase
FDA-2010-N-0568-0660	Goodhue County Health and Human Services - Comment	1/11/2011	Posted
FDA-2010-N-0568-0661	Lisa Marie Wind - Comment	1/11/2011	Posted
FDA-2010-N-0568-0662	Dalys Wright - Comment	1/11/2011	Posted
FDA-2010-N-0568-0663	Gwendolyn Stewart - Comment	1/11/2011	Posted
FDA-2010-N-0568-0664	North American Quitline Consortium - Comment	1/11/2011	Posted
FDA-2010-N-0568-0665	National Association of Tobacco Outlets, Inc. (NATO) - Comment	1/11/2011	Posted
FDA-2010-N-0568-0666	TobaccoHarmReduction.org - Comment	1/11/2011	Posted
FDA-2010-N-0568-0667	Tobacco Control Legal Consortium - Comment	1/11/2011	Posted
FDA-2010-N-0568-0668	J. Naumiec - Comment	1/11/2011	Posted
FDA-2010-N-0568-0669	Altria Client Services, on behalf of Philip Morris USA - Comment	1/11/2011	Posted
FDA-2010-N-0568-0670	Centro Campesino - Comment	1/11/2011	Posted
FDA-2010-N-0568-0671	Narayanan Iyer - Comment	1/11/2011	Posted
FDA-2010-N-0568-0672	Virginia Foundation for Healthy Youth (Y Street) - Comment	1/11/2011	Posted
FDA-2010-N-0568-0673	Jessica Apodaca - Comment	1/11/2011	Posted
FDA-2010-N-0568-0674	Sandra L. Johnson - Comment	1/11/2011	Posted
FDA-2010-N-0568-0675	Kristina Ann Clark - Comment	1/11/2011	Posted
FDA-2010-N-0568-0676	University of California at Merced - Comment	1/11/2011	Posted
FDA-2010-N-0568-0677	Denise Ayana Stiassny - Comment	1/11/2011	Posted
FDA-2010-N-0568-0678	Robert Wood Johnson Foundation - Comment	1/11/2011	Posted
FDA-2010-N-0568-0679	California Smokers' Helpline/University of California San Diego - Comment	1/11/2011	Posted
FDA-2010-N-0568-0680	American Association for Cancer Research - Comment	1/11/2011	Posted
FDA-2010-N-0568-0681	University of Waterloo & International Tobacco Control Policy Evaluation Project - Comment	1/11/2011	Posted
FDA-2010-N-0568-0682	American Association for Cancer Research - Comment	1/11/2011	Posted
FDA-2010-N-0568-0683	Council of Independent Tobacco Manufacturers of America (CITMA) - Comment	1/11/2011	Posted
FDA-2010-N-0568-0684	University of Waterloo - Comment	1/11/2011	Posted
FDA-2010-N-0568-0685	University of Waterloo - Comment	1/11/2011	Posted
FDA-2010-N-0568-0686	Frank Joseph Chaloupka - Comment	1/11/2011	Posted
FDA-2010-N-0568-0687	Food Marketing Institute (FMI) - Comment	1/11/2011	Posted
FDA-2010-N-0568-0747	Benjamin Toll - Comment	12/21/2010	Posted

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLUMBIA**

R.J. REYNOLDS TOBACCO)
COMPANY, et al.,)
)
Plaintiffs,)
)
v.)
)
UNITED STATES FOOD AND)
DRUG ADMINISTRATION, et al.,)
)
Defendants.)

No. 1:11-cv-1482 (RJL)

ORDER

The Court having considered plaintiffs’ motion for summary judgment, defendants’ motion for summary judgment, both parties’ memoranda of law, and the record herein, it is hereby

ORDERED that plaintiffs’ motion is DENIED and defendants’ motion is GRANTED. JUDGMENT is hereby granted in defendants’ favor, and plaintiffs shall take nothing.

Dated: _____

RICHARD J. LEON
United States District Judge